{
    "title": "Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia",
    "abstract": "Background Intermediate hyperglycaemia (IH) is characterised by one or more measurements of elevated blood glucose concentrations, such as impaired fasting glucose (IFG), impaired glucose tolerance (IGT) and elevated glycosylated haemoglobin A1c (HbA1c). These levels are higher than normal but below the diagnostic threshold for type 2 diabetes mellitus (T2DM). The reduced threshold of 5.6 mmol/L (100 mg/dL) fasting plasma glucose (FPG) for defining IFG, introduced by the American Diabetes Association (ADA) in 2003, substantially increased the prevalence of IFG. Likewise, the lowering of the HbA1c threshold from 6.0% to 5.7% by the ADA in 2010 could potentially have significant medical, public health and socioeconomic impacts.    Objectives To assess the overall prognosis of people with IH for developing T2DM, regression from IH to normoglycaemia and the difference in T2DM incidence in people with IH versus people with normoglycaemia.    Search methods We searched MEDLINE, Embase, ClincialTrials.gov and the International Clinical Trials Registry Platform (ICTRP) Search Portal up to December 2016 and updated the MEDLINE search in February 2018. We used several complementary search methods in addition to a Boolean search based on analytical text mining.    Selection criteria We included prospective cohort studies investigating the development of T2DM in people with IH. We used standard definitions of IH as described by the ADA or World Health Organization (WHO). We excluded intervention trials and studies on cohorts with additional comorbidities at baseline, studies with missing data on the transition from IH to T2DM, and studies where T2DM incidence was evaluated by documents or self\u2010report only.    Data collection and analysis One review author extracted study characteristics, and a second author checked the extracted data. We used a tailored version of the Quality In Prognosis Studies (QUIPS) tool for assessing risk of bias. We pooled incidence and incidence rate ratios (IRR) using a random\u2010effects model to account for between\u2010study heterogeneity. To meta\u2010analyse incidence data, we used a method for pooling proportions. For hazard ratios (HR) and odds ratios (OR) of IH versus normoglycaemia, reported with 95% confidence intervals (CI), we obtained standard errors from these CIs and performed random\u2010effects meta\u2010analyses using the generic inverse\u2010variance method. We used multivariable HRs and the model with the greatest number of covariates. We evaluated the certainty of the evidence with an adapted version of the GRADE framework.    Main results We included 103 prospective cohort studies. The studies mainly defined IH by IFG5.6 (FPG mmol/L 5.6 to 6.9 mmol/L or 100 mg/dL to 125 mg/dL), IFG6.1 (FPG 6.1 mmol/L to 6.9 mmol/L or 110 mg/dL to 125 mg/dL), IGT (plasma glucose 7.8 mmol/L to 11.1 mmol/L or 140 mg/dL to 199 mg/dL two hours after a 75 g glucose load on the oral glucose tolerance test, combined IFG and IGT (IFG/IGT), and elevated HbA1c (HbA1c5.7: HbA1c 5.7% to 6.4% or 39 mmol/mol to 46 mmol/mol; HbA1c6.0: HbA1c 6.0% to 6.4% or 42 mmol/mol to 46 mmol/mol). The follow\u2010up period ranged from 1 to 24 years. Ninety\u2010three studies evaluated the overall prognosis of people with IH measured by cumulative T2DM incidence, and 52 studies evaluated glycaemic status as a prognostic factor for T2DM by comparing a cohort with IH to a cohort with normoglycaemia. Participants were of Australian, European or North American origin in 41 studies; Latin American in 7; Asian or Middle Eastern in 50; and Islanders or American Indians in 5. Six studies included children and/or adolescents.  Cumulative incidence of T2DM associated with IFG5.6, IFG6.1, IGT and the combination of IFG/IGT increased with length of follow\u2010up. Cumulative incidence was highest with IFG/IGT, followed by IGT, IFG6.1 and IFG5.6. Limited data showed a higher T2DM incidence associated with HbA1c6.0 compared to HbA1c5.7. We rated the evidence for overall prognosis as of moderate certainty because of imprecision (wide CIs in most studies). In the 47 studies reporting restitution of normoglycaemia, regression ranged from 33% to 59% within one to five years follow\u2010up, and from 17% to 42% for 6 to 11 years of follow\u2010up (moderate\u2010certainty evidence).  Studies evaluating the prognostic effect of IH versus normoglycaemia reported different effect measures (HRs, IRRs and ORs). Overall, the effect measures all indicated an elevated risk of T2DM at 1 to 24 years of follow\u2010up. Taking into account the long\u2010term follow\u2010up of cohort studies, estimation of HRs for time\u2010dependent events like T2DM incidence appeared most reliable. The pooled HR and the number of studies and participants for different IH definitions as compared to normoglycaemia were: IFG5.6: HR 4.32 (95% CI 2.61 to 7.12), 8 studies, 9017 participants; IFG6.1: HR 5.47 (95% CI 3.50 to 8.54), 9 studies, 2818 participants; IGT: HR 3.61 (95% CI 2.31 to 5.64), 5 studies, 4010 participants; IFG and IGT: HR 6.90 (95% CI 4.15 to 11.45), 5 studies, 1038 participants; HbA1c5.7: HR 5.55 (95% CI 2.77 to 11.12), 4 studies, 5223 participants; HbA1c6.0: HR 10.10 (95% CI 3.59 to 28.43), 6 studies, 4532 participants. In subgroup analyses, there was no clear pattern of differences between geographic regions. We downgraded the evidence for the prognostic effect of IH versus normoglycaemia to low\u2010certainty evidence due to study limitations because many studies did not adequately adjust for confounders. Imprecision and inconsistency required further downgrading due to wide 95% CIs and wide 95% prediction intervals (sometimes ranging from negative to positive prognostic factor to outcome associations), respectively.  This evidence is up to date as of 26 February 2018.   Authors' conclusions Overall prognosis of people with IH worsened over time. T2DM cumulative incidence generally increased over the course of follow\u2010up but varied with IH definition. Regression from IH to normoglycaemia decreased over time but was observed even after 11 years of follow\u2010up. The risk of developing T2DM when comparing IH with normoglycaemia at baseline varied by IH definition. Taking into consideration the uncertainty of the available evidence, as well as the fluctuating stages of normoglycaemia, IH and T2DM, which may transition from one stage to another in both directions even after years of follow\u2010up, practitioners should be careful about the potential implications of any active intervention for people 'diagnosed' with IH.",
    "review_type": "Prognosis",
    "doi": "https://doi.org/10.1002/14651858.CD012661.pub2",
    "review_id": "CD012661",
    "criteria": {
        "Study design": "Prospective cohort studies investigating either the overall prognosis of people with IH for developing T2DM or IH versus normoglycaemia as a prognostic factor for developing T2DM (Altman 2001).",
        "Inclusion criteria": "To study the overall prognosis of people with IH and regression from IH to normoglycaemia, we included cohort studies in people with IH at baseline, defined by impaired fasting glucose (IFG), impaired glucose tolerance (IGT), elevated glycosylated haemoglobin A1c (HbA1c) or any combination of these. IH had to be established by standard cut\u2010off values for IFG, IGT or elevated HbA1c, as defined by ADA or WHO (ADA 1997; ADA 2003; ADA 2010; ICH 1997; IEC 2009; WHO 1998; WHO/IDF 2006). To study whether IH compared to normoglycaemia is a prognostic factor for developing T2DM, we included cohort studies in people with IH and normoglycaemia at baseline. We defined IH according to ADA and WHO descriptions. IFG5.6 threshold, usually defined as a fasting plasma glucose level between 5.6 mmol/L and 6.9 mmol/L at baseline.    IFG6.1 threshold, usually defined as a fasting plasma glucose level between 6.1 mmol/L and 6.9 mmol/L at baseline.    IGT, usually defined as a plasma glucose level between 7.8 mmol/L and 11.1 mmol/L two hours after a 75 g OGTT at baseline.    Isolated IFG was defined as IFG5.6 or IFG6.1 only (without IGT), and isolated IGT was defined as IGT only (without IFG5.6 or IFG6.1).    HbA1c5.7 threshold, usually defined as HbA1c measurement between 5.7% and 6.4% at baseline.    HbA1c6.0 threshold, usually defined as HbA1c measurement between 6.0% and 6.4% at baseline. IFG5.6 threshold, usually defined as a fasting plasma glucose level between 5.6 mmol/L and 6.9 mmol/L at baseline. IFG6.1 threshold, usually defined as a fasting plasma glucose level between 6.1 mmol/L and 6.9 mmol/L at baseline. IGT, usually defined as a plasma glucose level between 7.8 mmol/L and 11.1 mmol/L two hours after a 75 g OGTT at baseline. Isolated IFG was defined as IFG5.6 or IFG6.1 only (without IGT), and isolated IGT was defined as IGT only (without IFG5.6 or IFG6.1). HbA1c5.7 threshold, usually defined as HbA1c measurement between 5.7% and 6.4% at baseline. HbA1c6.0 threshold, usually defined as HbA1c measurement between 6.0% and 6.4% at baseline. Our outcome of primary interest was the diagnosis of newly developed T2DM (T2DM incidence). T2DM incidence should have been diagnosed by blood glucose measurements such as fasting plasma glucose (FPG), two\u2010hour postload glucose (PG) or HbA1c. Diagnosis could have been combined with self\u2010reported diabetes, physician\u2010diagnosed diabetes or use of antihyperglycaemic medications such as oral hypoglycaemic drugs, insulin or both.",
        "Types of participants": "To study the overall prognosis of people with IH and regression from IH to normoglycaemia, we included cohort studies in people with IH at baseline, defined by impaired fasting glucose (IFG), impaired glucose tolerance (IGT), elevated glycosylated haemoglobin A1c (HbA1c) or any combination of these. IH had to be established by standard cut\u2010off values for IFG, IGT or elevated HbA1c, as defined by ADA or WHO (ADA 1997; ADA 2003; ADA 2010; ICH 1997; IEC 2009; WHO 1998; WHO/IDF 2006).  To study whether IH compared to normoglycaemia is a prognostic factor for developing T2DM, we included cohort studies in people with IH and normoglycaemia at baseline.",
        "Definition of IH": "We defined IH according to ADA and WHO descriptions.    IFG5.6 threshold, usually defined as a fasting plasma glucose level between 5.6 mmol/L and 6.9 mmol/L at baseline.    IFG6.1 threshold, usually defined as a fasting plasma glucose level between 6.1 mmol/L and 6.9 mmol/L at baseline.    IGT, usually defined as a plasma glucose level between 7.8 mmol/L and 11.1 mmol/L two hours after a 75 g OGTT at baseline.    Isolated IFG was defined as IFG5.6 or IFG6.1 only (without IGT), and isolated IGT was defined as IGT only (without IFG5.6 or IFG6.1).    HbA1c5.7 threshold, usually defined as HbA1c measurement between 5.7% and 6.4% at baseline.    HbA1c6.0 threshold, usually defined as HbA1c measurement between 6.0% and 6.4% at baseline.",
        "Types of outcome measures": "Our outcome of primary interest was the diagnosis of newly developed T2DM (T2DM incidence). T2DM incidence should have been diagnosed by blood glucose measurements such as fasting plasma glucose (FPG), two\u2010hour postload glucose (PG) or HbA1c. Diagnosis could have been combined with self\u2010reported diabetes, physician\u2010diagnosed diabetes or use of antihyperglycaemic medications such as oral hypoglycaemic drugs, insulin or both.",
        "Exclusion criteria": "Intervention trials and study designs other than prospective cohort studies.   People with comorbidities at baseline (e.g. people with coronary heart disease and IGT).    Missing data on transition from IH to T2DM.   Follow\u2010up period after baseline assessment not specified (not possible to associate T2DM incidence with length of follow\u2010up).    T2DM incidence evaluated by documents (e.g. hospital records, retrospective use of registers) or self\u2010report only. Intervention trials and study designs other than prospective cohort studies. People with comorbidities at baseline (e.g. people with coronary heart disease and IGT). Missing data on transition from IH to T2DM. Follow\u2010up period after baseline assessment not specified (not possible to associate T2DM incidence with length of follow\u2010up). T2DM incidence evaluated by documents (e.g. hospital records, retrospective use of registers) or self\u2010report only.",
        "Search methods for identification of studies": "The fundamental challenge of this review question was to define the population of interest, that is, people with IH. We expected a great number of terms describing this population, such as people with prediabetes, mentions of IFG, IGT or HbA1c somewhere in the title or abstract of relevant publications, and terms like risk factors, predictors, prevalence, incidence and several other concepts which cannot be foreseen when developing a Boolean search strategy in a conceptual way. One option to address this problem would have been to design a highly sensitive search strategy, which would have resulted in a yield of more than 15,000 references, which was unfeasible for fast human screening but could be addressed in the future with robust automated classification algorithms. Instead, we designed a more specific Boolean search approach based on text analysis and augmented by the following complementary search methods. Identification of systematic reviews addressing our review question.   Careful checking of reference lists and Discussion sections of relevant studies.   A non\u2010human skill dependent search method based on PubMed's 'similar articles' algorithm. Identification of systematic reviews addressing our review question. Careful checking of reference lists and Discussion sections of relevant studies. A non\u2010human skill dependent search method based on PubMed's 'similar articles' algorithm. We developed the search strategy using analytical text mining of 44 relevant publications (range of publication years 2008 to 2015, from 31 journals) already known to review author BR. We used the tools PubReMiner, TerMine and AntConc and applied the prognosis filters by the Hedges Team (Wilczynski 2004; Wilczynski 2005). We searched the following sources from database inception to the specified date. MEDLINE Ovid Epub Ahead of Print, In\u2010Process & Other Non\u2010Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) (1946 to 15 December 2016 and then updated to 26 February 2018).    Embase Ovid (1974 to 2016 Week 50, last searched 15 December 2016).   ClinicalTrials.gov (searched 15 December 2016).    WHO International Clinical Trials Registry Platform (ICTRP) Search Portal (apps.who.int/trialsearch; searched 15 December 2016). MEDLINE Ovid Epub Ahead of Print, In\u2010Process & Other Non\u2010Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) (1946 to 15 December 2016 and then updated to 26 February 2018). Embase Ovid (1974 to 2016 Week 50, last searched 15 December 2016). ClinicalTrials.gov (searched 15 December 2016). WHO International Clinical Trials Registry Platform (ICTRP) Search Portal (apps.who.int/trialsearch; searched 15 December 2016). Before publication, we updated the MEDLINE search as reflected above. We restricted the update to MEDLINE because 98% of the publications of included studies identified up to the point of updating (on 26 February 2018) were indexed in MEDLINE. The search strategy consisted of two tiers. Prediabetes as predictor for cardiovascular disease (CVD), mortality, stroke, cancer, micro\u2010 and macrovascular complications.    Prediabetes as predictor for diabetes incidence. Prediabetes as predictor for cardiovascular disease (CVD), mortality, stroke, cancer, micro\u2010 and macrovascular complications. Prediabetes as predictor for diabetes incidence. We combined both strategies with the conjunction 'OR' because it was likely that search results for prediabetes as a predictor for complications also contained data on diabetes incidence. For details of all search strategies see Appendix 2. In addition, we extracted relevant publications from 16 identified systematic reviews (Echouffo\u2010Tcheugui 2016; Erqou 2013; Ford 2010; Hope 2016; Huang 2014b; Huang 2014a; Huang 2016; Lee 2012; Morris 2013; Santos\u2010Oliveira 2011; Sarwar 2010; Schottker 2016; Twito 2015; Xu 2015; Zhang 2012a; Zhong 2016). We extracted relevant publications after handsearching the full texts of included studies (Methods section, Discussion section, reference lists). On 15 March 2018 we ran PubMed's 'similar articles' algorithm with the 224 publications of included studies identified by our search methods so far ('seed publications' in Appendix 2). When using the 'similar articles' algorithm, search results in PubMed are retrieved and ranked according to pre\u2010calculated similarities of the seed publications. We downloaded the first 500 results (of 24,124), deduplicated them against the already identified seed publications and screened the resulting set.",
        "Boolean search": "We developed the search strategy using analytical text mining of 44 relevant publications (range of publication years 2008 to 2015, from 31 journals) already known to review author BR. We used the tools PubReMiner, TerMine and AntConc and applied the prognosis filters by the Hedges Team (Wilczynski 2004; Wilczynski 2005).  We searched the following sources from database inception to the specified date.    MEDLINE Ovid Epub Ahead of Print, In\u2010Process & Other Non\u2010Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) (1946 to 15 December 2016 and then updated to 26 February 2018).    Embase Ovid (1974 to 2016 Week 50, last searched 15 December 2016).   ClinicalTrials.gov (searched 15 December 2016).    WHO International Clinical Trials Registry Platform (ICTRP) Search Portal (apps.who.int/trialsearch; searched 15 December 2016).     Before publication, we updated the MEDLINE search as reflected above. We restricted the update to MEDLINE because 98% of the publications of included studies identified up to the point of updating (on 26 February 2018) were indexed in MEDLINE.  The search strategy consisted of two tiers.    Prediabetes as predictor for cardiovascular disease (CVD), mortality, stroke, cancer, micro\u2010 and macrovascular complications.    Prediabetes as predictor for diabetes incidence.    We combined both strategies with the conjunction 'OR' because it was likely that search results for prediabetes as a predictor for complications also contained data on diabetes incidence. For details of all search strategies see Appendix 2.",
        "Study extraction of relevant systematic reviews": "In addition, we extracted relevant publications from 16 identified systematic reviews (Echouffo\u2010Tcheugui 2016; Erqou 2013; Ford 2010; Hope 2016; Huang 2014b; Huang 2014a; Huang 2016; Lee 2012; Morris 2013; Santos\u2010Oliveira 2011; Sarwar 2010; Schottker 2016; Twito 2015; Xu 2015; Zhang 2012a; Zhong 2016).",
        "Reference checking of included studies": "We extracted relevant publications after handsearching the full texts of included studies (Methods section, Discussion section, reference lists).",
        "'Similar articles'\u2010based search method": "On 15 March 2018 we ran PubMed's 'similar articles' algorithm with the 224 publications of included studies identified by our search methods so far ('seed publications' in Appendix 2). When using the 'similar articles' algorithm, search results in PubMed are retrieved and ranked according to pre\u2010calculated similarities of the seed publications. We downloaded the first 500 results (of 24,124), deduplicated them against the already identified seed publications and screened the resulting set.",
        "Selection of studies": "Two review authors (BR and BH) independently scanned the title, abstract, or both, of every record retrieved in the literature searches to determine which studies to assess further. We investigated the full text of all potentially relevant articles, resolving discrepancies through consensus or by recourse to a third review author (MIM). We prepared a flow diagram of the number of studies identified and excluded at each stage in accordance with the PRISMA flow diagram of study selection (Liberati 2009).",
        "Data extraction and management": "For studies that fulfilled our inclusion criteria, one review author (BR) extracted key study characteristics, inclusion and exclusion criteria of study participants, stated aim of the study, definitions of prognosis, prognostic factor and outcome (normoglycaemia, intermediate glycaemia and T2DM incidence), baseline characteristics of study participants and data on transition from IH (as defined by IFG, IGT, elevated HbA1c or combinations thereof) to T2DM. Another author (MIM) checked these data extractions, and we resolved any disagreements by discussion or, if required, by consultation with a third review author (BH). We used parts of the checklist for critical appraisal and data extraction for systematic reviews of prediction modelling studies (CHARMS), which helps to evaluate prediction modelling studies (Moons 2014), and we established our own context\u2010specific data extraction sheets after piloting data extraction for 15 studies.",
        "Dealing with companion publications": "In the event of companion publications or multiple reports of a prospective cohort study (e.g. because of different time points investigated) we focused on the analysis of the publication describing the longest follow\u2010up from baseline and extracted data from shorter follow\u2010ups in case some measures were not reported in the publication on the longest follow\u2010up (e.g. the most recent paper might have described the association between elevated HbA1c and T2DM incidence, but an older publication might have described the association between IGT and T2DM incidence). Companion publications or multiple reports of a primary study were listed as secondary references under the primary reference of the included, ongoing or excluded study.",
        "Assessment of risk of bias in included studies": "One review author (BR) assessed the risk of bias of each included study and another review author (MIM) checked the accuracy of this assessment. We resolved any disagreements by consensus, or by consultation with a third review author (BH). We used a tailored version of the Quality In Prognosis Studies (QUIPS) tool for assessing risk of bias in studies of the prognostic factor IH versus normoglycaemia (Dretzke 2014; Hayden 2013; see Appendix 3). Our tool consisted of six risk of bias domains: study participation, study attrition, glycaemic status measurement, outcome measurement, study confounding; and statistical analysis and reporting. The study participation domain consisted of five items: description of the source population or population of interest, description of the baseline study sample, adequate description of the sampling frame and recruitment, adequate description of the period and place of recruitment, and adequate description of inclusion and exclusion criteria. The study attrition domain consisted of four items: description of attempts to collect information on participants who dropped out, reasons for loss to follow\u2010up provided, adequate description of participants lost to follow\u2010up, and no important differences between participants who completed the study and those who did not. The glycaemic status measurement domain consisted of four items: provision of clear definition or description of the glycaemic status, adequately valid and reliable method of measuring glycaemic status, reporting of continuous variables or use of appropriate cut points, and use of same method and setting of measurement of glycaemic status in all study participants. The outcome measurement domain consisted of three items: provision of clear definition of the outcome, use of adequately valid and reliable method of outcome measurement, and use of same method and setting of outcome measurement in all study participants. The study confounding domain consisted of the seven items: measurement of all important confounders, provision of clear definitions of the important confounders measured, adequately valid and reliable measurement of all important confounders, use of same method and setting of confounding measurement in all study participants, appropriate imputation methods used for missing confounders (if applicable), important potential confounders accounted for in the study design, and important potential confounders accounted for in the analysis. The statistical analysis and reporting domain consisted of two items: sufficient presentation of data to assess the adequacy of the analytic strategy, and adequate statistical model for the design of the study. There is no recommended tool for assessing risk of bias in studies of overall prognosis. Therefore, we applied the tailored QUIPS tool to these studies as well but without the domains for study confounding and statistical analysis and reporting because these were not suitable to basic calculations of cumulative incidence. We planned to investigate the influence of low risk of bias (low risk of bias in all domains) versus unclear/high risk of bias (unclear or high risk of bias in at least one of these domains).",
        "Measures of T2DM incidence and unit of analyses issues": "If more than one group from the same cohort study was eligible for inclusion in the same meta\u2010analysis, we included the groups only if separate information was available (e.g. data on T2DM incidence for female and male participants). If more than one time point of T2DM was available for a study (e.g. cumulative incidence data) we included data in the appropriate meta\u2010analysis for each time point separately and did not pool data across different follow\u2010up periods.",
        "Data synthesis": "Our primary aim for overall prognosis in people with IH was to provide a transparent overview of the whole data matrix describing a wide variety of possible associations between various isolated and combined definitions of IH and incident T2DM in dissimilar populations covering diverse time periods. We also evaluated whether IH compared to normoglycaemia is a prognostic factor for developing T2DM. First, we grouped studies on IH definitions, i.e. isolated IFG 5.6 mmol/L to 6.9 mmol/L (IFG5.6 threshold), isolated IFG 6.1 mmol/L to 6.9 mmol/L (IFG6.1 threshold), isolated IGT (glucose concentration 7.8 mmol/L to 11.1 mmol/L two hours after a 75 g glucose load on the OGTT), IFG and IGT combined, HbA1c 6.0% to 6.4% (HbA1c6.0 threshold), and HbA1c 5.7% to 6.4% (HbA1c5.7 threshold). Then we evaluated subgroups of different geographic locations/'ethnicities' for each IH definition. We expected the following outcome measures. Cases (cumulative incidence at follow\u2010up; e.g. 20 new diabetes cases out of 400 people with IFG at baseline (5%)) and cumulative incidence rates (cases per 1000 person\u2010years) for overall prognosis of people with IH.    Odds ratios (ORs), incidence rate ratios (IRRs), and hazard ratios (HRs) for IH versus normoglycaemia as a prognostic factor for developing T2DM. Cases (cumulative incidence at follow\u2010up; e.g. 20 new diabetes cases out of 400 people with IFG at baseline (5%)) and cumulative incidence rates (cases per 1000 person\u2010years) for overall prognosis of people with IH. Odds ratios (ORs), incidence rate ratios (IRRs), and hazard ratios (HRs) for IH versus normoglycaemia as a prognostic factor for developing T2DM. We pooled incidence and incidence rate ratios (IRR) using a random\u2010effects model to account for between\u2010study heterogeneity. For meta\u2010analysis of incidence data, we used a method for pooling proportions which uses the Freeman\u2010Tukey Double Arcsine Transformation to stabilise the variances (Freeman 1950). The meta\u2010analysis was performed using the Stata software user written programme metaprop (Stata 2015). For the confidence intervals (CI) for individual studies shown on the forest plots for incidence, we used the Wilson approach (Newcombe 1998). For meta\u2010analysis of IRRs, we first computed the log IRRs and their approximate standard errors and then used an inverse variance weighted random\u2010effects model to pool the log IRRs (Hasselblad 1994; Higgins 2011b). We exponentiated the pooled log IRR to obtain the pooled IRR. The meta\u2010analysis of log IRRs was performed using the Stata user written programme metan. If publications reported HRs with associated 95% CIs, we obtained standard errors from these CIs as described in chapter 7.7.7.3 of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011a), and we performed meta\u2010analysis using the generic inverse\u2010variance method (RevMan 2014). When possible, we reported both adjusted and unadjusted HRs, but we primarily used adjusted HRs from multivariable models of studies incorporating similar covariates (Dretzke 2014).",
        "Assessment of heterogeneity": "We expected substantial clinical heterogeneity between studies because of geographical/'ethnic' and methodological diversity. We did not intend to address statistical heterogeneity (inconsistency) using the I2 statistic because this statistic does not indicate how much the effect size varies, which is what people want to know when asking about the implications of heterogeneity (Borenstein 2017a). Also, the I2 statistic is problematic in the context of prognosis studies because individual studies often have large sample sizes resulting in narrow CIs, which can result in high I2 values even if inconsistency between studies is moderate (Iorio 2015). Instead, when there were at least three studies, we reported the range of the effects of the random\u2010effects meta\u2010analyses using prediction intervals (Borenstein 2017b; Higgins 2009; IntHout 2016; Riley 2011; Riley 2015). In a random\u2010effects meta\u2010analysis, the prediction interval reflects the whole distribution of effects across study populations, including the effect expected in a future study (IntHout 2016; Riley 2015).",
        "Certainty of the evidence": "We created a 'Summary of findings' table using Review Manager 5 (RevMan 2014). We used an adapted version of the GRADE framework for prognostic factor research for describing the influence of IFG, IGT, elevated HbA1c and both IFG and IGT on the development of T2DM (Huguet 2013). We justified all decisions to downgrade the certainty of evidence using footnotes, and we made comments to aid the reader's understanding of this Cochrane Review where necessary.",
        "Sensitivity analysis": "We planned to perform sensitivity analyses to explore the influence of the following factors (when applicable) on effect sizes by excluding: studies at high or unclear risk of bias;   very long or large studies to establish the extent to which they dominate the results. studies at high or unclear risk of bias; very long or large studies to establish the extent to which they dominate the results.",
        "Subgroup analysis": "Because we stratified the analyses by IH definition and geographical locations/'ethnicity', which we thought were the main sources of heterogeneity, we did not plan to perform subgroup analyses. However, if at least 10 studies specifying diabetes incidence data were included, we would have investigated age and sex by testing for interactions between subgroups. If T2DM incidence data were available for children and adolescents, we reported the results separately."
    },
    "search_strategy": {
        "Appendix 1. Glossary of terms": "Abbreviation    Explanation      ADA   American Diabetes Association     ALAT   Alanine aminotransferase     ASAT   Aspartate transaminase     BG   Blood glucose     BMI   Body mass index     BW   Body weight     CI   Confidence interval     FG   Fasting glucose     FBG   Fasting blood glucose     FINDRISC   Finnish Diabetes Risk Score     FPG   Fasting plasma glucose     G6PD   Glucose\u20106\u2010P\u2010dehydrogenase test     HbA1c   Glycosylated haemoglobin A1c     HbA1c5.7    Intermediate hyperglycaemia with HbA1c level 5.7%\u20106.4% at baseline (HbA1c 5.7% threshold)     HbA1c6.0    Intermediate hyperglycaemia with HbA1c level 6.0%\u20106.4% at baseline (HbA1c 6.0% threshold)     h\u2010CRP   High\u2010sensitivity C\u2010reactive protein     HOMA\u2010B(eta)   Homeostatic model assessment beta\u2010cell function     HOMA\u2010IR   Homeostatic model assessment for insulin resistance     HR   Hazard ratio     ICTRP   International Clinical Trials Registry Platform     IEC   International Expert Committee     IFG   Impaired fasting glucose     IFG5.6    Intermediate hyperglycaemia with impaired fasting plasma glucose level 5.6\u20136.9 mmol/L at baseline (IFG 5.6 mmol/L threshold)      IFG6.1    Intermediate hyperglycaemia with impaired fasting plasma glucose level 6.1\u20136.9 mmol/L at baseline (IFG 6.1 mmol/L threshold)      IFG/IGT   Combination of both IFG and IGT     i\u2010IFG   Isolated IFG     IGT   Impaired glucose tolerance (intermediate hyperglycaemia defined by IGT: plasma glucose 7.8\u201311.1 mmol/L 2 hours after a 75 g OGTT at baseline)      i\u2010IGT   Isolated IGT     IQR   Interquartile range     IRR   Incidence rate ratio     JDS   Japanese Diabetes Society     M   Men     NCEP   National cholesterol education program     NDDG   National Diabetes Data Group     NGSP   National Glycohemoglobin Standardization Program     NGT   Normal glucose tolerance     OGTT   Oral glucose tolerance test     OR   Odds ratio     PG   Postload glucose     QUIPS   Quality In Prognosis Studies tool     ROC   Receiver operating characteristics     RR   Risk ratio, relative risk     SD   Standard deviation     SE   Standard error     T2DM   Type 2 diabetes mellitus     W   Women     WHO   World Health Organization     \u03b3\u2010GT   Gamma\u2010glutamyl transferase/transpeptidase",
        "Appendix 2. Search strategies": "Search strategy overview      Tier 1: prediabetes as predictor for CVD, mortality, stroke, cancer, micro/macrovascular complications  ( 1. Population block (prediabetes AND prognosis filter) OR 2. Prediabetes risk factors / diagnostic criteria block ((IFG, IGT, HbA1c) ADJ6 prognosis terms)  ) AND 3. Outcomes block (diabetes complications, micro/macrovascular, mortality) Tier 2: prediabetes as predictor for diabetes incidence  ( 1. Population block (prediabetes AND prognosis filter) OR 2. Prediabetes risk factors / diagnostic criteria block ((IFG, IGT, HbA1c) ADJ6 prognosis terms)  ) AND 3. Outcomes block (diabetes incidence)     MEDLINE (Ovid SP)      Whole strategy (combining tier 1: 'prediabetes' as predictor for cardiovascular disease, mortality, stroke, cancer, micro/macrovascular complications and tier 2: 'prediabetes' as predictor for diabetes incidence)  1. Prediabetic state/ 2. (prediabet* or pre diabet*).tw. 3. intermediate hyperglyc?emi*.tw. 4. or/1\u20103 5. incidence.sh. or exp mortality/ or follow\u2010up studies.sh. or prognos*.tw. or predict*.tw. or course*.tw. [Wilczynski 2004: MEDLINE prognosis filter sensitivity maximizing]  6. prognosis/ or diagnosed.tw. or cohort*.mp. or predictor*.tw. or death.tw. or exp models, statistical/ [Wilczynski 2004: MEDLINE prognosis filter best balance]  7. or/5\u20106 8. 4 and 7 [population block (prediabetes + prognosis filter)]  9. ((impaired fasting adj2 glucose) or IFG or (impaired adj FPG)).tw. 10. (impaired glucose tolerance or IGT).tw. 11. (\"HbA(1c)\" or HbA1 or HbA1c or \"HbA 1c\" or ((glycosylated or glycated) adj h?emoglobin)).tw. 12. or/9\u201011 13. (predict* or associa* or prognos*).tw. 14. ((prognostic or predict*) adj2 model?).tw. 15. predictive value?.tw. 16. (risk adj (predict* or factor? or score)).tw. 17. or/13\u201016 18. (((impaired fasting adj2 glucose) or IFG or \"impaired FPG\" or impaired glucose tolerance or IGT or \"HbA(1c)\" or HbA1 or HbA1c or \"HbA 1c\" or ((glycosylated or glycated) adj h?emoglobin)) adj3 (predict* or associa* or prognos* or ((prognostic or predict*) adj2 model?) or predictive value? or (risk adj (predict* or factor? or score)))).tw. [12 adj3 17 // risk factor block]  19. 8 or 18 [block 1 or block 2]  20. complication?.tw. 21. mortality.tw. 22. (CHD or CVD).tw. 23. (coronary adj2 disease).tw. 24. (coronar* adj (event? or syndrome?)).tw. 25. (heart adj (failure or disease? or attack? or infarct*)).tw. 26. (myocardial adj (infarct* or isch?emi*)).tw. 27. cardiac failure.tw. 28. angina.tw. 29. revasculari*.tw. 30. (stroke or strokes).tw. 31. cerebrovascular.tw. 32. ((brain* or cerebr*) adj (infarct* or isch?emi*)).tw. 33. apoplexy.tw. 34. ((vascular or peripheral arter*) adj disease?).tw. 35. cardiovascular.tw. 36. (neuropath* or polyneuropath*).tw. 37. (retinopath* or maculopath*).tw. 38. (nephropath* or nephrotic or proteinuri* or albuminuri*).tw. 39. ((kidney or renal) adj (disease? or failure or transplant*)).tw. 40. ((chronic or endstage or end stage) adj (renal or kidney)).tw. 41. (CRD or CRF or CKF or CRF or CKD or ESKD or ESKF or ESRD or ESRF).tw. 42. (microvascular or macrovascular or ((micro or macro) adj vascular)).tw. 43. (cancer or carcino* or neoplas* or tumo?r?).tw. 44. (amputation? or ulcer* or foot or feet or wound*).tw. 45. or/20\u201044 [tier 1 strategy outcomes block]  46. 19 and 45 47. ((diabet* or type 2 or type II or T2D*) adj4 (progress* or inciden* or conversion or develop* or future)).tw. [tier 2 strategy outcomes block]  48. 19 and 47 49. 46 or 48 50. exp animals/ not humans/ 51. 49 not 50 52. (gestational or PCOS).tw. 53. 51 not 52 54. (comment or letter or editorial).pt. 55. 53 not 54 56. remove duplicates from 55     Embase (Ovid SP)      Whole strategy (combining tier 1: 'prediabetes' as predictor for cardiovascular disease, mortality, stroke, cancer, micro/macrovascular complications and tier 2: 'prediabetes' as predictor for diabetes incidence)  1. (prediabet* or pre diabet*).tw. 2. intermediate hyperglyc?emi*.tw. 3. or/1\u20102 4. exp disease course or risk*.mp. or diagnos*.mp. or follow\u2010up.mp. or ep.fs. or outcome.tw. [Wilczynski 2005: Embase prognosis filter sensitivity maximizing]  5. follow\u2010up.mp. or prognos*.tw. or ep.fs. [Wilczynski 2005: Embase prognosis filter best balance]  6. or/4\u20105 7. 3 and 6 [population block (prediabetes + prognosis filter)]  8. ((impaired fasting adj2 glucose) or IFG or (impaired adj FPG)).tw. 9. (impaired glucose tolerance or IGT).tw. 10. (\"HbA(1c)\" or HbA1 or HbA1c or \"HbA 1c\" or ((glycosylated or glycated) adj h?emoglobin)).tw. 11. or/8\u201010 12. (predict* or associa* or prognos*).tw. 13. ((prognostic or predict*) adj2 model?).tw. 14. predictive value?.tw. 15. (risk adj (predict* or factor? or score)).tw. 16. or/12\u201015 17. (((impaired fasting adj2 glucose) or IFG or \"impaired FPG\" or impaired glucose tolerance or IGT or \"HbA(1c)\" or HbA1 or HbA1c or \"HbA 1c\" or ((glycosylated or glycated) adj h?emoglobin)) adj3 (predict* or associa* or prognos* or ((prognostic or predict*) adj2 model?) or predictive value? or (risk adj (predict* or factor? or score)))).tw. [12 adj3 17 // risk factor block]  18. 7 or 17 [block 1 or block 2]  19. complication?.tw. 20. mortality.tw. 21. (CHD or CVD).tw. 22. (coronary adj2 disease).tw. 23. (coronar* adj (event? or syndrome?)).tw. 24. (heart adj (failure or disease? or attack? or infarct*)).tw. 25. (myocardial adj (infarct* or isch?emi*)).tw. 26. cardiac failure.tw. 27. angina.tw. 28. revasculari*.tw. 29. (stroke or strokes).tw. 30. cerebrovascular.tw. 31. ((brain* or cerebr*) adj (infarct* or isch?emi*)).tw. 32. apoplexy.tw. 33. ((vascular or peripheral arter*) adj disease?).tw. 34. cardiovascular.tw. 35. (neuropath* or polyneuropath*).tw. 36. (retinopath* or maculopath*).tw. 37. (nephropath* or nephrotic or proteinuri* or albuminuri*).tw. 38. ((kidney or renal) adj (disease? or failure or transplant*)).tw. 39. ((chronic or endstage or end stage) adj (renal or kidney)).tw. 40. (CRD or CRF or CKF or CRF or CKD or ESKD or ESKF or ESRD or ESRF).tw. 41. (microvascular or macrovascular or ((micro or macro) adj vascular)).tw. 42. (cancer or carcino* or neoplas* or tumo?r?).tw. 43. (amputation? or ulcer* or foot or feet or wound*).tw. 44. or/19\u201043 [tier 1 strategy outcomes block]  45. 18 and 44 46. ((diabet* or type 2 or type II or T2D*) adj4 (progress* or inciden* or conversion or develop* or future)).tw. [tier 2 strategy outcomes block]  47. 18 and 46 48. 45 or 47 [49\u201053: TSC Portal filter for exclusion of animal references]  49. exp animals/ or exp invertebrate/ or animal experiment/ or animal model/ or animal tissue/ or animal cell/ or nonhuman/  50. human/ or normal human/ or human cell/ 51. 49 and 50 52. 49 not 51 53. 48 not 52 54. (gestational or PCOS).tw. 55. 53 not 54 56. (comment or letter or editorial or conference).pt. 57. 55 not 56 58. remove duplicates from 57     ClinicalTrials.gov (Expert search)      ( prediabetes OR prediabetic OR \"pre diabetes\" OR \"pre diabetic\" OR \"intermediate hyperglycemia\" OR \"intermediate hyperglycaemia\" OR \"intermediate hyperglycemic\" OR \"intermediate hyperglycaemic\" OR \"impaired glucose tolerance\" OR \"impaired fasting glucose\" ) AND ( complication OR complications OR mortality OR CHD OR CVD OR coronary OR heart OR myocardial OR infarct OR infarction OR infarcts OR infarctions OR ischemia OR ischemic OR ischaemia OR ischaemic OR failure OR angina OR revascularization OR revascularisation OR revascularizations OR revascularisations OR stroke OR strokes OR cerebrovascular OR apoplexy OR vascular or peripheral OR cardiovascular OR neuropathy OR neuropathies OR polyneuropathy OR polyneuropathies OR retinopathy OR retinopathies OR maculopathy OR maculopathies OR nephropathy OR nephropathies OR nephrotic OR proteinuria OR proteinuric OR albuminuria OR kidney OR renal OR CRD OR CRF OR CKF OR CRF OR CKD OR ESKD OR ESKF OR ESRD OR ESRF OR microvascular OR macrovascular OR \"micro vascular\" OR \"macro vascular\" OR cancer OR carcinoma OR neoplasm OR neoplasms OR tumor OR tumors OR tumour OR tumours OR amputation OR amputations OR ulcer OR foot OR feet OR wounds OR ( diabetes OR diabetic OR \"type 2\" OR \"type II\" OR T2D OR T2DM ) AND ( progress OR progression OR progressed OR incident OR incidence OR conversion OR developed OR development OR future ) ) [OUTCOME]      ICTRP Search Portal (Standard search)      prediabet* AND prognos* OR prediabet* AND predict* OR prediabet* AND inciden* OR prediabet* AND mortality OR prediabet* AND prevent* OR prediabet* AND progress* OR prediabet* AND develop* OR pre diabet* AND prognos* OR pre diabet* AND predict* OR pre diabet* AND inciden* OR pre diabet* AND mortality OR pre diabet* AND prevent* OR pre diabet* AND progress* OR pre diabet* AND develop* OR impaired glucose tolerance AND prognos* OR impaired glucose tolerance AND predict* OR impaired glucose tolerance AND inciden* OR impaired glucose tolerance AND mortality OR impaired glucose tolerance AND prevent* OR impaired glucose tolerance AND progress* OR impaired glucose tolerance AND develop* OR impaired fasting glucose AND prognos* OR impaired fasting glucose AND predict* OR impaired fasting glucose AND inciden* OR impaired fasting glucose AND mortality OR impaired fasting glucose AND prevent* OR impaired fasting glucose AND progress* OR impaired fasting glucose AND develop* OR HbA* AND prognos* OR HbA* AND predict* OR HbA* AND inciden* OR HbA* AND mortality OR HbA* AND prevent* OR HbA* AND progress* OR HbA* AND develop*     Seed publications (for PubMed's 'similar articles'\u2010algorithm)      24355200[PMID] OR 16873795[PMID] OR 9705020[PMID] OR 25906786[PMID] OR 9363520[PMID] OR 21278140[PMID] OR 21676480[PMID] OR 21300382[PMID] OR 10862313[PMID] OR 18689695[PMID] OR 27596059[PMID] OR 12397006[PMID] OR 18673544[PMID] OR 21307378[PMID] OR 15220202[PMID] OR 22647753[PMID] OR 28258520[PMID] OR 10663216[PMID] OR 20573752[PMID] OR 20622160[PMID] OR 9300248[PMID] OR 2060716[PMID] OR 27459384[PMID] OR 12757990[PMID] OR 10414941[PMID] OR 21335372[PMID] OR 9653617[PMID] OR 20073428[PMID] OR 17309402[PMID] OR 17315136[PMID] OR 14025561[PMID] OR 10466767[PMID] OR 26273669[PMID] OR 28698884[PMID] OR 11311100[PMID] OR 14710970[PMID] OR 27933333[PMID] OR 27543801[PMID] OR 2035513[PMID] OR 12062857[PMID] OR 11978676[PMID] OR 11679461[PMID] OR 19224196[PMID] OR 14693710[PMID] OR 28278309[PMID] OR 17257284[PMID] OR 7859632[PMID] OR 2689122[PMID] OR 10937506[PMID] OR 27515749[PMID] OR 20484131[PMID] OR 26675051[PMID] OR 8866565[PMID] OR 17032347[PMID] OR 11686540[PMID] OR 26606421[PMID] OR 18282630[PMID] OR 8635647[PMID] OR 9243105[PMID] OR 8886564[PMID] OR 7589843[PMID] OR 9028719[PMID] OR 2407581[PMID] OR 28751960[PMID] OR 2912042[PMID] OR 28043048[PMID] OR 11916954[PMID] OR 16344402[PMID] OR 19531260[PMID] OR 19414206[PMID] OR 1216390[PMID] OR 22456865[PMID] OR 22510023[PMID] OR 22955996[PMID] OR 21705064[PMID] OR 21212932[PMID] OR 28768835[PMID] OR 9162608[PMID] OR 17000944[PMID] OR 25814432[PMID] OR 9406673[PMID] OR 11110508[PMID] OR 27740930[PMID] OR 24843430[PMID] OR 16518992[PMID] OR 18486512[PMID] OR 29133894[PMID] OR 29380232[PMID] OR 8894485[PMID] OR 28951335[PMID] OR 5226858[PMID] OR 27368062[PMID] OR 16100444[PMID] OR 15223223[PMID] OR 18452257[PMID] OR 27085081[PMID] OR 25245975[PMID] OR 6706044[PMID] OR 20827664[PMID] OR 20536946[PMID] OR 11606173[PMID] OR 10587859[PMID] OR 14967156[PMID] OR 7782724[PMID] OR 9754834[PMID] OR 11079739[PMID] OR 28004008[PMID] OR 17320447[PMID] OR 11772900[PMID] OR 2260546[PMID] OR 26885316[PMID] OR 25215305[PMID] OR 29074816[PMID] OR 18206734[PMID] OR 12590020[PMID] OR 26575606[PMID] OR 22640983[PMID] OR 24135387[PMID] OR 26840038[PMID] OR 24992623[PMID] OR 18485514[PMID] OR 27749572[PMID] OR 14578254[PMID] OR 15616025[PMID] OR 7748921[PMID] OR 17989310[PMID] OR 28371687[PMID] OR 8112189[PMID] OR 12610034[PMID] OR 12765960[PMID] OR 11784224[PMID] OR 9829346[PMID] OR 6702817[PMID] OR 3516770[PMID] OR 18697630[PMID] OR 11437858[PMID] OR 8612442[PMID] OR 8070301[PMID] OR 8454106[PMID] OR 9203444[PMID] OR 12519316[PMID] OR 19414203[PMID] OR 8335178[PMID] OR 1892482[PMID] OR 2261821[PMID] OR 27515716[PMID] OR 15036828[PMID] OR 15983331[PMID] OR 8875091[PMID] OR 8720611[PMID] OR 3751746[PMID] OR 20508383[PMID] OR 17914548[PMID] OR 7497867[PMID] OR 16600415[PMID] OR 23283714[PMID] OR 21738002[PMID] OR 8922541[PMID] OR 25624343[PMID] OR 7481176[PMID] OR 12414877[PMID] OR 11106838[PMID] OR 3527626[PMID] OR 17143605[PMID] OR 18060659[PMID] OR 12627316[PMID] OR 20002472[PMID] OR 17259503[PMID] OR 11068083[PMID] OR 29018885[PMID] OR 3054559[PMID] OR 25350916[PMID] OR 21107436[PMID] OR 7075915[PMID] OR 19131461[PMID] OR 17536075[PMID] OR 18316395[PMID] OR 2752891[PMID] OR 20855549[PMID] OR 20200384[PMID] OR 23497506[PMID] OR 24083174[PMID] OR 10097917[PMID] OR 9405904[PMID] OR 3542644[PMID] OR 20978739[PMID] OR 15189364[PMID] OR 25962707[PMID] OR 27239315[PMID] OR 18226046[PMID] OR 12777437[PMID] OR 12582008[PMID] OR 8314414[PMID] OR 8482427[PMID] OR 6507426[PMID] OR 18535192[PMID] OR 10333940[PMID] OR 16990660[PMID] OR 19046200[PMID] OR 10812323[PMID] OR 10480514[PMID] OR 17536076[PMID] OR 18249214[PMID] OR 20934897[PMID] OR 28632742[PMID] OR 27810987[PMID] OR 18405128[PMID] OR 8680609[PMID] OR 20578203[PMID] OR 16720024[PMID] OR 15451912[PMID] OR 15533586[PMID] OR 21270194[PMID] OR 10333943[PMID] OR 27863979[PMID] OR 11781759[PMID] OR 15175438[PMID] OR 15793193[PMID] OR 11194248[PMID] OR 26913636[PMID] OR 7712700[PMID] OR 14578234[PMID] OR 21718910[PMID] OR 15161800[PMID]",
        "Appendix 3. QUIPS tool signalling questions": "Study ID      Signalling question    Authors' judgement for 'yes'      Study participation: yes/noa/unclearb/NAc       a. Adequate participation in the study by eligible people   NA: usually participants with information on glycaemic status and follow\u2010up data providing information on development of type 2 diabetes are selected from a greater study cohort (e.g. study evaluating several cardiovascular risk factors)      b. Description of the source population or population of interest   Source population for cohort with intermediate hyperglycaemia is clearly described     c. Description of the baseline study sample   Number of people with intermediate hyperglycaemia at baseline is clearly described     d. Adequate description of the sampling frame and recruitment   Way of establishing the source population, selection criteria and key characteristics of the source population clearly described      e. Adequate description of the period and place of recruitment   Time period and place of recruitment for both baseline and follow\u2010up examinations are clearly described      f. Adequate description of inclusion and exclusion criteria   Definiton of people with normoglycaemia, intermediate hyperglycaemia or diabetes mellitus and description of other inclusion and exclusion criteria      Study participation: risk of bias rating (high/low/unclear)    High: most items are answered with 'no'; Low: all items answered with 'yes'; Unclear: most items are answered with 'unclear'  Note: potentially a single item may introduce a high risk of bias, depending on study specifics      Study attrition: yes/no/unclear/NA      a. Adequate response rate for study participants   NA: usually participants with information on glycaemic status and follow\u2010up data providing information on development of type 2 diabetes are selected from a greater study cohort (e.g. study evaluating several cardiovascular risk factors)      b. Attempts to collect information on participants who dropped out described   Attempts to collect information on participants who dropped out are described (e.g. telephone contact, mail, registers)      c. Reasons for loss to follow\u2010up provided   Reasons on participants who dropped out are available (e.g. deceased participants between baseline and follow\u2010up, participants moving to another location)      d. Adequate description of participants lost to follow\u2010up   Key characteristics of participants lost to follow\u2010up are described (age, sex, glucose status at baseline, body mass index)      e. No important differences between participants who completed the study and those who did not    Study authors described differences between participants completing the study and those who did not as not important or information provided to judge the differences      Study attrition: risk of bias rating (high/low/unclear)    High: most items are answered with 'no'; Low: all items answered with 'yes'; Unclear: most items are answered with 'unclear'  Note: potentially a single item may introduce a high risk of bias, depending on study specifics      Glycaemic status measurement: yes/no/unclear/NA      a. Clear definition or description provided   Measurements for glycaemic status are provided (e.g. IFG, IGT, elevated HbA1c)     b. Adequately valid and reliable method of measurement   Ideally measurements for glycaemic status are repeated to ensure diagnosis, single measurements are accepted as well; technique for glucose measurement or HbA1c measurement described      c. Continuous variables reported or appropriate cut points used   Standard categories for intermediate hyperglycaemia (FPG 5.6\u20136.9 mmol/L (IFG5.6), FPG 6.1\u20136.9 mmol/L (IFG6.1), 2\u2010h PG 7.8 to < 11.0 mmol/L (IGT), HbA1c 6.0\u20136.4% (HbA1c6.0), HbA1c 5.7\u20136.4% (HbA1c5.7))      d. Same method and setting of measurement used in all study participants   Measurements of glycaemic status are the same for all study participants     e. Adequate proportion of the study sample had complete data   NA: usually participants with information on glycaemic status and follow\u2010up data providing information on development of type 2 diabetes are selected from a greater study cohort (e.g. study evaluating several cardiovascular risk factors)      f. Appropriate methods of imputation were used for missing data   NA: missing laboratory measurements for glycaemic status cannot be reliably imputed     Glycaemic status measurement: risk of bias rating (high/low/unclear)    High: most items are answered with 'no'; Low: all items answered with 'yes'; Unclear: most items are answered with 'unclear'  Note: potentially a single item may introduce a high risk of bias, depending on study specifics      Outcome measurement: yes/no/unclear      a. Clear definition of the outcome provided   Measurement of type 2 diabetes mellitus has to be defined     b. Use of adequately valid and reliable method of outcome measurement   Measurement of type 2 diabetes mellitus: a glucose (FPG, PG) or HbA1c measurement has to be a part of the diagnosis (self\u2010reported diabetes alone will not be accepted)      c. Use of same method and setting of outcome measurement in all study participants   Measurements of type 2 diabetes mellitus are the same for all study participants     Outcome measurement: risk of bias rating (high/low/unclear)    High: most items are answered with 'no'; Low: all items answered with 'yes'; Unclear: most items are answered with 'unclear'  Note: potentially a single item may introduce a high risk of bias, depending on study specifics      Study confounding: yes/no/unclear      a. Measurement of all important confounders   Important confounders are: age, sex, family history of diabetes, 'ethnicity', body mass index, blood pressure and hypertension, smoking and drinking status, socioeconomic status, comedications and comorbidities, physical activity      b. Provision of clear definitions of the important confounders measured   Measurement of confounders has to be clearly described     c. Adequately valid and reliable measurement of all important confounders   Measurement of confounders is valid and reliable     d. Use of same method and setting of confounding measurement in all study participants   Measurements of confounders are the same for all study participants     e. Appropriate imputation methods used for missing confounders (if applicable)   Strategy to impute missing confounder data is described     f. Important potential confounders were accounted for in the study design   Methods section of the publication describes strategy to account for confounders     g. Important potential confounders were accounted for in the analysis   Important confounders are accounted for in multivariable logistic regression and Cox proportional hazards models      Study confounding measurement: risk of bias rating (high/low/unclear)    High: most items are answered with 'no'; Low: all items answered with 'yes'; Unclear: most items are answered with 'unclear'  Note: potentially a single item may introduce a high risk of bias, depending on study specifics      Statistical analysis and reporting: yes/no/unclear/NA      a. Sufficient presentation of data to assess the adequacy of the analytic strategy   Mean or median values, including confidence intervals or standard errors or standard deviations      b. Strategy for model building is appropriate and based on a conceptual framework or model    NA: we do not anticipate conceptual frameworks or explicit model building strategies for this type of research question (focusing on one prognostic factor only)      c. Statistical model is adequate for the study design   Mainly incidence rates, uni\u2010 and multivariate logistic regression, Cox proportional hazard model      d. No selective reporting of results   NA: development of type 2 diabetes mellitus and potentially regression to normoglycaemia from intermediate hyperglycaemia are the only outcomes; if missing the study will be excluded      Statistical analysis and reporting: risk of bias rating (high/low/unclear)    High: most items are answered with 'no'; Low: all items answered with 'yes'; Unclear: most items are answered with 'unclear'  Note: potentially a single item may introduce a high risk of bias, depending on study specifics      aNo: no or no relevant information to answer the signalling question  bUnclear: not enough information to answer signalling question with yes or no cNA (not applicable): signalling question not appropriate for this type of prognostic review  FPG: fasting plasma glucose; HbA1c: glycosylated haemoglobin A1c; IFG: impaired fasting glucose; IGT: impaired glucose tolerance; PG: postload glucose (after an oral glucose tolerance test)",
        "Appendix 4. Major cohort studies": "Cohort study acronym    Full study name      ADDITION   Anglo\u2010Danish\u2010Dutch study of Intensive Treatment in People with Screen Detected Diabetes in Primary Care (Rasmussen 2008)      \u2014   Ansung\u2010Ansan Cohort Study (part of the Korean Genome and Epidemiology Study (KoGES)) \u2010 (Han 2017)      Asturias   Asturias Study (Valdes 2008)      ARIC   Atherosclerosis Risk in Communities study (Warren 2017)      ATTICA   Province of Attica, Greece Study (Filippatos 2016)      AusDiab   Australian Diabetes, Obesity and Lifestyle Study (Magliano 2008)      BLSA   Baltimore Longitudinal Study of Aging (Meigs 2003)      BLSA   Beijing Longitudinal Study on Aging (Liu 2016)      \u2014   Beijing Project as part of the National Diabetes Survey (Wang 2007)      BMES   Blue Mountains Eye Study (Cugati 2007)      \u2014   Botnia Study (Lyssenko 2005)      \u2014   Bruneck Study (Bonora 2011)      CUPS\u201019   Chennai Urban Population Study\u201019 (Mohan 2008)      CURES   Chennai Urban Rural Epidemiology Study (Anjana 2015)      ChinaMUCA   China Multicenter Collaborative Study of Cardiovascular Epidemiology (Liu 2017)      CODAM   Cohort on Diabetes and Atherosclerosis Maastricht (Den Biggelaar 2016)      DESIR   Data from an Epidemiological Study on the Insulin Resistance Syndrome (Gautier 2010)      \u2014   Ely Study (Forouhi 2007)      EPIC\u2010Norfolk cohort   European Prospective Investigation of Cancer Norfolk cohort (Chamnan 2011)      \u2014   Finnish Cohorts of the Seven Countries Study (Stengard 1992)      None   Framingham Heart Study (Levitzky 2008)      GOS   Geelong Osteoporosis Study (De Abreu 2015)      Health ABC   Health, Aging, and Body Composition Study (Lipska 2013)      \u2014   Hoorn Study (Rijkelijkhuizen 2007)      None   Hong Kong Cardiovascular Risk Factor Prevalence Study (Wat 2001)      IRAS   Insulin Resistance Atherosclerosis Study (Hanley 2005)      ICS   Isfahan Cohort Study (baseline survey of the Isfahan Healthy Heart Program) (Sadeghi 2015)      IDPS   Isfahan Diabetes Prevention Study (Janghorbani 2015)      Israel GOH Study   Israel Study of Glucose Intolerance, Obesity and Hypertension (Bergman 2016)      ILSA   Italian Longitudinal Study on Aging (Motta 2010)      \u2014   Japanese American Community Diabetes Study (McNeely 2003)      JPHC Study   Japanese Public\u2010Health Center\u2010based prospective (Diabetes) Study (Noda 2010)      \u2014   Kansai Healthcare Study (Sato 2009)      \u2014   Kinmen Study (Li 2003)      KORA S4/F4   Kooperative Gesundheitsfroschung in der Region Augsburg (Rathmann 2009)      KoGES   Korean Genome Epidemiology Study\u2010Kangwha Study (Song 2015)      \u2014   Kurihashi Lifestyle Cohort Study (Nakagami 2016)      \u2014   Mexico City Diabetes Study (Ferrannini 2009)      MESA   Multi\u2010Ethnic Study of Atherosclerosis (Yeboah 2011)      \u2014   Nauru Study (Dowse 1991)      \u2014   Paris Prospective Study (Charles 1997)      \u2014   Pima Indian Study (Gila River Indian Community) (Wheelock 2016)      \u2014   Pizarra study (Soriguer 2008)      PIFRECV   Programa de Investigaci\u00f3n de Factores de Riesgo de Enfermedad Cardiovascular (Leiva 2014)      \u2014   Rotterdam study (Ligthart 2016)      SALSA   Sacramento Area Latino Study on Aging (Garcia 2016)      SAHS   San Antonio Heart Study (Lorenzo 2003)      \u2014   San Luis Valley Diabetes Study (Marshall 1994)      \u2014   Singapore Impaired Glucose Tolerance Follow\u2010up Study (Wong 2003)      SIMES   Singapore Malay Eye Study (Man 2017)      SDPP   Stockholm Diabetes Prevention Programme (Alvarsson 2009a)     SHS   Strong Heart Study (Wang 2011)      \u2014   Study within the WHO\u2010assisted National Diabetes Programme (Schranz 1989)      SUNSET/HELIUS   Surinamese in the Netherlands: study on health and ethnicity/Healthy life in an urban setting (Admiraal 2014)      TLGS   Tehran Lipid and Glucose Study (Derakhshan 2016)      TOPICS   Toranomon Hospital Health Management Center Study (Heianza 2012)      \u2014   Yonchon study (Shin 1997)      \u2014   Zanjan Healthy Heart Study (Sharifi 2013)",
        "Appendix 5. Definition of normoglycaemia, intermediate hyperglycaemia and incident type 2 diabetes": "Study ID    Normoglycaemia (mmol/L or %)    Intermediate hyperglycaemia (mmol/L or %)    Incident type 2 diabetes (mmol/L or %)    OGTT measurement (glucose load)    OGTT at baseline    OGTT at follow\u2010up    Notes      Admiraal 2014     \u2014   IFG: FPG 5.7\u20136.9   FPG \u2265 7.0; HbA1c \u2265 6.5; self\u2010reported diabetes   \u2014   \u2014   \u2014   \u2014     Aekplakorn 2006     \u2014   IFG: FPG \u2265 5.6 to < 7.0; IGT: 2\u2010h PG \u2265 7.8 to < 11.1   FPG \u2265 7.0; 2\u2010h PG \u2265 11; diagnosis and/or receipt of antihyperglycaemic medication   75 g   Yes   No   \u2014     Ammari 1998     \u2014   IGT: 2\u2010h PG 7.8 to < 11.1 (WHO 1985)   2\u2010h PG \u2265 11.1 (WHO 1985)   75 g   Yes   Yes   \u2014     Anjana 2015     FPG < 5.6 and 2\u2010h PG < 7.8   i\u2010IGT: 2\u2010h PG 7.8\u201311.0 and FPG > 5.6; i\u2010IFG: FPG 5.6\u20136.9 and 2\u2010h PG < 7.8; prediabetes: FPG 5.6\u20136.9 or 2\u2010h PG 7.8\u201311.0 (i\u2010IGT or i\u2010IFG or IFG/IGT)    FPG \u2265 7.0; 2\u2010h PG \u2265 11.1; diagnosed; antihyperglycaemic medication   75 g   Yes   Unclear   \u2014     Bae 2011     \u2014   HbA1c 5.7\u20136.4, HbA1c 6.0\u20136.4   FPG \u2265 7.0; HbA1c \u2265 6.5; history of diabetes; antihyperglycaemic medication   None   None   None   \u2014     Baena\u2010Diez 2011     FPG < 6.1   IFG: 6.1\u20136.9   FPG \u2265 7.0 (measured twice)   \u2014   \u2014   \u2014   \u2014     Bai 1999     \u2014   IGT: 7.8 to < 11.1 (WHO 1985)   2\u2010h PG \u2265 11.1 (WHO 1985)   75 g   Yes   Yes   \u2014     Bergman 2016     FPG < 5.6 + and no antihyperglycaemic medication and 2\u2010h BG < 7.8 (if available)   FPF 5.6\u20137.8 (7.7?); 2\u2010h BG 7.8\u201311.0   FPG \u2265 7.8, 2\u2010h BG \u2265 11.1; self\u2010reported   100 g   Yes   Unclear   \u2014     Bonora 2011     \u2014   HbA1: 6.0\u20136.49; IFG: not defined, probably FPG 5.6\u20136.9   FPG \u2265 7.0; HbA1c \u2265 6.5; diabetes treatment   75 g   Yes   Unclear   \u2014     Cederberg 2010     \u2014   IFG: 6.1\u20136.9, 2\u2010h PG < 7.8; IGT: FPG > 7.0, 2\u2010h PG 7.8 to < 11.1 (WHO 2009); elevated HbA1c: 5.7\u20136.4    2\u2010h PG: \u2265 11.1, confirmed by 2 OGTTs   \u2014   \u2014   \u2014   Diabetes incidence and IFG/IGT not exactly defined     Chamnan 2011     \u2014   HbA1c 6.0\u20136.4   HbA1c \u2265 6.5; reported physician\u2010diagnosed diabetes or diabetes medications; antihyperglycaemic medication; diagnosis through registers    \u2014   \u2014   \u2014   \u2014     Charles 1997     \u2014   IGT: 2\u2010h PG \u2265 7.8 to < 11.1 (WHO 1985)   2\u2010h PG \u2265 11.1 (WHO 1985); physician diagnosed diabetes   75 g   Yes   Yes   2nd and 4th examination     Chen 2003     FPG < 6.1   IFG: FPG 6.1\u20137.0   FPG \u2265 7.0   \u2014   \u2014   \u2014   \u2014     Chen 2017     FPG < 5.6 and 2\u2010h PG < 7.8   IFG: FPG 5.6\u20136.9 + 2\u2010h PG \u2264 7.8; IGT: FPG < 5.6 + 2\u2010h PG 7.8\u201311.0; IFG/IGT: FPG 5.6\u20136.9 + 2\u2010h PG 7.8\u201311.0    FPG \u2265 7.0; 2\u2010h PG \u2265 11.1; previously diagnosed diabetes   75 g   Yes   Unclear   \u2014     Coronado\u2010Malagon 2009     ADA 2007   ADA 2007 (IFG/IGT: 5.6\u20136.9/7.8 to < 11.1)   ADA 2007 (\u2265 7.0/\u2265 11.1)   \u2014   \u2014   \u2014   \u2014     Cugati 2007     \u2014   IFG: FPG 5.6\u20136.9 (originally FPG \u2265 6.1 to < 7.0)   FPG \u2265 7.0; self\u2010reported diabetes history; antihyperglycaemic medication   \u2014   \u2014   \u2014   \u2014     De Abreu 2015     \u2014   IFG: 5.5\u20136.9   FPG \u2265 7.0; self\u2010reported; antihyperglycaemic medication   \u2014   \u2014   \u2014   \u2014     Den Biggelaar 2016     FPG < 6.1 and 2\u2010h PG < 7.8   FPG 6.1\u20136.9; 2\u2010h PG 7.8\u201311.1   FPG \u2265 7.0; 2\u2010h PG \u2265 11.1   75 g   Yes   Unclear   \u2014     Derakhshan 2016     FPG \u2264 5.55 and 2\u2010h PG \u2264 7.77   5.55 \u2264FPG < 7.0; 7.77 \u2264 2\u2010h PG \u2264 11.1; no antihyperglycaemic medication   FPG \u2265 7.0; 2\u2010h PG \u2265 11.1; antihyperglycaemic medication   82.5 g   Yes   Unclear   Glucose monohydrate solution, equivalent to 75 g anhydrous glucose     Dowse 1991     FPG and 2\u2010h PG < 7.8   IGT: FPG < 7.8 and 2\u2010h PG \u2265 7.8 to < 11.1   2\u2010h PG \u2265 11.1 (WHO 1985); FPG \u2265 7.8   75 g   Yes   Yes   \u2014     Ferrannini 2009     \u2014   IFG: FPG 6.1\u20136.9; IGT: FPG < 7.0 and 2\u2010h PG 7.8\u201311.1; i\u2010IFG6.1/i\u2010IFG5.6: 2\u2010h PG < 7.8 and FPG 6.1\u20136.9/5.6\u20136.1; i\u2010IGT/i\u2010IGT6.1/i\u2010IGT5.6    FPG \u2265 7.0; 2\u2010h PG \u2265 11.1   75 g   Yes   Yes   \u2014     Filippatos 2016     \u2014   IFG5.6: FBG 5.6\u20136.9    FBG > 6.9; antihyperglycaemic medication   None   None   None   \u2014     Forouhi 2007     FPG < 5.6   IFG6.1: FPG 6.1\u20136.9 (FPG < 7.0 and 2\u2010h PG < 11.1)  (all) IFG5.6: FPG 5.6\u20136.9    FPG \u2265 7.0; 2\u2010h PG \u2265 11.1; doctor diagnosis or treatment for diabetes   75 g   Yes   Yes   \u2014     Garcia 2016     \u2014   Prediabetes: FBG 5.6\u20136.9   FPG \u2265 7.0; self\u2010reported; antihyperglycaemic medication; diabetes comedication of death    \u2014   \u2014   \u2014   \u2014     Gautier 2010     \u2014   IFG: FPG 5.6\u20136.9   FPG \u2265 7.0; treatment for diabetes (at one of the 3\u2010yearly examinations)   \u2014   \u2014   \u2014   \u2014     Gomez\u2010Arbelaez 2015     \u2014   IFG: \u2265 5.6 to < 7.0; IGT: \u2265 7.8 to < 11.1; HbA1c \u2265 5.7 to \u2264 6.4   FPG \u2265 7.0; OGTT \u2265 11.1; HbA1c \u2265 6.5   OGTT   Yes   Yes   OGTTs from hospital's database     Guerrero\u2010Romero 2006     FPG < 6.1 and 2\u2010h PG < 7.8   IGT: 2\u2010h PG \u2265 7.8 to < 11.1   2\u2010h PG: \u2265 11.1   OGTT   Yes   Yes   OGTT: as baseline and each year during the 5\u2010year follow\u2010up     Han 2017     FPG < 5.6 and 2\u2010h PG < 7.8   IFG: FPG 5.6\u20136.9 and no diagnosis of diabetes IGT: 2\u2010h PG 7.8 to < 11.1 i\u2010IFG5.6: IFG without IGT  i\u2010IGT: IGT without IFG IGT, IGT: IFG + IGT 'Prediabetes': IFG or IGT   FPG \u2265 7.0; 2\u2010h PG \u2265 11.1; HbA1c \u2265 6.5; current antihyperglycaemic treatment   75 g   Yes   Yes   OGTT was performed every 2 years     Hanley 2005     \u2014   IFG,IGT (WHO 1999)   Unclear   75 g   Yes   No   \u2014     Heianza 2012     Absence of IFG or elevated HbA1c   IFG: FPG 5.6\u20136.9 or FPG 6.1\u20136.9; HbA1c 5.7\u20136.4 or 6.0\u20136.4; IFG/HbA1c = 'prediabetes'   FPG \u2265 7.0; HbA1c \u2265 6.5%; self\u2010reported clinician\u2010diagnosed diabetes   \u2014   \u2014   \u2014   \u2014     Inoue 1996     \u2014   IGT: \u2265 7.8 to < 11.1 (presumed WHO 1985)   IGT: \u2265 11.1(presumed WHO 1985)   75 g   Yes   Yes   OGGT was performed every year     Janghorbani 2015     FPG < 5.6 and 2\u2010h PG < 7.8   i\u2010IGT: FPG < 5.6 and 2\u2010h PG 7.8\u201311.1; i\u2010IFG: 5.6\u20136.9 and 2\u2010h PG < 7.8; IFG/IGT: 5.6\u20136.9 and 2\u2010h PG 7.8\u201311.1    FPG \u2265 11.1; antihyperglycaemic medication; 2nd FPG \u2265 7.0; 2\u2010h PG \u2265 11.1   75 g   Yes   Yes   \u2014     Jaruratanasirikul 2016     FPG < 5.6   i\u2010IGT: FPG < 5.6 and 2\u2010h PG 7.8 to < 11.1   FPG > 7.0; 2\u2010h PG \u2265 11.1   1.75 g/kg (maximum 75 g) glucose solution   Yes   No   \u2014     Jeong 2010     \u2014   IFG: FPG \u2265 5.6 to < 7.0; IGT: 2\u2010h PG \u2265 7.8 to < 11.1: 'prediabetes': IFG or IGT   FPG \u2265 7.0; 2\u2010h PG \u2265 11.1   75 g   Yes   Yes   \u2014     Jiamjarasrangsi 2008a     \u2014   IFG: FPG \u2265 5.6 to < 7.0   FPG \u2265 7.0   \u2014   \u2014   \u2014   \u2014     Kim 2005     FPG < 5.0   IFG6.1: FPG 6.1 to < 7.0 (group 4, = 276)  IFG5.6: FPG 5.6 to < 6.1    FPG \u2265 7.0; antihyperglycaemic treatment   \u2014   \u2014   \u2014   \u2014     Kim 2008     \u2014   IFG5.6: FPG 5.6\u20137.0; IFG6.1: FPG 6.1\u20137.0    FPG \u2265 7.0   \u2014   \u2014   \u2014   \u2014     Kim 2014     \u2014   i\u2010IFG: FPG 5.6\u20136.9 and 2\u2010h PG < 7.8; i\u2010IGT: 2\u2010h PG 7.8\u201311.1 and FPG < 5.6; IFG/IGT: combined glucose intolerance; HbA1c: 5.7\u20136.4    FPG \u2265 7.0; 2\u2010h PG \u2265 11.1; HbA1c \u2265 6.5   75 g   Yes   Unclear   \u2014     Kim 2016a     \u2014   FPG 5.6\u20136.9; HbA1c 5.7\u20136.4   FPG \u2265 7.0; HbA1c \u2265 6.5; antihyperglycaemic medications   \u2014   \u2014   \u2014   \u2014     Kleber 2010     \u2014   IGT: 2\u2010h PG > 7.7: IFG: FPG \u2265 5.5 (WHO definition)   ADA 2000   1.75 g/kg body weight (maximum 75 g) flavoured glucose   Yes   \u2014     Kleber 2011     \u2014   IGT: not reported (presumed 7.8\u201311.1)   \"ADA\" (2000 criteria, 2\u2010h PG \u2265 11.1)   1.75 g/kg body weight (max. 75 g)   Yes   Yes      Ko 1999     WHO/NDDG 1979   WHO/NDDG 1979   WHO/NDDG 1979   \u2014   Yes   Yes   \u2014     Ko 2001     FPG < 6.1   IFG: FPG 6.1\u20136.9   FPG \u2265 7.0   75 g   Yes   Yes   Annual OGTTs     Larsson 2000     FPG < 5.3 and 2\u2010h BG < 7.8   i\u2010IFG: BG 5.3\u20135.9 and 2\u2010h BG < 7.8; i\u2010IGT: FPG < 5.3 and 2\u2010h BG 7.8\u201311.0; IFG/IGT: BG 5.3\u20135.9 and 2\u2010h BG 7.8\u201311.0    FPG \u2265 7.0; 2\u2010h PG \u2265 11.1   75 g   Yes   Yes   NGT at baseline vs follow\u2010up: FPG < 5.3 vs < 6.1; FPG 5.3: 15% conversion factor as recommended by the WHO (blood glucose > plasma glucose)      Latifi 2016     \u2014   5.6 \u2264 FPG < 7.0   FPG \u2265 7.0; antihyperglycaemic medication   \u2014   \u2014   \u2014   \u2014     Lecomte 2007     FPG < 6.1; no personal history of diabetes; no hypoglycaemic treatment   IFG6.1: FPG 6.1\u20136.9; no personal history of diabetes; no hypoglycaemic treatment    FPG \u2265 7.0; personal history of diabetes; hypoglycaemic treatment   \u2014   \u2014   \u2014   \u2014     Lee 2016     \u2014   HbA1c 5.7\u20136.4   HbA1c \u2265 6.5   \u2014   \u2014   \u2014   \u2014     Leiva 2014     \u2014   IFG: 5.6\u20137.0 (low range: 5.6\u20136.1; high range: 6.1\u20136.9)   FPG \u2265 7.0 (2 cons. days), HbA1c \u2265 6.5   \u2014   \u2014   \u2014   \u2014     Levitzky 2008     \u2014   IFG5.6: FPG 5.6\u20136.9; IFG6.1: FPG 6.1\u20136.9    FPG \u2265 7.0; antihyperglycaemic medication   \u2014   \u2014   \u2014   \u2014     Li 2003     FPG < 6.1 and 2\u2010h PG < 7.8   i\u2010iFG:FPG 6.1\u20137.0 and 2\u2010h PG < 7.8; i\u2010IGT: FPG < 6.1 and 2\u2010h PG 7.8\u201311.1; IFG/IGT: FPG 6.1\u20137.0 and 2\u2010h PG 7.8\u201311.1    FPG \u2265 7.0; 2\u2010h PG \u2265 11.0; antihyperglycaemic medications   75 g   Yes   Yes   \u2014     Ligthart 2016     FBG \u2264 6.0   FBG > 6.0 and < 7.0; non\u2010fasting BG > 7.7 and < 11.1   FBG \u2265 7.0; non\u2010fasting BG \u2265 11.1; antihyperglycaemic medication   \u2014   \u2014   \u2014   \u2014     Lipska 2013     FPG < 5.6 and HbA1c < 5.7   i\u2010IFG: FPG 5.6\u20136.9 and HbA1c < 5.7; i\u2010HbA1c: 5.7\u20136.4 and FPG > 5.6; IFG and HbA1c: FPG 5.6\u20136.9 and HbA1c 5.7\u20136.4    Single HbA1c \u2265 6.5 (years 2,6,7); self\u2010report of physician diagnosis (annually); antihyperglycaemic agent (years 1,2,4,6,7)    \u2014   \u2014   \u2014   \u2014     Liu 2008     \u2014   IFG 5.6\u20136.9   FPG \u2265 7.0; 2\u2010h PG \u2265 11.0; antihyperglycaemic medication   \u2014   \u2014   \u2014   \u2014     Liu 2014     WHO   IFG; IGT (WHO)   WHO   75 g   Yes   Unclear   \u2014     Liu 2016     \u2014   FPG 6.1\u20136.9   FPG \u2265 7.0; self\u2010reported; antihyperglycaemic medication   \u2014   \u2014   \u2014   \u2014     Liu 2017     FPG 3.9\u20135.5   FG 5.6\u20136.9   FG \u2265 7.0; using insulin/hypoglycaemic agents; self\u2010reported   \u2014   \u2014   \u2014   \u2014     Lorenzo 2003     \u2014   IFG: FPG 6.1\u20136.9; IGT: 2\u2010h PG 7.8 to < 11.1(WHO 1999)   FPG: \u2265 7.0; 2\u2010h PHG: \u2265 11.1 (WHO 1999/1985)   75 g   Yes   Yes   \u2014     Lyssenko 2005     FPG < 6.1   IFG: FPG \u2265 6.1; WHO 1999 criteria   WHO 1999 criteria   75 g   Yes   Yes   \u2014     Magliano 2008     FPG < 6.1 and 2\u2010h PG < 7.8   IFG: FPG 6.1\u20136.9 and 2\u2010h PG < 7.8; IGT: FPG < 7.0 and 2\u2010h PG \u2264 7.8 to < 11.1   FPG \u2265 7.0; 2\u2010h PG \u2265 11.1; current antihyperglycaemic medication   75 g   Yes   Yes   \u2014     Man 2017     Not 'prediabetes', not diabetes   HbA1c 5.7\u20136.4; no self\u2010reported diabetes or antihyperglycaemic medication   Random glucose \u2265 11.1 or HbA1c > 6.4; self\u2010reported history or antihyperglycaemic medication    \u2014   \u2014   \u2014   \u2014     Marshall 1994     \u2014   IGT: 2\u2010h PG \u2265 7.8 to < 11.1 (WHO 1985)   2\u2010h PG \u2265 11.1 (WHO 1985)   75 g   Yes   Yes   \u2014     McNeely 2003     \u2014   IFG: FPG \u2265 6.1 to < 7.0; IGT: 2\u2010h PG \u2265 7.8 to < 11.1   FPG \u2265 7.0; 2\u2010h PG \u2265 11.1; antihyperglycaemic medication prescribed by a physician   75 g   Yes   Yes   \u2014     Meigs 2003     FPG < 6.1 and 2\u2010h PG \u2264 7.8   IFG: FPG 6.1\u20136.9 and 2\u2010h PG \u2264 7.8; IGT: FPG < 6.1 and 2\u2010h PG 7.8\u201311.0; IFG/IGT   FPG \u2265 7.0; 2\u2010h PG \u2265 11.1 (IFG\u2010IGT person: diabetes defined by OGTT)   Before 07/1977: 1.75 g glucose/kg BW, average 143 g; from 07/1977: 40 g/kg body surface area, average 78 g (men) and 68 g (women)    Yes   Yes   Serial OGTTs over subsequent biennial examinations     Mohan 2008     \u2014   IFG: FPG \u2265 6.1 to < 7; IGT: 2\u2010h PG \u2265 7.8 to < 11.1   FPG \u2265 7; 2\u2010h PG \u2265 11.1   75 g   Yes   Yes   \u2014     Motala 2003     Both FPG and 2\u2010h PG < 7.8 (WHO 1985)   IGT: FPG < 7.8 and 2\u2010h PG 7.8 to < 11.1 (WHO 1985)   FPG \u2265 7.8; 2\u2010h PG \u2265 11.1 (WHO 1985)   75 g glucose monohydrate dissolved in 250 mL of water (modified OGTT)   Yes   Yes   \u2014     Motta 2010     FPG < 6.1   IFG: 6.1 to < 7.0   FPG \u2265 7.0   \u2014   Yes    \u2014     Mykk\u00e4nen 1993     FPG and 2\u2010h PG < 7.8   IGT: FPG < 7.8 and 2\u2010h PG 7.8\u201311.1 (WHO 1985)   FPG \u2265 7.8; 2\u2010h PG \u2265 11.1 (WHO 1985)   75 g   Yes   Yes   \u2014     Nakagami 2016     \u2014   HbA1c 5.7\u20136.4, FPG 5.5\u20136.9   FPG \u2265 7.0, HbA1c \u2265 6.5; physician diagnosis of diabetes   \u2014   \u2014   \u2014   \u2014     Nakanishi 2004     FPG < 6.1   IFG: FPG 6.1\u20136.9   FPG \u2265 7.0; antihyperglycaemic medication   \u2014   \u2014   \u2014   \u2014     Noda 2010     \u2014   Taken from table 2: FPG levels: IFG 5.6 and 6.1   FPG \u2265 7.0; HbA1c \u2265 6.1%; self\u2010reported   \u2014   \u2014   \u2014   \u2014     Park 2006     \u2014   IFG: FPG \u2265 5.6   FPG \u2265 7.0   \u2014   \u2014   \u2014   \u2014     Peterson 2017     FPG < 6.1 and 2\u2010h PG < 7.8   IGT: FPG < 7.0 and 2\u2010h PG \u2265 7.8 to < 11.1   FPG \u2265 7.0; 2\u2010h PG \u2265 11.1   \u2014   Yes   Yes   2 standardised OGTT at baseline with about 1 week's interval to verify glucose status     Qian 2012     FPG < 6.1 and 2\u2010h PG < 7.8   i\u2010IFG: 6.1\u20136.9 and 2\u2010h PG < 7.8; i\u2010IGT: < 6.1 and 2\u2010h PG 7.8\u201311.0; IFG/IGT: 6.1\u20136.9 and 2\u2010h PG 7.8\u201311.0    FPG \u2265 7.0; 2\u2010h PG \u2265 11.1   75 g   Yes   Unclear   \u2014     Rajala 2000     2\u2010h PG < 7.8   IGT: 2\u2010h PG 7.8 to < 11.1   2\u2010h PG \u2265 11.1; 2x FPG \u2265 6.7   75 g   Yes   Yes   New cases identified by OGTTs in 1994 and 1996\u20138     Ramachandran 1986     \u2014   IGT: 7.8\u201311.0 (presumed NDDG 1979)   2\u2010h PG > 11.0 (presumed NDDG 1979)   75 g   Yes   Yes   \u2014     Rasmussen 2008     \u2014   IFG (i\u2010IFG): FBG 5.6 to < 6.1 and 2\u2010h BG < 7.8; IGT (i\u2010IGT): FBG < 6.1 and 2\u2010h BG 7.8 to < 11.1; IFG/IGT    FBG \u2265 6.1 or 2\u2010h BG \u2265 11.1   75 g   Yes   Unclear   \u2014     Rathmann 2009     WHO 1999   IFG: FPG 6.1\u20136.9; IGT: 2\u2010h PG 7.8 to < 11.1; 'prediabetes': i\u2010IFG, i\u2010IGT and IFG/IGT   FPG \u2265 7.0; 2\u2010h PG \u2265 11.1; validated physician diagnosis   75 g   Yes   Yes   \u2014     Rijkelijkhuizen 2007     ADA 1997/2003   IFG5.6: FPG 5.6\u20137.0; IFG6.1: FPG 6.1\u20137.0; IGT: 2\u2010h PG 7.8 to < 11.1    FPG \u2265 7.0; 2\u2010h PG: \u2265 11.1   75 g   Yes   Yes   \u2014     Sadeghi 2015     \u2014   IFG: FPG \u2265 5.5 and < 7.0; IGT: 2\u2010h OGTT \u2265 7.8 and < 11.1   FPG > 7.0; 2\u2010h OGTT > 11.1; IFG/IGT; antihyperglycaemic medication   \u2014   Yes   Yes   \u2014     Sasaki 1982     FPG < 7.8 and 2\u2010h PG < 7.8 (WHO 1980)   IGT: FPG < 7.8 and 2\u2010h PG 7.8\u201311.1 (WHO 1980)   FPG \u2265 7.8 or 2\u2010h PG \u2265 11.1 (WHO 1980)   50 g   Yes   Yes   \u2014     Sato 2009     \u2014   (Table 1): IFG: FPG group 6.1\u20136.9; HbA1c\u2010group: 6.0\u20136.4   FPG \u2265 7.0; antihyperglycaemic medication   \u2014   \u2014   \u2014   \u2014     Schranz 1989     \u2014   IGT: 2\u2010h PG \u2265 7.8 to < 11.1 (WHO 1985)   2\u2010h PG \u2265 11.1 (WHO 1985)   OGTT   Yes   Yes   \u2014     Sharifi 2013     \u2014   FPG 5.6\u20137.0   FPG > 7.0 (2 measurements); diabetes diagnosis based on documents   OGTT   Yes (twice)   \u2014   \u2014     Shin 1997     \u2014   Assumed WHO 1985 criteria   \"WHO criteria\"; antihyperglycaemic medication   75 g   Yes   Yes   \u2014     S\u00f6derberg 2004     \u2014   IFG: FPG \u2265 6.1 to < 7.0 and 2\u2010h PG < 7.8; IGT: FPG < 7.0 and 2\u2010h PG \u2265 7.8 to < 11.1   FPG \u2265 7.0; 2\u2010h PG \u2265 11.1   75 g   Yes   Yes   \u2014     Song 2015     \u2014   IFG: FPG 5.6\u20136.9   FPG \u2265 7.0; HbA1c \u2265 6.5; antihyperglycaemic medication   \u2014   \u2014   \u2014   \u2014     Song 2016a     \u2014   IFG: FG 5.6\u20136.9; IGT: 2\u2010h G 7.8\u201311.0   FG \u2265 7.0; 2\u2010h G \u2265 11.0; HbA1c \u2265 6.5; self\u2010reported   75 g   Yes   Yes   100 g steamed bread at follow\u2010up     Soriguer 2008     BG < 5.6 and 2\u2010h BG < 7.8   IFG: BG 5.6\u20136.1 and 2\u2010h BG < 7.8; IGT: BG < 5.6 and 2\u2010h BG 7.8\u201311.1   BG > 6.1 or 2\u2010h BG > 11.1   75 g   Yes   Yes   \u2014     Stengard 1992     \u2014   IGT: 2\u2010h PG 7.8\u201311.1   2\u2010h PG \u2265 11.1 (WHO 1985); antihyperglycaemic medications   75 g   Yes   Yes   \u2014     Toshihiro 2008     FPG < 6.1 and 2\u2010h PG < 7.8   IFG: FPG 6.1\u20136.9 and 2\u2010h PG < 7.8; IGT: FPG < 7.0 and 2\u2010h PG 7.8\u201311.1   FPG \u2265 7.0; 2\u2010h PG > 11.1; non\u2010fasting PG > 11.1   75 g   Yes   Yes   Annual OGTT during the observation period (3.2 years)     Vaccaro 1999     FPG < 5.6; 2\u2010h PG < 6.7; 2\u2010h PG < 6.7   IFG: FPG 5.6\u20136.0; IGT: 2\u2010h PG 6.7\u20139.9   FPG> 6.1; antihyperglycaemic medications; 2\u2010h PG \u2265 10.0   75 g   Yes   No   Retrospective classification; note thresholds (whole blood)     Valdes 2008     FPG < 5.6   IFG5.6: 5.6\u20136.1; IFG6.1: 6.1\u20136.9    FPG \u2265 7.0; 2\u2010h PG \u2265 11.1; clinical diabetes diagnosis; antihyperglycaemic medication, diet    75 g   Yes   Yes   \u2014     Vijayakumar 2017     \u2014   FG 5.6\u20136.9; 2\u2010h PG 7.8\u201311.9; HbA1c 5.7\u20136.4   FPG \u2265 7.0; 2\u2010h PG \u2265 11.1; previous clinical diagnosis   75 g   Yes   Yes   HbA1c new method = \u22120.1916 + (0.9829 \u00d7 HbA1c old method)     Viswanathan 2007     FPG and 2\u2010h PG < 6.1 and < 7.8   IGT: 2\u2010h PG 7.8 to < 11.1   Not defined, presumably by OGTT   75 g   Yes   Yes   All participants underwent a second OGTT to confirm the diagnosis in order to be included in the study; follow\u2010up: a reminder letter was sent every 6 months to participants to undergo an OGTT      Wang 2007     \u2014   IFG: FPG 6.1\u20136.9; IGT: 2\u2010h PG 7.8\u201311.0   FPG \u2265 7.0; 2\u2010h PG \u2265 11.1   75 g   Yes   Unclear   \u2014     Wang 2011     FPG < 5.6; HbA1c < 6.0; no FPG/HbA1c   IFG: 5.6 to < 7.0; HbA1c 6.0 to < 6.5   Diabetes status: FPG \u2265 7.0; antihyperglycaemic medication; HbA1c \u2265 6.5, antihyperglycaemic medication; FPG/HbA1c: \u2265 6.5 or FPG \u2265 7.0 or antihyperglycaemic medication    \u2014   \u2014   \u2014   \u2014     Warren 2017     \u2014   FPG 5.6\u20136.9 (ADA); FG 6.1\u20136.9 (WHO); 2\u2010h 7.8\u201311.0 (ADA); HbA1c 5.7\u20136.4 (ADA); 6.0\u20136.4 (IEC)    Self\u2010report of physician diagnosis; antihyperglycaemic medication reported during a study visit or annual telephone call    75 g   Yes (visit 4)   Unclear   \u2014     Wat 2001     FPG and 2\u2010h PG < 7.8   IGT: FPG < 7.8 and 2\u2010h PG 7.8 to < 11.1   FPG \u2265 7.8; 2\u2010h PG \u2265 11.1   75 g   Yes   Yes   \u2014     Weiss 2005     FPG < 5.6 and 2\u2010h PG < 7.8   IGT: FPG < 5.6 and 2\u2010h PG 7.8\u201311.1   FPG \u2265 7.0; 2\u2010h PG > 11.1; presentation of hyperglycaemia (more than 2 random glucose measurements > 11.1), glucosuria, polydipsia, and polyuria    1.75 g/kg body weight flavoured glucose orally (up to a maximum of 75 g)   Yes   Yes   OGTT was repeated every 18\u201324 months     Wheelock 2016     \u2014   IGT: 2\u2010h PG \u2265 7.8 to < 11.1   FPG \u2265 7.0; 2\u2010h PG \u2265 11.1; previous diagnosis   75 g   Yes   Unclear   Modified OGTT     Wong 2003     \u2014   IGT: 2\u2010h PG \u2265 7.8 to < 11.1   FPG \u2265 7.0; 2\u2010h PG \u2265 11.1; physician diagnosed diabetes   75 g   Yes   Yes   \u2014     Yeboah 2011     FPG < 5.6   IFG: FPG 5.6\u20136.9   FPG > 6.9; antihyperglycaemic medication during examinations 2,3, 4   \u2014   \u2014   \u2014   \u2014     Zethelius 2004     \u2014   IGT: 2\u2010h PG 7.8 to < 11.1   FPG \u2265 7.0; antihyperglycaemic medications   75 g   Yes   No   \u2014     BG: blood glucose; BW: body weight; FPG: fasting plasma glucose; HbA1c: glycosylated haemoglobin A1c; i\u2010IFG: (isolated) impaired fasting glucose; i\u2010IGT: (isolated) impaired glucose tolerance; IFG/IGT: both impaired fasting glucose and impaired glucose tolerance; NDDG: National Diabetes Data Group; NGT: normal glucose tolerance; OGTT: oral glucose tolerance test; PG: postload glucose; WHO: World Health Organization",
        "Appendix 6. Number of participants with and without intermediate hyperglycaemia at baseline": "Study ID    N participants with/without IH    Definitions of IH at baseline      'Prediabetes'a (%)    Elevated HbA1c (%)    IFG (%)    IGT (%)    IFG/HbA1c (%)    IFG/IGT (%)      Admiraal 2014     IFG5.6 total: 111/456    \u2014   \u2014   IFG5.6: Total 24.3 South\u2010Asian Surinamese 34.4 African Surinamese 21.1 \"Ethnic Dutch\" 22.7    \u2014   \u2014   \u2014     Aekplakorn 2006     IFG5.6: 223/2667    \u2014   \u2014   IFG5.6: 8.4    \u2014   \u2014   \u2014     Ammari 1998     IGT: 68   \u2014   \u2014   \u2014   100   \u2014   \u2014     Anjana 2015     'Prediabetes' (i\u2010IFG, i\u2010IGT or both): 299/1376   21.7   \u2014   i\u2010IFG5.6: 4.9    i\u2010IGT: 11.8   \u2014   5.0     Bae 2011     HbA1c5.7: 1791/9723; HbA1c6.0: 412/1791    \u2014   HbA1c5.7: 18.4 HbA1c6.0: 4.2    \u2014   \u2014   \u2014   \u2014     Baena\u2010Diez 2011     IFG6.1: 115    \u2014   \u2014   IFG6.1: 100    \u2014   \u2014   \u2014     Bai 1999     IGT: 252/696   \u2014   \u2014   \u2014   36.2   \u2014   \u2014     Bergman 2016     IGT: 68/853   \u2014   \u2014   \u2014   8   \u2014   \u2014     Bonora 2011     HbA1c6.0: 70/842    \u2014   8.3   \u2014   \u2014   \u2014   \u2014     Cederberg 2010     IFG6.1: 40/553 IGT: 103/553 IFG/IGT: 15/553    \u2014   \u2014   IFG6.1: 7.2    18.7   \u2014   2.7     Chamnan 2011     HbA1c6.0: 370/5735    \u2014   HbA1c6.0: 6.5    \u2014   \u2014   \u2014   \u2014     Charles 1997     IGT: 418/4089; i\u2010IFG6.1: 476/5042    \u2014   \u2014   i\u2010IFG6.1: 9.4    10.2   \u2014   \u2014     Chen 2003     IFG6.1: 156/600    \u2014   \u2014   IFG6.1: 26    \u2014   \u2014   \u2014     Chen 2017     i\u2010IFG5.6: 329/1347 i\u2010IGT: 192/1347 IFG/IGT: 209/1347    \u2014   \u2014   i\u2010IFG5.6: 24.4    i\u2010IGT: 14.2   15.5   \u2014     Coronado\u2010Malagon 2009     'Prediabetes': 217/656   33.1   \u2014   \u2014   \u2014   \u2014   \u2014     Cugati 2007     IFG5.6: 244/2123    \u2014   \u2014   IFG5.6: 11.5    \u2014   \u2014   \u2014     De Abreu 2015     IFG5.6: 187/1167    \u2014   \u2014   IFG5.6: 16    \u2014   \u2014   \u2014     Den Biggelaar 2016     IFG6.1 and/or IGT: 122/476    25.6   \u2014   \u2014   \u2014   \u2014   \u2014     Derakhshan 2016     IFG5.6 and/or IGT: 523/8231    IFG5.6 and/or IGT: 6.4    \u2014   \u2014   \u2014   \u2014   \u2014     Dowse 1991     IGT: 105/1201   \u2014   \u2014   \u2014   8.7   \u2014   \u2014     Ferrannini 2009     i\u2010IFG5.6: 65/1941 i\u2010IFG6.1: 17/1941 IGT: 179/1941 i\u2010IGT(IFG5.6): 57/1941 i\u2010IGT(IFG6.1): 29/1941    \u2014   \u2014   i\u2010IFG5.6: 3.3 i\u2010IFG6.1: 0.9    IGT: 9.2 i\u2010IGT5.6: 2.9 i\u2010IGT6.1: 1.5    \u2014   \u2014     Filippatos 2016     IFG5.6: 279/1485    \u2014   \u2014   IFG5.6: 18.8    \u2014   \u2014   \u2014     Forouhi 2007     IFG6.1: 257/1040  IFG5.6: 633/1040    \u2014   \u2014   IFG5.6: 60.9  IFG6.1: 24.7    \u2014   \u2014   \u2014     Garcia 2016     IFG5.6: 310/1777    \u2014   \u2014   IFG5.5: 17.5   \u2014   \u2014   \u2014     Gautier 2010     IFG5.6: 979    \u2014   \u2014   IFG5.6: 100    \u2014   \u2014   \u2014     Gomez\u2010Arbelaez 2015     'Prediabetes': 186/772 (Men: 61/772, women: 125/772)    24.1   \u2014   \u2014   \u2014   \u2014   \u2014     Guerrero\u2010Romero 2006     IGT: 75/375   \u2014   \u2014   \u2014   20   \u2014   \u2014     Han 2017     i\u2010IFG5.6: 199/7542  i\u2010IGT: 1512/7542 IFG/IGT: 198/7542   \u2014   \u2014   i\u2010IFG5.6: 2.6    i\u2010IGT: 20.0   \u2014   2.6     Hanley 2005     IGT: 274/882   \u2014   \u2014   \u2014   31.6   \u2014   \u2014     Heianza 2012     IFG5.6: 1680/6241 IFG6.1: 380/6241 HbA1c5.7: 822/6241 HbA1c6.0: 203/6241 IFG5.6/HbA1c5.7: 2092/6241    \u2014   HbA1c5.7: 13.2 HbA1c6.0: 3.3    IFG5.6: 26.9 IFG6.1: 6.1    \u2014   33.5   \u2014     Inoue 1996     IGT: 37   \u2014   \u2014   \u2014   100   \u2014   \u2014     Janghorbani 2015     i\u2010IFG5.6: 304/1530 i\u2010IGT: 198/1530 IFG/IGT: 268/1530    \u2014   \u2014   i\u2010IFG5.6: 19.9    i\u2010IGT: 12.9   \u2014   17.5     Jaruratanasirikul 2016     i\u2010IGT: 27/177   \u2014   \u2014   \u2014   i\u2010IGT: 15.3   \u2014   \u2014     Jeong 2010     IFG5.6: 16% IGT: 5.3%    \u2014   \u2014   IFG5.6: 16    5.3   \u2014   \u2014     Jiamjarasrangsi 2008a     IFG5.6: 320/2370    \u2014   \u2014   IFG5.6: 13.5    \u2014   \u2014   \u2014     Kim 2005     IFG6.1: 276/2964    \u2014   \u2014   IFG6.1: 9.3    \u2014   \u2014   \u2014     Kim 2008     IFG total: 1829/7211 IFG5.6: 1335/7211 IFG6.1: 494/7211    \u2014   \u2014   IFG total: 25.4 IFG5.6: 18.5 IFG6.1: 6.9    \u2014   \u2014   \u2014     Kim 2014     i\u2010IFG5.6: 158/406 i\u2010IGT: 65/406 IFG/IGT: 119/406 i\u2010HbA1c5.7: 64/406    \u2014   i\u2010HbA1c5.7: 15.8    i\u2010IFG5.6: 38.9    i\u2010IGT: 16   \u2014   29.3     Kim 2016a     IFG5.6: 3544/17971 HbA1c5.7: 1713/17971 IFG5.6/HbA1c5.7: 1951/17971    \u2014   HbA1c5.7: 9.5    IFG5.6: 19.7    \u2014   10.9   \u2014     Kleber 2010     IGT: 79   \u2014   \u2014   \u2014   100   \u2014   \u2014     Kleber 2011     IGT: 119   \u2014   \u2014   \u2014   100   \u2014   \u2014     Ko 1999     IGT: 123   \u2014   \u2014   \u2014   100   \u2014   \u2014     Ko 2001     IFG6.1: 55/319    \u2014   \u2014   IFG6.1: 17.2    \u2014   \u2014   \u2014     Larsson 2000     i\u2010IFG6.1: 42/265 i\u2010IGT: 66/265 IFG/IGT: 30/265    \u2014   \u2014   i\u2010IFG6.1: 15.8    i\u2010IGT: 24.9   \u2014   11.3     Latifi 2016     IFG5.6: 124/593    \u2014   \u2014   IFG5.6: 20.9    \u2014   \u2014   \u2014     Lecomte 2007     IFG6.1: 743    \u2014   \u2014   IFG6.1: 100    \u2014   \u2014   \u2014     Lee 2016     HbA1c5.7: 3497    \u2014   HbA1c5.7: 100    \u2014   \u2014   \u2014   \u2014     Leiva 2014     IFG6.1: 28/94    \u2014   \u2014   IFG6.1: 29.8    \u2014   \u2014   \u2014     Levitzky 2008     Not reported   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014     Li 2003     i\u2010IFG6.1: 42/644 i\u2010IGT: 118/644 IFG/IGT: 49/644    \u2014   \u2014   i\u2010IFG6.1: 6.5    i\u2010IGT: 18.3   \u2014   7.6     Ligthart 2016     IFG6.1: 1382/10,050    \u2014   \u2014   IFG6.1: 13.8    \u2014   \u2014   \u2014     Lipska 2013     IFG5.6: 189/1690 i\u2010HbA1c5.7: 207/1690 IFG/HbA1c: 169/1690    \u2014   i\u2010HbA1c: 12.2   IFG5.6: 11.2    \u2014   10.0   \u2014     Liu 2008     IFG5.6: 169/1844    \u2014   \u2014   IFG5.6: 9.2    \u2014   \u2014   \u2014     Liu 2014     'Prediabetes' (IFG or IGT): 450/2271   19.8   \u2014   \u2014   \u2014   \u2014   \u2014     Liu 2016     IFG6.1: 222/1857    \u2014   \u2014   IFG6.1: 12.0    \u2014   \u2014   \u2014     Liu 2017     IFG5.6: 3607/18610    \u2014   \u2014   IFG5.6: 19.4    \u2014   \u2014   \u2014     Lorenzo 2003     IFG6.1: 29/1734 IGT: 202/1734    \u2014   \u2014   IFG6.1: 1.7    11.6   \u2014   \u2014     Lyssenko 2005     i\u2010IFG6.1: 263/2115 i\u2010IGT: 250/2115 IFG/IGT: 173/2115    \u2014   \u2014   i\u2010IFG6.1: 12.4    i\u2010IGT: 11.8   \u2014   8.2     Magliano 2008     Not reported   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014     Man 2017     HbA1c5.7: 675/1137    \u2014   HbA1c5.7: 59.4    \u2014   \u2014   \u2014   \u2014     Marshall 1994     IGT: 123   \u2014   \u2014   \u2014   100   \u2014   \u2014     McNeely 2003     5\u20136 years: IFG6.1: 30/465 IGT: 178/465 10 years: IFG6.1: 28/412 IGT: 157/412    \u2014   \u2014   5\u20136 years: IFG6.1: 6.5 10 years: IFG6.1: 6.8    5\u20136 years: 38.3 10 years: 38.1    \u2014   \u2014     Meigs 2003     i\u2010IFG5.6: 126/753 i\u2010IGT(IFG5.6): 115/753 IFG5.6/IGT: 103/753  i\u2010IFG6.1: 20/753 i\u2010IGT(IFG6.1): 218/753 IFG6.1/IGT: 27/753    \u2014   \u2014   i\u2010IFG5.6: 16.7 i\u2010IFG6.1: 2.7    i\u2010IGT5.6: 15.3  i\u2010IGT6.1: 29    \u2014   IFG5.6/IGT: 13.7 IFG6.1/IGT: 3.6      Mohan 2008     IGT: 37/513   \u2014   \u2014   \u2014   7.2   \u2014   \u2014     Motala 2003     IGT: 35/563   \u2014   \u2014   \u2014   6.2   \u2014   \u2014     Motta 2010     IFG6.1: 295/2603    \u2014   \u2014   IFG6.1: 11.3    \u2014   \u2014   \u2014     Mykk\u00e4nen 1993     IGT: 203/892   \u2014   \u2014   \u2014   22.8   \u2014   \u2014     Nakagami 2016     IFG5.6: 467/2267  IFG6.1: 134/2267 HbA1c5.7: 583/2267  HbA1c6.0: 156/2267    \u2014   HbA1c5.7: 25.7  HbA1c6.0: 6.9    IFG5.6: 20.6  IFG6.1: 5.9    \u2014   \u2014   \u2014     Nakanishi 2004     IFG6.1: 246/5588    \u2014   \u2014   IFG6.1: 4.4    \u2014   \u2014   \u2014     Noda 2010     IGF5.6: 558/2207 IFG6.1: 153/2207    \u2014   \u2014   IFG5.6: 25.3 IFG6.1: 6.9    \u2014   \u2014   \u2014     Park 2006     IFG5.6: 321/5296    \u2014   \u2014   IFG5.6: 6.1   \u2014   \u2014   \u2014     Peterson 2017     IGT: 29/74   \u2014   \u2014   \u2014   39.2   \u2014   \u2014     Qian 2012     i\u2010IFG6.1: 46/1042 i\u2010IGT: 120/1042 IFG/IGT: 33/1042    \u2014   \u2014   i\u2010IFG6.1: 4.4    i\u2010IGT:11.5   \u2014   3.2     Rajala 2000     IGT: 100   \u2014   \u2014   \u2014   100   \u2014   \u2014     Ramachandran 1986     IGT: 107   \u2014   \u2014   \u2014   100   \u2014   \u2014     Rasmussen 2008     i\u2010IFG5.6: 607/1510 i\u2010IGT 903/1510    \u2014   \u2014   i\u2010IFG5.6: 40.2    i\u2010IGT: 59.8   \u2014   \u2014     Rathmann 2009     i\u2010IFG6.1: 71/887 i\u2010IGT: 120/887 IFG/IGT: 47/887    \u2014   \u2014   i\u2010IFG6.1: 8    i\u2010IGT: 13.5   \u2014   5.3     Rijkelijkhuizen 2007     IFG5.6: 488/1428 IFG6.1: 149/1428    \u2014   \u2014   IFG5.6: 34.2 IFG6.1: 10.4    \u2014   \u2014   \u2014     Sadeghi 2015     'Prediabetes' (IFG5.6 and/or IGT): 373/2980    12.5   \u2014   \u2014   \u2014   \u2014   \u2014     Sasaki 1982     IGT: 13/207   \u2014   \u2014   \u2014   6.3   \u2014   \u2014     Sato 2009     Unclear   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014     Schranz 1989     IGT: 75/2128   \u2014   \u2014   \u2014   3.5   \u2014   \u2014     Sharifi 2013     IFG5.6: 123    \u2014   \u2014   IFG5.6: 100    \u2014   \u2014   \u2014     Shin 1997     IGT: 153/1193   \u2014   \u2014   \u2014   12.8   \u2014   \u2014     S\u00f6derberg 2004     i\u2010IFG6.1: 87\u201398: 402/6690 87\u201392: 149/3193 92\u201398: 253/3437 IGT: 87\u201398: 1253/6690 87\u201392: 600/3193 92\u201398: 662/3437    \u2014   \u2014   i\u2010IFG6.1: 87\u201398: 6 87\u201392: 4.7 92\u201398: 7.4    87\u201398: 18.9 87\u201392: 18.8 92\u201398: 19.3   \u2014   \u2014     Song 2015     IFG5.6: 321/2467    \u2014   \u2014   IFG5.6: 13    \u2014   \u2014   \u2014     Song 2016a     'Prediabetes': 344   100   \u2014   \u2014   \u2014   \u2014   \u2014     Soriguer 2008     IFG5.6: 56/714 IGT: 54/714 IFG/IGT: 28/714    \u2014   \u2014   IFG5.5: 7.8   7.6   \u2014   3.9     Stengard 1992     IGT: 234/637   \u2014   \u2014   \u2014   36.7   \u2014   \u2014     Toshihiro 2008     IFG6.1: 14/128 IFG and/or IGT: 114/128    IFG and/or IGT: 89.1   \u2014   IFG6.1: 10.9    \u2014   \u2014   \u2014     Vaccaro 1999     i\u2010IFG5.6: 36/1141 i\u2010IGT: 861141 IFG/IGT: 11/1141    \u2014   \u2014   i\u2010IFG5.6: 3.1    i\u2010IGT: 7.5   \u2014   1.0     Valdes 2008     IFG5.6: 114/630  IFG6.1: 52/630 IGT: 50/630    \u2014   \u2014   IFG5.6: 18.1 IFG6.1: 8.3    7.9   \u2014   \u2014     Vijayakumar 2017     IFG5.6 adults: 423/2005  IFG5.6 children: 193/2095  HbA1c5.7 adults: 168/2005 HbA1c5.7 children: 62/2095  IGT adults: 347/2005 IGT children: 170/2095 IFG/IGT adults: 169/2005 IFG/IGT children: 53/2095    \u2014   HbA1c5.7 adults: 8.4 HbA1c5.7 children: 3.0    IFG5.6 adults: 21.1 IFG5.6 children: 9.2    Adults: 17.3 Children: 8.1    \u2014   IFG/IGT adults: 8.4 IFG/IGT children: 2.5      Viswanathan 2007     IGT: 619/1659   \u2014   \u2014   \u2014   37.3   \u2014   \u2014     Wang 2007     IGT: 141/541   \u2014   \u2014   \u2014   26   \u2014   \u2014     Wang 2011     i\u2010IGT total: 135/10 i\u2010IGT men: 29/447 i\u2010IGT women: 106/635    \u2014   \u2014   \u2014   i\u2010IGT total: 12.5 i\u2010IGT men: 6.5 i\u2010IGT women: 16.7    \u2014   \u2014     Warren 2017     IFG5.6: 4112/10844 IFG6.1: 1213/10844 IGT: 2009/7194 HbA1c5.7: 2027/10844  HbA1c6.0: 970/10844    \u2014   HbA1c5.7: 19  HbA1c6.0: 9    IFG5.6: 38 IFG6.1: 11    28   \u2014   \u2014     Wat 2001     IGT: 322   \u2014   \u2014   \u2014   100   \u2014   \u2014     Weiss 2005     i\u2010IGT(IFG5.6): 33/117    \u2014   \u2014   \u2014   i\u2010IGT: 28.2   \u2014   \u2014     Wheelock 2016     IGT: 169/5532   \u2014   \u2014   \u2014   3.1   \u2014   \u2014     Wong 2003     IGT: 291   \u2014   \u2014   \u2014   100   \u2014   \u2014     Yeboah 2011     IFG5.6: 940/6753    \u2014   \u2014   IFG5.6: 13.9    \u2014   \u2014   \u2014     Zethelius 2004     IGT: 201/667   \u2014   \u2014   \u2014   30.1   \u2014   \u2014     aTerm 'prediabetes' as used by study authors (usually defined by various combinations of glycaemic status measurements, e.g. IFG and/or IGT)  FG: fasting glucose; FPG: fasting plasma glucose; HbA1c: glycosylated haemoglobin A1c; HbA1c5.7/6.0 : HbA1c threshold 5.7% or 6.0% (usually reflecting 5.7% to 6.4% and 6.0% to 6.4%, respectively); HbA1c/IFG: both HbA1c and IFG; i\u2010: isolated;IFG 5.6/6.1 : impaired fasting glucose (threshold 5.6 mmol/L or 6.1 mmol/L); IGT: impaired glucose tolerance; IFG/IGT: both IFG and IGT; PG: postload glucose;IH: intermediate hyperglycaemia; T2DM: type 2 diabetes mellitus",
        "Appendix 7. Follow\u2010up time and type of outcome measurement of the development of type 2 diabetes": "Study ID    Length of follow\u2010up    Time\u2010points of measurements    Outcome measurement of the development of T2DM    Notes      Admiraal 2014     10 years   Baseline, follow\u2010up   Incidence, odds ratio   Data for total population/South\u2010Asian Surinamese/African Surinamese/\"Ethnic Dutch\"     Aekplakorn 2006     12 years   Baseline, follow\u2010up   Incidence, odds ratio   \u2014     Ammari 1998     2 years   Baseline, follow\u2010up   Incidence   \u2014     Anjana 2015     Median 9.1 years (IQR 2.6)   Baseline, follow\u2010up   Incidence, incidence rate   \u2014     Bae 2011     4 years (mean 47.2 months)   Baseline, follow\u2010up (partially annually/biannually)   Incidence, incidence rate, hazard ratio   \u2014     Baena\u2010Diez 2011     10 years   Baseline, follow\u2010up   Incidence   \u2014     Bai 1999     1 year   Baseline, follow\u2010up   Incidence   \u2014     Bergman 2016     24 years   Baseline, follow\u2010up   Incidence, odds ratio   Also adjusted for fasting blood glucose; 100 g OGTT     Bonora 2011     15 years   Baseline, follow\u2010up (5, 10, 15 years)   Incidence, incidence rate, hazard ratio   HbA1c category used: 6.0% to 6.49%     Cederberg 2010     Mean 9.7 years (SD 0.7)   Baseline, follow\u2010up   Incidence, risk ratio   Total incident cases = mixture of isolated and combined intermediate glycaemic conditions     Chamnan 2011     Median 3 years   Baseline, follow\u2010up   Incidence, odds ratio   Data for HbA1c 6.0% to 6.4% group, focus on clinically and/or biochemically diagnosed diabetes      Charles 1997     2 years   Baseline, follow\u2010up (5 annual clinical examinations)   Incidence   \u2014     Chen 2003     3 years   Baseline, follow\u2010up   Incidence, odds ratio   Also adjusted for apolipoprotein B     Chen 2017     3 years   Baseline, follow\u2010up   Incidence   \u2014     Coronado\u2010Malagon 2009     1 and 2 years   Baseline, follow\u2010up   Incidence, relative risk   Results are given for year 1/year 2 of follow\u2010up     Cugati 2007     10 years   Baseline, follow\u2010up (5 and 10 years)   Incidence, odds ratio   Odds\u2010ratio, age\u2010and sex\u2010adjusted     De Abreu 2015     10 years   Baseline, follow\u2010up   Incidence, incidence rate, odds ratio   Age\u2010standardised incidence rate; additional covariates: metabolic syndrome, fasting glucose at baseline      Den Biggelaar 2016     7 years   Baseline, follow\u2010up   Incidence   \u2014     Derakhshan 2016     Median 11.7 years (IQR 8.4\u201313.2)   Baseline, follow\u2010up   Incidence rate, hazard ratio   \u2014     Dowse 1991     Approx. 5 years   Baseline, follow\u2010up   Incidence, incidence rate, odds ratio   Incidence rates for the periods 1975/76\u20131982 and 1982\u20131987     Ferrannini 2009     7 years   Baseline, follow\u2010up   Incidence, relative risk   \u2014     Filippatos 2016     10 years   Baseline, follow\u2010up (intermediate 5 \u2010year follow\u2010up)   Incidence, odds ratio   \u2014     Forouhi 2007     10 years   Baseline, follow\u2010up   Incidence, incidence rate, hazard ratio   Cumulative incidence increased across increasing age groups and was higher in men than in women      Garcia 2016     Approx. 9 years   Baseline, follow\u2010up (every 12\u201315 months, max. 6 follow\u2010ups)   Incidence   \u2014     Gautier 2010     9 years   Baseline, follow\u2010up (3\u2010yearly examinations)   Incidence   \u2014     Gomez\u2010Arbelaez 2015     Approx. 2 years   Baseline, follow\u2010up   Incidence, incidence rate   Rate was given in terms of per 100 person\u2010years (recalculated to 1000 person\u2010years)     Guerrero\u2010Romero 2006     5 years   Baseline, follow\u2010up   Incidence, incidence rate   \u2014     Han 2017     12 years   Baseline, follow\u2010up (biannually)   Incidence, incidence rate, hazard ratio   \u2014     Hanley 2005     Average 5.2 years (range 4.5\u20136.6)   Baseline, follow\u2010up   Incidence, odds ratio   \u2014     Heianza 2012     Median 5 years   Baseline, follow\u2010up (annual follow\u2010ups)   Incidence, incidence rate, hazard ratio   Adjusted odds ratios: mean age and sex\u2010adjusted     Inoue 1996     2.5 years   Baseline, follow\u2010up   Incidence   \u2014     Janghorbani 2015     Mean 6.8 years (SD 1.7)   Baseline, follow\u2010up (OGTT at 3\u2010year intervals)   Incidence, incidence rate, hazard ratio   Date for cohort without hypertension     Jaruratanasirikul 2016     3\u20136 years   Baseline, follow\u2010up   Incidence   \u2014     Jeong 2010     5 years   Baseline, follow\u2010up   Odds ratio   Also adjusted for ALAT, ASAT, \u03b3\u2010GT, h\u2010CRP     Jiamjarasrangsi 2008a     Mean 2.6 years (SD 0.97)   Baseline, follow\u2010up (annual follow\u2010ups, 1\u20134 years)   Incidence   \u2014     Kim 2005     5 years   Baseline, follow\u2010up   Incidence, hazard ratio   \u2014     Kim 2008     2 years   Baseline, follow\u2010up   Incidence   \u2014     Kim 2014     Median 46 months   Baseline, follow\u2010up (every 3\u20136 months, up to 9 years)   Incidence   81 participants were diagnosed with diabetes with a conversion rate of 20% (81/406); conversion rates are given within prediabetes groups (e.g. 24/158 i\u2010IFG converters = 15.2%)      Kim 2016a     Mean 5.2 years (range 3.1\u20136.7)   Baseline, follow\u2010up   Incidence, odds ratio   \u2014     Kleber 2010     1 year   Baseline, follow\u2010up   Incidence   \u2014     Kleber 2011     Mean 3.9 years (SD 0.6)   Baseline, follow\u2010up   Incidence   \u2014     Ko 1999     Mean 1.4 years (range 0.9\u20137.6)   Baseline, follow\u2010up (annual OGTTs)   Incidence   \u2014     Ko 2001     Median 1.7 years   Baseline, follow\u2010up (annual OGTTs)   Incidence   \u2014     Larsson 2000     Mean 10 years (SD 1 year 10 months)   Baseline, follow\u2010up   Incidence   \u2014     Latifi 2016     Median 5 years   Baseline, follow\u2010up   Incidence, incidence rate, odds ratio   \u2014     Lecomte 2007     5 years   Baseline, follow\u2010up   Incidence   \u2014     Lee 2016     Mean 3.7 years (SD 2.3)   Baseline, follow\u2010up   Incidence   \u2014     Leiva 2014     6 years   Baseline, follow\u2010up   Incidence, hazard ratio   \u2014     Levitzky 2008     4 years   Baseline, follow\u2010up (approx. 4\u2010year intervals)   Incidence, odds ratio   \u2014     Li 2003     5 years   Baseline, follow\u2010up (examination every 2 years)   Incidence, incidence rate, hazard ratio   Incidence rates for 5\u2010year cumulative incidence; further adjustments for HOMA\u2010IR and HOMA beta\u2010cell      Ligthart 2016     14.7 years   Baseline, follow\u2010up (blood glucose measures approx. every 4 years)   Incidence rate   \u2014     Lipska 2013     7 years   Baseline (year 4), follow\u2010up (years 5,6,7)   Incidence, odds ratio   IFG6.1: sensitivity analysis, analysis for 'ethnicity', sex analysis      Liu 2008     5 years   Baseline, follow\u2010up   Incidence, incidence rate, relative risk   \u2014     Liu 2014     3 years   Baseline, follow\u2010up   Incidence, incidence rate   No exact definition of 'prediabetes' and diabetes incidence     Liu 2016     Median 10.9 years (IQR 8.0\u201315.3)   Baseline, follow\u2010up   Hazard ratio   Subdistribution hazard ratios; also adjusted for self\u2010rated health     Liu 2017     7.8 years   Baseline, follow\u2010up   Odds ratio   \u2014     Lorenzo 2003     7\u20138 years   Baseline, follow\u2010up   Incidence, odds ratio   Also adjusted for NCEP metabolic syndrome definition, fasting insulin     Lyssenko 2005     Median 6 years (range 2\u201312)   Baseline, follow\u2010up (every 2\u20133 years)   Incidence, hazard ratio   1372 persons 1 visit, 392 persons 2 visits, 219 persons 3 visits, 132 persons 4 visits     Magliano 2008     5 years   Baseline, follow\u2010up   Incidence, incidence rate, odds ratio   5\u2010year cumulative incidence rate was standardised to the 1998 Australian population (age and sex\u2010specific incidence rates)      Man 2017     6 years   Baseline, follow\u2010up   Incidence, incidence rate, risk ratio   Male: female, age standardised rate     Marshall 1994     Mean 22.6 months (range 11\u201340)   Baseline, follow\u2010up   Incidence   \u2014     McNeely 2003     10 years   Baseline, follow\u2010up (5\u20136 years and 10 years)   Incidence   \u2014     Meigs 2003     5 years, 10 years   Baseline, follow\u2010up (3 to 10 biennial examinations)   Incidence, incidence rate   \u2014     Mohan 2008     Mean 8 years (SD 1.3)   Baseline, follow\u2010up   Incidence, incidence rate   \u2014     Motala 2003     10 years   Baseline, follow\u2010up   Incidence   \u2014     Motta 2010     3 years   Baseline, follow\u2010up   Incidence   \u2014     Mykk\u00e4nen 1993     Mean 3.5 years (42 months (SD 4))   Baseline, follow\u2010up   Incidence, odds ratio   \u2014     Nakagami 2016     5 years   Baseline, follow\u2010up   Incidence, hazard ratio   \u2014     Nakanishi 2004     7 years   Baseline, follow\u2010up (annual health examinations)   Incidence, incidence rate, relative risk   Also adjusted for all other components of the metabolic syndrome at study entry     Noda 2010     5 years   Baseline, follow\u2010up   Incidence   \u2014     Park 2006     Mean 4.1 years   Baseline, follow\u2010up (annual examinations)   Incidence, incidence rate   \u2014     Peterson 2017     10 years   Baseline, follow\u2010up   Incidence   \u2014     Qian 2012     5 years   Baseline, follow\u2010up   Incidence   \u2014     Rajala 2000     4.6 years (1.9\u20136.4)   Baseline, follow\u2010up (including a separate cohort)   Incidence, incidence rate   \u2014     Ramachandran 1986     Reverters: 3.3 years (SD 2) Converters: 5.1 years (SD 3.5)   Baseline, follow\u2010up (\"periodically\")   Incidence   All individuals were advised a calorie\u2010restricted high carbohydrate high\u2010fibre diet     Rasmussen 2008     3.5 years i\u2010IFG5.6: median 2.5 years i\u2010IGT: median 2.1 years    Baseline, follow\u2010up   Incidence, incidence rate   \u2014     Rathmann 2009     7 years   Baseline, follow\u2010up   Incidence, incidence rate, odds ratio   \u2014     Rijkelijkhuizen 2007     Mean 6.4 years   Baseline, follow\u2010up   Incidence, incidence rate   \u2014     Sadeghi 2015     7 years   Baseline, follow\u2010up (biannual)   Incidence, incidence rate   \u2014     Sasaki 1982     7 years   Baseline, follow\u2010up   Incidence,odds ratio   \u2014     Sato 2009     4 years   Baseline, follow\u2010up   Odds ratio   \u2014     Schranz 1989     6 years   Baseline, follow\u2010up   Incidence   \u2014     Sharifi 2013     7 years   Baseline, follow\u2010up   Incidence   \u2014     Shin 1997     2 years   Baseline, follow\u2010up   Incidence   \u2014     S\u00f6derberg 2004     11 years   Baseline, follow\u2010up   Incidence, incidence rate   Incidence rates are given for periods 1987\u20131992 and 1992\u20131998, stratified by men:women     Song 2015     Median 3.97 years   Baseline, follow\u2010up   Incidence, relative risk   Also adjusted for glucose     Song 2016a     Mean 10.8 years (range 10.5\u201312)   Baseline, follow\u2010up (additional follow\u2010up 2014)   Incidence   \u2014     Soriguer 2008     Mean 6 years   Baseline, follow\u2010up   Incidence, incidence rate, relative risk   \u2014     Stengard 1992     5 years   Baseline, follow\u2010up   Incidence, odds ratio   \u2014     Toshihiro 2008     Mean 3.2 years (SD 0.1)   Baseline, follow\u2010up (annual OGTT)   Incidence   \u2014     Vaccaro 1999     11.5 years   Baseline, follow\u2010up   Incidence, odds ratio   Odds ratios probably unadjusted     Valdes 2008     Mean 6.3 years (5.9\u20136.8)   Baseline, follow\u2010up   Incidence, incidence rate, odds ratio   Also adjusted for 2\u2010h PG     Vijayakumar 2017     Adults median 4.6 years (IQR 2.8\u20137.9 ) Children: median 5.2 years (IQR 2.7\u20139.6)    Baseline, follow\u2010up (examinations every 2 years)   Incidence, incidence rate   Data for adults/children; incidence rate taken from figure 2 (boys:men; girls:women)     Viswanathan 2007     Median 5 years   Baseline, follow\u2010up (reminder to undergo an OGTT every 6 months)   Incidence, odds ratio   Also adjusted for FPG and 2\u2010h PG     Wang 2007     5 years   Baseline, follow\u2010up   Incidence, risk ratio   \u2014     Wang 2011     4 years   Baseline, follow\u2010up   Odds ratio   Unclear which confounders were used in the multivariate model     Warren 2017     Cohort 1 (visit 2): 22 years Cohort 2 (visit 4): 16 years   Baseline, follow\u2010up (3 visits every 3 years, 5th visit 2011\u201313)   Hazard ratio   Data for IFG5.6, IFG6.1, HbA1c5.7, HbA1c6.0, IGT (cohort 2 only)      Wat 2001     2 years   Baseline, follow\u2010up   Incidence   \u2014     Weiss 2005     Mean 20.4 months (SD 10.3)   Baseline, follow\u2010up (biannual)   Incidence   \u2014     Wheelock 2016     Median 12.4 years (IQR 6.0\u201322.9)   Baseline, follow\u2010up (approx. annual intervals for repeated OGTTs)   Incidence   Non\u2010overweight participants with IGT cohort and overweight participants with IGT group     Wong 2003     8 years   Baseline, follow\u2010up   Incidence   Odds ratios from Tai 2004     Yeboah 2011     7.5 years   Baseline, follow\u2010up (3 examinations)   Incidence, hazard ratio   \u2014     Zethelius 2004     7 years   Baseline, follow\u2010up   Odds ratio   Also adjusted for (split) proinsulin, intact insulin     ALAT: alanine aminotransferase; ASAT: aspartate transaminase; FG: fasting glucose; FPG: fasting plasma glucose; h\u2010CRP: high\u2010sensitivity C\u2010reactive protein; HOMA\u2010beta: homeostatic model assessment of beta\u2010cell function; HOMA\u2010IR: homeostatic model assessment of insulin resistance; HbA1c: glycosylated haemoglobin A1c; HbA1c5.7/6.0 : HbA1c threshold 5.7% or 6.0% (usually reflecting 5.7% to 6.4% and 6.0% to 6.4%, respectively); HbA1c/IFG: both HbA1c and IFG; i\u2010: isolated; IFG5.6/6.1 : impaired fasting glucose (threshold 5.6 mmol/L or 6.1 mmol/L); IGT: impaired glucose tolerance; IFG/IGT: both IFG and IGT; IQR: interquartile range; NCEP: national cholesterol education program; OGTT: oral glucose tolerance test; PG: postload glucose; SD: standard deviation; T2DM: type 2 diabetes mellitus; \u03b3\u2010GT: gamma\u2010glutamyl transferase/transpeptidase",
        "Appendix 8. Baseline characteristics (I)": "Study ID    Setting    N participants in original cohort (several phases of the cohort study)    N study sample (several phases of the cohort study)    Notes      Admiraal 2014     Amsterdam, The Netherlands   2975   456   Baseline data for total cohort included in the analyses (N = 456)/South\u2010Asian Surinamese (N = 90)/African Surinamese (N = 190)/\"ethnic Dutch\" (N = 176)      Aekplakorn 2006     Bangkok, Thailand   3499/3245   2667   Baseline data for cohort becoming diabetic (N = 361)     Ammari 1998     Jordan   Unclear   121/68\u2013200/144 (controls)   Few baseline data reported for study population (N = 212)     Anjana 2015     Chennai, India   26,001   3589/2207   Baseline data for cohort becoming diabetic at follow\u2010up (N = 176)     Bae 2011     South Korea   10,959   9723   Baseline data for the total cohort (N = 9723)     Baena\u2010Diez 2011     Barcelona, Spain   2248   168   Baseline data for prediabetic cohort (N = 115)     Bai 1999     Chennai, India   4885/1082   1082/696   Baseline data for the IGT cohort (N = 252)     Bergman 2016     Israel   1970   1037   Baseline data for IGT cohort (N = 24)     Bonora 2011     Bruneck (South Tyrol), Italy   1000   936   No baseline data (except white participants aged > 40 years, N = 919)     Cederberg 2010     Finland   593   553/499   Baseline data for the cohort (total N = 553, men N = 223, women N = 330)     Chamnan 2011     Norfolk (East Anglia), UK   77,630/25,639   6372/5735   Baseline data for HbA1c6.0\u20106.4 cohort (N = 370)      Charles 1997     Paris, France   Unclear   7540 (2nd clinical examination)/4089   Baseline data for individuals with IGT converting to T2DM (N = 32)     Chen 2003     Penghu, Taiwan   1601   1306/600   Baseline data for cohort converting to T2DM (N = 26)     Chen 2017     China   8845   1374   Baseline data for i\u2010IFG/i\u2010IGTand IFG/IGT across age groups < 40 years + > 60 years (data indicate range across groups) (i\u2010IFG < 40 years N = 51 and > 60 years N = 278; i\u2010IGT < 40 years N = 41 and > 60 years N = 151; IFG/IGT: < 40 years N = 34 and > 60 years N = 175)      Coronado\u2010Malagon 2009     Mexico   820   656   Baseline characteristics for the prediabetic cohort (N = 217)     Cugati 2007     Australia, Blue Mountains region   4433/3654   2335 (5 years)/1952 (10 years)/2123 complete data (10 years)   Baseline data for people without diabetes (N = 3437)     De Abreu 2015     Australia   Unclear   1167/395 (IFG5.6)    Baseline data for IFG cohort at baseline (N = 187)     Den Biggelaar 2016     The Netherlands   574/491   476   Baseline data for prediabetic group (N = 122)     Derakhshan 2016     Tehran, Iran   12808   8231   Baseline data for prediabetes group with normal blood pressure     Dowse 1991     Nauru, Micronesia   1497/1201   830 (1982/1987\u2010including 143 nondiabetic person from 1975/76)   No baseline data provided     Ferrannini 2009     Mexico   3505   2282/1963   Baseline characteristics: range across different definitions of prediabetes     Filippatos 2016     Attica, Greece   4056/3042/1875   1485   Baseline data for IFG5.6 cohort (N = 343)      Forouhi 2007     Ely (Cambridgeshire), UK   1571/1122 (phase 1)/912 (phase 2)   683 (phase 3)   Baseline data for IFG6.1 cohort (N = 257)      Garcia 2016     Sacramento (CA), USA   1789   1777   Baseline data for prediabetic cohort (N = 310)     Gautier 2010     France   3817   979   No baseline data     Gomez\u2010Arbelaez 2015     Columbia   2012   772   Baseline data for the total cohort (N = 772)     Guerrero\u2010Romero 2006     Durango, Mexico   Unclear   375   Baseline data for IGT cohort at baseline progressing to T2DM (N = 20); all individuals were counselled on the importance of diet and physical exercise (standard care for the whole cohort)      Han 2017     Ansung\u2010Ansan, South Korea   10,030   7542   Baseline data for i\u2010IFG, i\u2010IGT and IFG/IGT cohort     Hanley 2005     USA   1625   822   Baseline data for diabetic cohort at follow\u2010up (N = 131); participants were recruited from 2 population\u2010based studies: the San Antonio Heart Study and the San Luis Valley diabetes study      Heianza 2012     Japan   32057   6636/6241   Baseline data for total cohort (N = 6241)     Inoue 1996     Gunma (Gyeonggi), Japan   Unclear   Unclear   Baseline data for the IGT cohort (N = 37)     Janghorbani 2015     Isfahan, Iran   3370   1489   Baseline data for i\u2010IFG, i\u2010IGT and IFG/IGT cohort at baseline (N = 770); first\u2010degree relatives of people with T2DM      Jaruratanasirikul 2016     Thailand   181   177 (157)   Baseline data for IGT cohort (N = 27)     Jeong 2010     Dalseong County, South Korea   1806/1599   1474   1287 participants were re\u2010evaluated in 2008 and 187 new participants \"added to the study\"; baseline data for participants with incident diabetes (N = 135)      Jiamjarasrangsi 2008a     Bangkok, Thailand   3989   3243/2370   Baseline data for total cohort becoming diabetic at follow\u2010up (N = 48)     Kim 2005     Seoul, South Korea   20,203/15,936   2964   Baseline data for FPG group 4 (6.1\u20137.0) with baseline and follow\u2010up (N = 276)     Kim 2008     Incheon, South Korea   7510   7211   Baseline data for IFG5.6/IFG6.1 cohort (N = 1335/494)      Kim 2014     Seoul, South Korea   418   418   Baseline data for i\u2010IFG (N = 158)/i\u2010IGT (N = 65)/IFG/IGT (N = 119)/i\u2010HbA1c (N = 64); total (N = 406)      Kim 2016a     Seoul, South Korea   19,356   17,971   2 baseline data cohorts: prediabetes by FPG only and HbA1c only (N = 3544 and N = 1713)      Kleber 2010     Germany   79   79   Baseline data for IGT cohort (N = 79)     Kleber 2011     Germany   128   128   Baseline data for IFG cohort (N = 128)     Ko 1999     Hong Kong   123   123   Baseline data for the IGT cohort (N = 123)     Ko 2001     Hong Kong   657   319   Baseline data for IFG cohort (N = 55)     Larsson 2000     Sweden   1843   265   Baseline data for i\u2010IGT (N = 66)/i\u2010IFG (N = 42)/IFG/IGT (N = 30); 265 follow\u2010up participants were randomly sampled from each glucose tolerance group of the original cohort and invited for follow\u2010up      Latifi 2016     Ahvaz (Khuzestan), Iran   12,514/6640   Unclear/593   Baseline for prediabetic cohort becoming diabetic at follow\u2010up     Lecomte 2007     France   56,650   4532   Baseline data for IFG cohort attending both examinations (N = 743)     Lee 2016     South Korea   6246   5528   Baseline data for the total cohort (N = 3497)     Leiva 2014     Chile   1007   177   Most baseline data for cohort becoming diabetic at follow\u2010up (N = 94 with IFG)     Levitzky 2008     Framingham (MA), USA   Unclear   3634   Baseline data for individuals on first exam, free of cardiovascular disease (N = 4058)     Li 2003     Kinmen, Taiwan   Unclear   644   Baseline data for i\u2010IGT (N = 118)/i\u2010IFG (N = 42)/IFG/IGT (N = 49)     Ligthart 2016     Rotterdam, The Netherlands   14,926/11,740   11,740/10,050   Baseline data for prediabetic cohort (N = 1382)     Lipska 2013     USA   3075   1690   Baseline data for i\u2010IFG (N = 189)/i\u2010HbA1c5.7 (N = 207)/IFG/HbA1c (N = 169)      Liu 2008     Jiang Su province, China   6400/5888   1844   Baseline data for non\u2010diabetic participants (N = 1844); M (N = 788)/W (N = 1056)     Liu 2014     Shanghai, China   4556   3174   Baseline data for the prediabetic cohort converting to T2DM (N = 78)     Liu 2016     Beijing, China   2101   1857   Baseline data for participants without diabetes at baseline (N = 1857)     Liu 2017     China   27,020   23,626/18,610   Baseline data for IFG cohort at baseline (N = 3607)     Lorenzo 2003     San Antonio (TX), USA   2941/2569   1734   Baseline data for cohort converting to T2DM (N = 195)     Lyssenko 2005     Finland   Unclear   2115   Baseline data for IFG\u2010IGT individuals who converted to T2DM (N = 86)     Magliano 2008     Australia   20,347/11,247   6537   Baseline data for cohort becoming diabetic at follow\u2010up (N = 224)     Man 2017     Singapore   3280   1279/1137   Baseline data for incident diabetes cohort (N = 127)     Marshall 1994     Colorado, USA   1321   173/134   Baseline data for IGT cohort converting to T2DM (N = 20)     McNeely 2003     Seattle (WA), USA   518   465 (5 years)/412 (10 years)   Baseline data for cohort converting to T2DM at 5\u20136 years (N = 50) and 10 years (N = 74)      Meigs 2003     Baltimore (MD) and Washington, D.C., USA   Unclear   815/753   Baseline data for the IFG\u2010IGT cohort (N = 265); follow\u2010up time: at least 6 years 77%, at least 10 years 44%, at least 16 years 16%, at least 20 years 4.5%      Mohan 2008     Chennai, India   1061   513   Baseline data for cohort becoming diabetic at follow\u2010up (N = 64)     Motala 2003     Durban (KwaZulu\u2010Natal), South Africa   2479   563   Baseline data for responders (both baseline and follow\u2010up examination) (N = 563)     Motta 2010     Italy   2603   2603   No baseline data provided     Mykk\u00e4nen 1993     Kuopio (Northern Savonia), Finland   1300   1054/892   Baseline data for cohort developing T2DM (N = 69)     Nakagami 2016     Japan   6012   2770/2267   Baseline data for cohort converting to T2DM (N = 99)     Nakanishi 2004     Japan   Unclear/6812   5746   Baseline characteristics for IFG cohort (N = 246)     Noda 2010     Japan   22387   2207   Baseline characteristics for the total cohort (N = 2207)     Park 2006     South Korea   6305   5557   Baseline data for incident diabetic participants with IFG at baseline (N = 40)     Peterson 2017     Sweden   119   87/74/29   Baseline data for IGT cohort (N = 29)     Qian 2012     Shanghai, China   1869   1042   Baseline data for cohort progressing to T2DM (N = 377)     Rajala 2000     Oulo (North Ostrobothnia), Finland   1008/768   183 (1st)/193 (2nd, other group)   Few baseline data for IGT cohort (N = 171)     Ramachandran 1986     Madras, India   Unclear   107   Baseline data for the diabetic cohort at follow\u2010up (N = 39)     Rasmussen 2008     Denmark   1821   1510/1002   Baseline data for IFG (N = 607)/IGT cohort (N = 903)     Rathmann 2009     Augsburg (Bavaria), Germany   2656   1202   Baseline data for total cohort (follow\u2010up participants, age\u2010group 55\u201374 years, N = 887)      Rijkelijkhuizen 2007     The Netherlands   2484/1513   1428   Baseline data for IFG6.1 (N = 149)/IFG5.6 (N = 488)      Sadeghi 2015     Isfahan, Iran   6323   2980   Baseline data for prediabetic cohort becoming diabetic at follow\u2010up (N = 131)     Sasaki 1982     Osaka, Japan   507   207   Baseline data for the IGT cohort (N = 13)     Sato 2009     Japan   12,647   9116/6804   Baseline data for cohort becoming diabetic at follow\u2010up (N = 659)     Schranz 1989     Malta   2128   1422   Baseline data for diabetic cohort at follow\u2010up (N = 166)     Sharifi 2013     Zanjan, Iran   2941   395   Baseline data for active participants (N = 123)     Shin 1997     Yonchon County, South Korea   2520/2293   2248/1193   Baseline data for individuals converting to T2DM (N = 67)     S\u00f6derberg 2004     Mauritius   5083/6616/6291   Unclear   Baseline data for cohort 1987\u20131998 (N = 2631), 10 years follow\u2010up; 3 cohorts 1987\u20131992 (N = 3680), 1992\u20131998 (N = 4178), 1987\u20131998 (N = 2631)      Song 2015     South Korea   4899   2079   Baseline data for prediabetic cohort (men N = 154; women N = 167; total N = 321)     Song 2016a     Shanghai, China   2132   778/526   Baseline data for prediabetic cohort (N = 334)     Soriguer 2008     Pizarra (Andalusia), Spain   1051   824   Baseline data for final sample of follow\u2010up (N = 714)     Stengard 1992     Finland   1711   716/637   Baseline data for IGT cohort converting to T2DM (N = 17)     Toshihiro 2008     Japan   732   128   Baseline data for cohort becoming diabetic at follow\u2010up (N = 36); participants with IFG and/or IGT were given advice about lifestyle modifications once or twice a year      Vaccaro 1999     Naples, Italy   1285/1245   1141/560   Baseline data for total cohort (follow\u2010up examination N = 560)     Valdes 2008     Spain   1626/1034   943/630   Baseline data for IFG5.6\u20136.1 (N = 114)/IFG6.1\u20136.9 (N = 52)      Vijayakumar 2017     Phoenix (AZ), USA   Unclear   2095 (10\u201319 years)/2005 (20\u201339 years)   Baseline data for adults/children with HbA1c 5.7%\u20106.4% (children N = 62, adults N = 168)      Viswanathan 2007     India (probably Chennai)   4084   1659   Baseline data for IGT group (N = 619); participants were given advice on preventive measures such as dietary modifications and regular exercise      Wang 2007     Beijing, China   20,682/1566   902   Baseline data for cohort with incident diabetes and no coronary heart disease (N = 67)      Wang 2011     Arizona/North/South Dakota/Oklahoma, USA   Unclear   2849/1670 (2nd exam)   No baseline data     Warren 2017     USA, 4 communities   15,792   Cohort 1, N = 10844: 1990\u20131992 (FG, HbA1c) as baseline Cohort 2, N = 7194: 1996\u20131998 (FG, 2\u2010h glucose) as baseline   2 different baseline cohorts; 4 prediabetes definitions (visit 2: IFG5.6\u20136.9 N = 4112; HbA1c5.7\u20106.4 N = 2027; visit 4: IFG5.6\u20136.9 N = 2142; IGT N = 2009)      Wat 2001     Hong Kong   2900   434/322   Baseline data for IGT cohort (N = 322)     Weiss 2005     Conneticut, USA   129   117   Baseline data for IGT cohort (N = 33)     Wheelock 2016     Arizona, USA   Unclear   5532   Baseline data for the full cohort (N = 5532); prediabetic cohort = non\u2010overweight (N = 37) + IGT group and overweight + IGT group (N = 132); 5\u201311 years/12\u201319 years      Wong 2003     Singapore   3568   469/291   Baseline data for IGT group (N = 291)     Yeboah 2011     USA   6814   6814/6753   Baseline data for IFG cohort (N = 940)     Zethelius 2004     Uppsala, Sweden   2322/1221/1010   840/667   Baseline data for cohort converting to T2DM (N = 26)     FG: fasting glucose; FPG: fasting plasma glucose; HbA1c: glycosylated haemoglobin A1c; HbA1c5.7/6.0 : HbA1c threshold 5.7% or 6.0% (usually reflecting 5.7% to 6.4% and 6.0% to 6.4%, respectively); HbA1c/IFG: both HbA1c and IFG; i\u2010: isolated; IFG5.6/6.1 : impaired fasting glucose (threshold 5.6 mmol/L or 6.1 mmol/L); IGT: impaired glucose tolerance; IFG/IGT: both IFG and IGT; PG: postload glucose; T2DM: type 2 diabetes mellitus",
        "Appendix 9. Baseline characteristics (II)": "Study ID    Sex, % women    Age (SD), years    'Ethnicity', % white    'Ethnicity', % Arabian/Asian/(Pima) Indians    'Ethnicity', % Hispanic    'Ethnicity', % Black    Family history of diabetes, %    BMI (SD), kg/m2     Notes      Admiraal 2014     59 57 68 51    45 44 44 47    39   20   \u2014   42   55 77 59 38    26.4 25.7 27.4 25.6    Total cohort South\u2010Asian Surinamese African Surinamese \"Ethnic Dutch\" (the Netherlands)      Aekplakorn 2006     19   43.6 (5.0)   \u2014   100   \u2014   \u2014   53   24.8 (3.2)   \u2014     Ammari 1998     \u2014   63% > 40   \u2014   100   \u2014   \u2014   99   \u2014   \u2014     Anjana 2015     61   47 (13.1)   \u2014   100   \u2014   \u2014   47   25.8 (4.3)   \u2014     Bae 2011     25   44.7 (5.4)   \u2014   100   \u2014   \u2014   \u2014   23.8 (2.8)   \u2014     Baena\u2010Diez 2011     52   61.2 (11.8)   \u2014   \u2014   100   \u2014   26   \u2014   \u2014     Bai 1999     35   Mainly 40\u201360+   \u2014   100   \u2014   \u2014   \u2014   \u2014   \u2014     Bergman 2016     38   50.5 (8.3)   42   29   \u2014   47   \u2014   Men: 26.5 (3.8) Women: 26.8 (5.2)    \u2014     Bonora 2011     \u2014   \u2014   100   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014     Cederberg 2010     \u2014   \u2014   100   \u2014   \u2014   \u2014   \u2014   Men: 27.6 (3.5) Women: 27.9 (4.5)    \u2014     Chamnan 2011     54   62.4 (8.2)   100   \u2014   \u2014   \u2014   14   26.6 (4.0)   \u2014     Charles 1997     0   48.8 (1.8)   100   \u2014   \u2014   \u2014   \u2014   27 (4)   \u2014     Chen 2003     49   59.6   \u2014   100   \u2014   \u2014   21   25.7 (3.1)   \u2014     Chen 2017     54\u201358   40\u201367   \u2014   100   \u2014   \u2014   9\u201337   23.8\u201324.8   \u2014     Coronado\u2010Malagon 2009     10   47.9 (8.6)   \u2014   \u2014   100   \u2014   \u2014   26.8 (3.0)   \u2014     Cugati 2007     57   67.4   100   \u2014   \u2014   \u2014   19   26   \u2014     De Abreu 2015     100   53.8 (IQR 44.0\u201364.4)   Mostly white Australians   \u2014   \u2014   \u2014   \u2014   27.7 (IQR 24.3\u201331.4)   \u2014     Den Biggelaar 2016     39   60.8 (IQR 55.3\u201364.9)   100   \u2014   \u2014   \u2014   \u2014   28.0 (IQR 26.5\u201331.2)   \u2014     Derakhshan 2016     56   42.8 (11.7)   \u2014   100   \u2014   \u2014   \u2014   26.9 (4.1)   \u2014     Dowse 1991     \u2014   \u2014   \u2014   100   \u2014   \u2014   \u2014   \u2014   \u2014     Ferrannini 2009     52\u201370   47\u201350   \u2014   \u2014   100   \u2014   27\u201345   29.1\u201330.5   \u2014     Filippatos 2016     35   46.4 (12.4)   100   \u2014   \u2014   \u2014   22   27.4 (4.7)   \u2014     Forouhi 2007     44   55.5 (7.9)   100   \u2014   \u2014   \u2014   \u2014   27.8 (4.6)   \u2014     Garcia 2016     \u2014   69.8 (6.9)   \u2014   \u2014   49   \u2014   \u2014   31.1 (5.6)   \u2014     Gautier 2010     31   30\u201364   100   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014     Gomez\u2010Arbelaez 2015     70   58 (12)   \u2014   \u2014   100   \u2014   \u2014   27.4 (4.6)   \u2014     Guerrero\u2010Romero 2006     \u2014   38   \u2014   \u2014   100   \u2014   \u2014   32.9 (5.6)   \u2014     Han 2017     28 60 33   50.4 (8.3) 53.1 (8.9) 52.4 (8.7)   \u2014   100 100 100   \u2014   \u2014   15 12 15   25.5 (3.4) 24.9 (3.2) 25.4 (3.2)   i\u2010IFG5.6  i\u2010IGT IFG/IGT     Hanley 2005     60   56.2 (7.9)   38   \u2014   36   26   \u2014   \u2014   \u2014     Heianza 2012     25   49.9 (8.7)   \u2014   100   \u2014   \u2014   \u2014   22.8 (2.8)   \u2014     Inoue 1996     \u2014   \u2014   \u2014   100   \u2014   \u2014   \u2014   23.2   \u2014     Janghorbani 2015     \u2014   44.4 42.9  44.1   \u2014   100   \u2014   \u2014   100   29.2 29.0 30.0    i\u2010IFG i\u2010IGT IFG/IGT      Jaruratanasirikul 2016     37   12.4 (2.3)   \u2014   100   \u2014   \u2014   \u2014   35.3 (5.8) BMI SDS: 3.66 (0.86)    \u2014     Jeong 2010     \u2014   61 (9)   \u2014   100   \u2014   \u2014   7   24.6 (3.2)   \u2014     Jiamjarasrangsi 2008a     67   49.5 (12)   \u2014   100   \u2014   \u2014   15   26.9 (0.6)   \u2014     Kim 2005     15   50.7 (7.2)   \u2014   100   \u2014   \u2014   9   24.6 (2.2)   \u2014     Kim 2008     7 5    41 43    \u2014   100   \u2014   \u2014   9 8    24 25    IFG5.6 IFG6.1      Kim 2014     49 57 48 56    60.2 (11.3) 63.0 (11.0)  59.1 (10.1) 59.3 (10.1)   \u2014   100   \u2014   \u2014   29 14 22 16    24.7 (3.0) 23.2 (3.5) 25.1 (3.3) 24.9 (4.7)    i\u2010IFG i\u2010IGT IFG/IGT i\u2010HbA1c      Kim 2016a     24 47    49.5 51.2    \u2014   100   \u2014   \u2014   22 22    24.4 23.9    IFG HbA1c     Kleber 2010     51   13.1 (2.1)   100   \u2014   \u2014   \u2014   \u2014   31.8 (6.3) BMI SDS: 2.56 (0.62)    \u2014     Kleber 2011     53   13.5 (2.1)   100   \u2014   \u2014   \u2014   \u2014   31.7 (6.1)   \u2014     Ko 1999     88   22\u201326   \u2014   100   \u2014   \u2014   \u2014   \u2014   \u2014     Ko 2001     84   37.4 (9.3)   \u2014   100   \u2014   \u2014   38   25.9 (4.0)   \u2014     Larsson 2000     100   66 (2.3)   100   \u2014   \u2014   \u2014   \u2014   24.6 26.2 26.7    i\u2010IGT i\u2010IFG IFG/IGT (age at follow\u2010up)      Latifi 2016     38   46.6 (12.5)   \u2014   100   \u2014   \u2014   80   \u2014   \u2014     Lecomte 2007     0   44.5 (7.5)   100   \u2014   \u2014   \u2014   3   26.4 (3.6)   \u2014     Lee 2016     33   46.1 (8.5)   \u2014   100   \u2014   \u2014   24   24.8 (3.1)   \u2014     Leiva 2014     57   25\u201380   \u2014   \u2014   100   \u2014   \u2014   33.1 (4.3)   \u2014     Levitzky 2008     53   Women: 48 Men: 49   Mainly white   \u2014   \u2014   \u2014   \u2014   Men: 27.3 (3.9) Women: 25.6 (5.4)   \u2014     Li 2003     57 36 53    56.1 48.4 58.9    \u2014   100   \u2014   \u2014   \u2014   24.8 23.8 25.5    i\u2010IGT i\u2010IFG IFG/IGT      Ligthart 2016     51   66.6 (9.4)   92   \u2014   \u2014   \u2014   \u2014   27.9 (4.2)   \u2014     Lipska 2013     33 60 47    76.6 76.7 76.6    82 36 60    \u2014   \u2014   \u2014   \u2014   27.9 27.9 29.0    i\u2010IFG i\u2010HbA1c IFG + HbA1c      Liu 2008     57   Men: 52 Women: 50    \u2014   100   \u2014   \u2014   Men: 6 Women: 8    \u2014   \u2014     Liu 2014     48   68.6 (6.7)   \u2014   100   \u2014   \u2014   \u2014   23.5 (3.0)   \u2014     Liu 2016     \u2010   Men: 70 Women: 69    \u2014   100   \u2014   \u2014   \u2014   \u2014   \u2014     Liu 2017     50   50.9 (9.7)   \u2014   100   \u2014   \u2014   \u2014   24.2 (3.6)   \u2014     Lorenzo 2003     61   47.7 (0.8)   19   \u2014   81   \u2014   46   31.3   \u2014     Lyssenko 2005     50   52 (11)   100   \u2014   \u2014   \u2014   100   \u2014   \u2014     Magliano 2008     49   55.8 (12.0)   85   \u2014   \u2014   \u2014   31   Men: 29.3 (0.4) Women: 29.7 (0.6)    \u2014     Man 2017     57   54.4 (9.7)   \u2014   100   \u2014   \u2014   39   28.5 (5.3)   \u2014     Marshall 1994     75   58.6   40   \u2014   60   \u2014   53   29.2   \u2014     McNeely 2003     52 41   58.9 57.5    100   \u2014   \u2014   60 62   24.9 25.1   5\u20136 years follow\u2010up 10 years follow\u2010up      Meigs 2003     28   61.8 (14)   95   \u2014   \u2014   \u2014   29   \u2265 25: 60%   \u2014     Mohan 2008     \u2014   43 (14)   \u2014   100   \u2014   \u2014   28   24.4 (4.4)   \u2014     Motala 2003     60   36.4 (13.9)   \u2014   100   \u2014   \u2014   45   22.6 (6.0)   \u2014     Motta 2010     \u2014   65\u201384   100   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014     Mykk\u00e4nen 1993     57   68.6   100   \u2014   \u2014   \u2014   29   29   \u2014     Nakagami 2016     27   53 (7)   \u2014   100   \u2014   \u2014   19   24.6 (3.5)   \u2014     Nakanishi 2004     0   49 (5.8)   \u2014   100   \u2014   \u2014   16   24.6 (3.0)   \u2014     Noda 2010     63   Men: 62.4 Women: 61.5   \u2014   100   \u2014   \u2014   \u2014   Men: 24.1 (3.0) Women: 24.2 (3.2)   \u2014     Park 2006     0   36.4 (3.9)   \u2014   100   \u2014   \u2014   \u2014   24.8 (3.0)   \u2014     Peterson 2017     48   61.4 (0.8)   100   \u2014   \u2014   \u2014   \u2014   26.9 (5.4)   \u2014     Qian 2012     \u2014   60 (13)   \u2014   100   \u2014   \u2014   \u2014   24.9 (3.7)   \u2014     Rajala 2000     58   \u2014   100   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014     Ramachandran 1986     31   48   \u2014   100   \u2014   \u2014   49   25.2   \u2014     Rasmussen 2008     43 56    59.9 61.2    100   \u2014   \u2014   \u2014   \u2014   29.1 29.6    IFG IGT     Rathmann 2009     49   63.2 (5.4)   100   \u2014   \u2014   \u2014   23   28.1 (4.0)   \u2014     Rijkelijkhuizen 2007     46 53    62.5 61.5    100   \u2014   \u2014   \u2014   \u2014   27.6 27.0    IFG6.1 IFG5.6      Sadeghi 2015     59   51.3 (9.8)   \u2014   100   \u2014   \u2014   20   29.4 (4.5)   \u2014     Sasaki 1982     54   57.4   \u2014   100   \u2014   \u2014   \u2014   \u2014   \u2014     Sato 2009     0   48.6 (4.2)   \u2014   100   \u2014   \u2014   20   24.7 (3.3)   \u2014     Schranz 1989     56   Women: 59.8 Men: 57.7   100   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014     Sharifi 2013     63   40 (14)   \u2014   100   \u2014   \u2014   \u2014   27.5 (4)   \u2014     Shin 1997     34   59.6   \u2014   100   \u2014   \u2014   6   24.5   \u2014     S\u00f6derberg 2004     56   41.2   \u2014   70   \u2014   30   \u2014   23.9   \u2014     Song 2015     52   56\u201357   \u2014   100   \u2014   \u2014   Men: 10 Women: 22   Men: 25.2 (2.7) Women: 25.8 (3.4)   \u2014     Song 2016a     63   57.2 (10.0)   \u2014   100   \u2014   \u2014   \u2014   \u2014   \u2014     Soriguer 2008     65   45.0 (13.4)   100   \u2014   \u2014   \u2014   58   28.3 (5.2)   \u2014     Stengard 1992     0   70.8 (4.8)   100   \u2014   \u2014   \u2014   \u2014   26.1 (4.2)   \u2014     Toshihiro 2008     0   50.5 (5.8)   \u2014   100   \u2014   \u2014   \u2014   24.9 (3.3)   \u2014     Vaccaro 1999     23   44.1 (4.0)   100   \u2014   \u2014   \u2014   \u2014   26.9 (4.4)   \u2014     Valdes 2008     \u2014   54.8 56.7    100   \u2014   \u2014   \u2014   \u2014   28.2 29.8    IFG5.6 IFG6.1      Vijayakumar 2017     97 79    29.9 14    \u2014   100   \u2014   \u2014   \u2014   39.1 32.0   Adults Children     Viswanathan 2007     39   42.4 (9.8)   \u2014   100   \u2014   \u2014   \u2014   \u2014   \u2014     Wang 2007     46   47.9 (10.7)   \u2014   100   \u2014   \u2014   \u2014   25.2 (3.5)   \u2014     Wang 2011     \u2014   \u2014   \u2014   100   \u2014   \u2014   \u2014   \u2014   \u2014     Warren 2017     48   57.6 (5.7)   \u2014   \u2014   \u2014   25   25   28.9 (5.2)   Data for cohort 1 (IFG5.6)      Wat 2001     57   51    100   \u2014   \u2014   \u2014   25.6   \u2014     Weiss 2005     73   12.5 (2.7)   45   39   12   \u2014   \u2014   36.6 (8.7) BMI z score: 2.42 (0.41)    \u2014     Wheelock 2016     53   11.4 (3.6)   100   100   \u2014   \u2014   \u2014   Percentile: 87.6   \u2014     Wong 2003     53   43.8   \u2014   100   \u2014   \u2014   28   25.2   \u2014     Yeboah 2011     44   64.2 (9.8)   31   15   25   30   \u2014   30.1 (5.7)   \u2014     Zethelius 2004     0   77   100   \u2014   \u2014   \u2014   \u2014   26.7 (3.2)   \u2014     BMI: body mass index; FG: fasting glucose; FPG: fasting plasma glucose; i\u2010HbA1c: (isolated) glycosylated haemoglobin A1c; HbA1c5.7/6.0 : HbA1c threshold 5.7% or 6.0% (usually reflecting 5.7% to 6.4% and 6.0% to 6.4%, respectively); HbA1c/IFG: both HbA1c and IFG; i\u2010: isolated; IFG5.6/6.1 : impaired fasting glucose (threshold 5.6 mmol/L or 6.1 mmol/L); IGT: impaired glucose tolerance; IFG/IGT: both IFG and IGT; IQR: interquartile range; SD: standard deviation; SDS: standard deviation score",
        "Appendix 10. Baseline characteristics (III)": "Study ID    Mean (SD)/median (IQR)/range systolic BP, mmHg    Mean (SD)/median (IQR)/range diastolic BP (SD), mmHg    Smoking: current and/or past, %    Medications, %    Comorbidities, %    Mean (SD)/median (IQR)/range FPG, mmol/L    Mean (SD)/median (IQR)/range 2\u2010h glucose, mmol/L    Mean (SD)/median (IQR)/range HbA1c, %    Notes      Admiraal 2014     \u2014   \u2014   38 26 41 41    \u2014   Hypertension: 26 26 32 19   5.2 5.3 5.2 5.3    \u2014   \u2014   Total cohort South\u2010Asian Surinamese African Surinamese \"Ethnic Dutch\"      Aekplakorn 2006     \u2014   \u2014   42   \u2014   Hypertension: 33   \u2014   \u2014   \u2014   \u2014     Ammari 1998     \u2014   \u2014   \u2014   \u2014   Hypertension: 47   \u2014   \u2014   \u2014   \u2014     Anjana 2015     129 (21)   78 (11)   13   \u2014   \u2014   5.2 (0.6)   8.7 (1.4)   6.2 (0.7)   \u2014     Bae 2011     113 (14)   76 (10)   \u2014   \u2014   \u2014   5.3 (0.5)   \u2014   5.4 (0.3)   \u2014     Baena\u2010Diez 2011     \u2014   \u2014   33   \u2014   Hypercholesterolaemia: 38 Hypertriglyceridaemia: 15 Hypertension: 55    \u2014   \u2014   \u2014   \u2014     Bai 1999     \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014     Bergman 2016     128 (16)   84 (10)   38   \u2014   \u2014   5.2 (0.5)   8.6 (1.0)   \u2014   \u2014     Bonora 2011     \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014     Cederberg 2010     Men: 142 Women: 142    Men: 80 Women: 79    Men: 18 Women: 15    \u2014   \u2014   Men: 5.0 Women: 5.0    Men: 6.8 Women: 7.0    \u2014   \u2014     Chamnan 2011     139 (17)   84 (11)   15   BP lowering: 21 Corticosteroids: 4    \u2014   \u2014   \u2014   \u2014   \u2014     Charles 1997     \u2014   \u2014   \u2014   \u2014   \u2014   6.6 (0.8)   9.3 (0.9)   \u2014   \u2014     Chen 2003     \u2014   \u2014   38   \u2014   Hypertension: 46   \u2014   \u2014   \u2014   \u2014     Chen 2017     \u2014   \u2014   12\u201324   \u2014   Hypertension: 28\u201355   5.1\u20136.1   5.9\u20139.2   \u2014   Range for i\u2010IFG, i\u2010IGT and IFG/IGT cohorts separated by < 40 years and > 60 years     Coronado\u2010Malagon 2009     \u2014   \u2014   \u2014   \u2014   \u2014   5.9 (0.3)   \u2014   \u2014   \u2014     Cugati 2007     146   83   \u2014   \u2014   \u2014   5   \u2014   \u2014   \u2014     De Abreu 2015     128 (IQR 114\u2013140)   79 (IQR 72\u201386)   13   \u2014   Hypertension: 43   5.3 (IQR 5.0\u20135.8)   \u2014   \u2014   \u2014     Den Biggelaar 2016     141 (IQR 132\u2013155)   83 (IQR 78\u201392)   18   \u2014   \u2014   6.0 (IQR 5.5\u20136.3)   8.8 (IQR 7.8\u20139.9)   5.8 (IQR 5.6\u20136.1)   \u2014     Derakhshan 2016     \u2014   \u2014   26   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014     Dowse 1991     \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014     Ferrannini 2009     118\u2013128   71\u201378   \u2014   \u2014   \u2014   4.9\u20136.4   6.7\u20139.5   \u2014   Range for i\u2010IFG5.6, i\u2010IFG6.1, i\u2010IGT, IGT5.6 and IGT6.1 cohorts      Filippatos 2016     127 (17)   82 (10)   62   \u2014   Hypertension: 36 Hypercholesterolaemia: 54   5.9 (0.3)   \u2014   \u2014   \u2014     Forouhi 2007     136 (16)   82 (10)   52   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014     Garcia 2016     \u2014   \u2014   58   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014     Gautier 2010     \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014     Gomez\u2010Arbelaez 2015     \u2014   \u2014   \u2014   \u2014   \u2014   5.2 (0.7)   6.0 (1.8)   6.5 (1.3)   \u2014     Guerrero\u2010Romero 2006     \u2014   \u2014   \u2014   \u2014   Dyslipidaemia: 41 Hypertension: 24    6.4 (0.6)   \u2014   \u2014   \u2014     Han 2017     120 (17) 119 (18) 124 (18)   78 (12) 76 (12) 80 (11)   64 34 59   \u2014   Hypertension: 28 27 36   5.9 (0.3) 4.8 (0.4) 5.9 (0.3)   6.1 (1.2) 8.9 (0.9) 9.3 (0.9)   5.5 (0.4) 5.5 (0.4) 5.7 (0.4)   i\u2010IFG5.6  i\u2010IGT IFG/IGT     Hanley 2005     132 (20)   79 (10)   \u2014   BP lowering: 38 Lipid lowering: 7    \u2014   5.9 (0.7)   8.5 (1.7)   \u2014   \u2014     Heianza 2012     125 (16)   76 (11)   \u2014   \u2014   \u2014   5.3 (0.5)    5.3 (0.3)   \u2014     Inoue 1996     142 (9)   73 (7)   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014     Janghorbani 2015     116\u2013117   76\u201377   \u2014   \u2014   Hypertension: 20\u201323   5.1\u201361   5.9\u20139.2   5.1\u20135.3   Range for i\u2010IFG, i\u2010IGT and IFG/IGT cohorts     Jaruratanasirikul 2016     124 (15)   77 (9)   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014     Jeong 2010     139 (21)   87 (12)   43   \u2014   \u2014   \u2014   \u2014   5.7 (0.5)   \u2014     Jiamjarasrangsi 2008a     \u2014   \u2014   4   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014     Kim 2005     \u2014   \u2014   \u2014   \u2014   \u2014   6.4 (0.2)   \u2014   \u2014   \u2014     Kim 2008     128/132   80/83   \u2014   \u2014   \u2014   5.8/6.4   \u2014   \u2014   \u2014     Kim 2014     127\u2013129   78   20\u201331   \u2014   \u2014   \u2014   \u2014   \u2014   Range for i\u2010IFG, i\u2010IGT, IFG/IGT and i\u2010HbA1c cohorts     Kim 2016a     116\u2013120   72\u201375   24\u201325   \u2014   \u2014   5.1\u20135.9   \u2014   5.3\u20135.8   Range for IFG and HbA1c cohorts     Kleber 2010     120 (16)   73 (13)   \u2014   \u2014   \u2014   5.1 (1.1)   8.5   5.6 (0.7)   \u2014     Kleber 2011     120 (14)   73 (12)   \u2014   \u2014   \u2014   4.8 (0.4)   8.4 (0.6)   \u2014   \u2014     Ko 1999     \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014     Ko 2001     125 (21)   78 (10)   2   \u2014   \u2014   6.5 (0.3)   9.1 (2.1)   6.2 (0.6)   \u2014     Larsson 2000     \u2014   \u2014   \u2014   \u2014   \u2014   4.7/5.5/5.5   8.6/6.8/8.7   \u2014   \u2014     Latifi 2016     \u2014   \u2014   \u2014   \u2014   Hypertension: 40   \u2014   \u2014   \u2014   \u2014     Lecomte 2007     135 (13)   81 (10)   23   \u2014   Hypertension: 48   6.4 (0.2)   \u2014   \u2014   \u2014     Lee 2016     125 (15)   81 (11)   20   \u2014   Hypertension: 22   \u2014   \u2014   5.9 (0.2)   \u2014     Leiva 2014     134 (16)   77 (10)   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014     Levitzky 2008     Women: 122 Men: 127    \u2014   Women: 29 Men: 28    Antihypertensives: Women: 14 Men: 16    Hypertension: Women: 26 Men: 35    \u2014   \u2014   \u2014   \u2014     Li 2003     136\u2013138   85\u201387   \u2014   \u2014   \u2014   5.4\u20136.4   6.8\u20139.1   \u2014   Range for i\u2010IFG, i\u2010IGT and IFG/IGT cohorts     Ligthart 2016     145 (21)   81 (12)   50   BP lowering: 33 Lipid lowering: 18    Stroke: 3 CHD: 8  Hypertension: 64   \u2014   \u2014   \u2014   \u2014     Lipska 2013     140\u2013143   \u2014   54\u201365   \u2014   \u2014   5.1\u20136.1   \u2014   5.3\u20135.9   Range for i\u2010IFG, i\u2010HbA1c and IFG/HbA1c cohorts     Liu 2008     Men: 126 Women: 124    Men: 80 Women: 77    \u2014   \u2014   \u2014   Men: 5.3 Women: 5.4    \u2014   \u2014   \u2014     Liu 2014     132 (16)   82 (8)   \u2014   \u2014   \u2014   5.8 (0.8)   9.2 (1.2)   \u2014   \u2014     Liu 2016     \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014     Liu 2017     128 (21)   81 (11)   37   \u2014   \u2014   5.9 (0.4)   \u2014   \u2014   \u2014     Lorenzo 2003     124   75   \u2014   \u2014   \u2014   5.3   7.6   \u2014   \u2014     Lyssenko 2005     140   85 (11)   \u2014   \u2014   \u2014   6.3 (IQR 5.8\u20136.6)   8.3 (1.6)   5.7 (0.4)   \u2014     Magliano 2008     \u2014   \u2014   48   \u2014   \u2014   6   8   5.5   \u2014     Man 2017     145 (20)   80 (12)   13   \u2014   Hypertension: 74   \u2014   \u2014   \u2014   \u2014     Marshall 1994     \u2014   \u2014   \u2014   \u2014   \u2014   6.1   9.5   \u2014   \u2014     McNeely 2003     139 137    80 80    \u2014   \u2014   \u2014   5.5 5.6    9.0 8.8    \u2014   5\u20136 years follow\u2010up 10 years follow\u2010up     Meigs 2003     \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014     Mohan 2008     127 (19)   81 (11)   \u2014   \u2014   \u2014   4.5 (0.6)   \u2014   \u2014   \u2014     Motala 2003     119 (19)   78 (13)   \u2014   \u2014   \u2014   4.6 (1.8)   6.2 (3.8)   \u2014   \u2014     Motta 2010     \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014     Mykk\u00e4nen 1993     159   84   1   Antihypertensives: 24   Hypertension: 47   6.2   8.4   \u2014   \u2014     Nakagami 2016     134 (18)   82 (12)   35   \u2014   \u2014   6.0 (0.6)   \u2014   6.0 (0.3)   \u2014     Nakanishi 2004     133 (16)   81 (11)   53   \u2014   Dyslipidaemia: 40 Proteinuria: 5 Hypertension: 35    6.4 (0.2)   \u2014   \u2014   \u2014     Noda 2010     \u2014   \u2014   \u2014   \u2014   \u2014   Men: 5.4 Women: 5.2    \u2014   Men: 5.0 Women: 5.1    \u2014     Park 2006     \u2014   \u2014   \u2014   \u2014   \u2014   6.0 (0.3)   \u2014   \u2014   \u2014     Peterson 2017     \u2014   75 (11)   \u2014   \u2014   \u2014   \u2014   \u2014   5.5 (0.4)   \u2014     Qian 2012     126 (21)   81 (12)   \u2014   \u2014   \u2014   5.2 (0.7)   6.1 (1.5)   \u2014   \u2014     Rajala 2000     \u2014   \u2014   \u2014   \u2014   Hypertension: 49   \u2014   \u2014   \u2014   \u2014     Ramachandran 1986     \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014     Rasmussen 2008     140\u2013142   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   Range for IFG and IGT cohorts     Rathmann 2009     133 (19)   80 (10)   49   Lipid lowering: 11   Hypertension: 49   5.5 (0.5)   6.3 (1.7)   5.6 (0.4)   \u2014     Rijkelijkhuizen 2007     139\u2013145   84\u201385   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   Range for IFG5.6 and IFG6.1 cohorts      Sadeghi 2015     127 (21)   81 (11)   14   \u2014   \u2014   5.7 (0.7)   8.4 (1.5)   \u2014   \u2014     Sasaki 1982     \u2014   \u2014   \u2014   \u2014   \u2014   5.6 (0.9)   9.0 (0.9)   \u2014   \u2014     Sato 2009     \u2014   \u2014   91   \u2014   \u2014   6.0 (0.6)   \u2014   5.6 (0.6)   \u2014     Schranz 1989     \u2014   \u2014   \u2014   \u2014   \u2014   Women: 7.2 Men: 6.2    Women: 10.8 Men: 9.7    \u2014   \u2014     Sharifi 2013     130 (12)   79 (8)   5   \u2014   Hypertriglyceridaemia: 48 Hypertension: 25    \u2014   \u2014   \u2014   \u2014     Shin 1997     130   84   \u2014   \u2014   \u2014   6.1   6.7   \u2014   \u2014     S\u00f6derberg 2004     125   77   27   \u2014   \u2014   5.5   6.5   \u2014   \u2014     Song 2015     123\u2013127   76\u201380   2\u201327   \u2014   Dyslipidaemia: 64\u201366 Hypertension: 35\u201344    \u2014   \u2014   5.7\u20135.8   Ranges for male and female cohorts     Song 2016a     134 (20)   85 (12)   23   \u2014   \u2014   6.0 (0.4)   5.9 (1.6)   \u2014   \u2014     Soriguer 2008     \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014     Stengard 1992     156   88   \u2014   \u2014   Hypertension: 53   5.4 (1.1)   9.7 (0.8)   \u2014   \u2014     Toshihiro 2008     126 (12)   81 (10)   47   \u2014   \u2014   6.1 (0.6)   8.8 (1.3)   \u2014   \u2014     Vaccaro 1999     \u2014   \u2014   \u2014   \u2014   \u2014   4.2 (0.8)   4.5 (1.7)   \u2014   \u2014     Valdes 2008     135\u2013144   84\u201392   \u2014   \u2014   \u2014   5.8\u20136.4   6.4\u20137.3   4.9\u20135.1   Ranges for IFG5.6 and IFG6.1 cohorts      Vijayakumar 2017     \u2014   \u2014   \u2014   \u2014   \u2014   A: 5.4/C: 5.2   A: 6.7/C: 6.5   A: 5.8/C: 5.7   \u2014     Viswanathan 2007     \u2014   \u2014   \u2014   \u2014   \u2014   6.1 (0.7)   8.9 (1.0)   \u2014   \u2014     Wang 2007     124 (19)   78 (11)   28   \u2014   Hypertension: 36   5.8 (0.9)   7.4 (1.7)   \u2014   \u2014     Wang 2011     \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014     Warren 2017     \u2014   \u2014   22   \u2014   Hypertension: 38   6.0 (0.4)   \u2014   5.6 (0.4)   Data for cohort 1 (IFG5.6)      Wat 2001     126   78   \u2014   \u2014   \u2014   5.4   8.9   \u2014   \u2014     Weiss 2005     \u2014   \u2014   \u2014   \u2014   \u2014   5.2   8.9   \u2014   \u2014     Wheelock 2016     \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   5.4 (1.2)   \u2014   \u2014     Wong 2003     125   74   24   \u2014   \u2014   5.7   8.9   \u2014   \u2014     Yeboah 2011     132 (21)   74 (11)   50   BP lowering: 56 Lipid lowering (statins): 17    \u2014   6.0 (0.4)   \u2014   \u2014   \u2014     Zethelius 2004     \u2014   \u2014   \u2014   \u2014   \u2014   5.7 (0.7)   7.9 (1.9)   \u2014   \u2014     2\u2010h: 2\u2010h measurement after an OGTT; BP: blood pressure; CHD: coronary heart disease; FG: fasting glucose; FPG: fasting plasma glucose; HbA1c: glycosylated haemoglobin A1c; HbA1c5.7/6.0 : HbA1c threshold 5.7% or 6.0% (usually reflecting 5.7% to 6.4% and 6.0% to 6.4%, respectively); HbA1c/IFG: both HbA1c and IFG; i\u2010: isolated; IFG5.6/6.1 : impaired fasting glucose (threshold 5.6 mmol/L or 6.1 mmol/L);IGT: impaired glucose tolerance; IFG/IGT: both IFG and IGT; IQR: interquartile range; OGTT: oral glucose tolerance test; SD: standard deviation",
        "Appendix 11. Cumulative incidence as the measurement for the development of T2DM": "Study ID (years of follow\u2010up)    Diabetes cumulative incidence      NGT cohort    IFG5.6 cohort    i\u2010IFG5.6 cohort    IFG6.1 cohort    i\u2010IFG6.1 cohort    IGT cohort    i\u2010IGT cohort    IFG/IGT cohort    HbA1c cohort      Admiraal 2014  (10)    Unclear/354   Total cohort: 51/111 (45.9%) Asian 13/31 (41.9%) African 14/40 (35%) \"Ethnic Dutch\" 3/40 (7.5%)    \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014     Aekplakorn 2006  (12)    Unclear/2444   65/223 (29.1%)   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014     Ammari 1998  (2)    10/144 (6.9%)   \u2014   \u2014   \u2014   \u2014   10/68 (14.7%)   \u2014   \u2014   \u2014     Anjana 2015  (9.1)    209/1077 (19.4%)   \u2014   32/67 (47.8%)   \u2014   \u2014   \u2014   86/163 (52.8%)   58/69 (84.1%)   \u2014     Bae 2011  (4)    228/7932 (2.9%)   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   HbA1c5.7: 373/1791 (20.8%)  HbA1c6.0: 187/412 (45.4%)      Baena\u2010Diez 2011  (10)    0 (IFG cohort)   \u2014   \u2014   33/115 (28.7%)   \u2014   \u2014   \u2014   \u2014   \u2014     Bai 1999  (1)    1/444 (0.2%)   \u2014   \u2014   \u2014   \u2014   14/252 (5.6%)   \u2014   \u2014   \u2014     Bergman 2016  (20)    202/739 (27.3%)   \u2014   \u2014   \u2014   \u2014   68/114 (59.6%)   \u2014   \u2014   \u2014     Bonora 2011  (15)    29/710 (4.1%)   \u2014    10 years: 18/55 (32.7%)    \u2014   \u2014   10 years: 8/53 (15.1%)    10 years: 9/19 (47.4%)    HbA1c6.0: 20/70 (28.6%)      Cederberg 2010  (9.7)    11/410 (2.7%)   \u2014   \u2014   15/40 (37.8%)   6.3%   38/103 (37.1%)   23.4%   \u2014   HbA1c5.7: 9/24 (37.5%)      Chamnan 2011  (3)    37/5365 (0.7%)   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   HbA1c6.0: 26/370 (7%)      Charles 1997  (2)    27/3671 (0.7%)   \u2014   \u2014   \u2014   3 years: 15/476 (3.2%)   2 years: 32/418 (7.7%)   \u2014   \u2014   \u2014     Chen 2003  (3)    11/444 (2.5%)   \u2014   \u2014   15/156 (9.6%)   \u2014   \u2014   \u2014   \u2014   \u2014     Chen 2017  (3)    60/644 (9.3%)   \u2014   40/329 (12.2%)   \u2014   \u2014   \u2014   45/192 (23.4%)   71/209 (34%)   \u2014     Coronado\u2010Malagon 2009a  (1, 2)    Year 1: 3/439 (0.7%) Year 2: 3/439 (0.6%)   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014     Cugati 2007  (10)    108/1512 (7.1%)   69/229 (30%)   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014     De Abreu 2015  (10)    11/342 (3.2%)   21/187 (11.2%)   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014     Den Biggelaar 2016b  (7)    17/294 (5.8%)   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014     Derakhshan 2016c  (11.7)    162/3611 (4.5%)   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014     Dowse 1991  (6.2)    14/215 (6.5%)   \u2014   \u2014   \u2014   \u2014   13/51 (25.5%)   \u2014   \u2014   \u2014     Ferrannini 2009  (7)    89/1594 (5.6%)   \u2014   11/65 (16.9%)   \u2014   1/17 (5.9%)   \u2014   31/179 (17.3%) 3 years: 44/188 (23.4%)   \u2014   \u2014     Filippatos 2016  (10)    120/1206 (10.0%)   71/279 (25.4%)   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014     Forouhi 2007  (10)    8/407 (2%)   53/633 (8.3%)   \u2014   34/257 (24.7%)   \u2014   4.4 years: 17/170 (10%)   \u2014   \u2014   \u2014     Garcia 2016  (9)    132/881 (15.0%)   169/310 (54.5%)   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014     Gautier 2010  (9)    0 (IFG cohort)   142/979 (14.5%)   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014     Gomez\u2010Arbelaez 2015d  (2)    Unclear/586   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014     Guerrero\u2010Romero 2006  (5)    1/272 (0.4%)   \u2014   \u2014   \u2014   \u2014   20/67 (29.9%)   \u2014   \u2014   \u2014     Han 2017  (12)    657/5633 (11.7%)   \u2014   81/199 (40.7%)   \u2014   \u2014   \u2014   624/1512 (41.3%)   138/198 (69.7%)   10 years: HbA1c5.7: 881/2830 (31.1%)      Hanley 2005  (5.2)    5 years: 47/603 (7.8%)   \u2014   \u2014   \u2014   \u2014   88/274 (32.1%) 5 years: 101/303 (33.3%)   \u2014   \u2014   \u2014     Heianza 2012  (5)    4.7 years: 34/4149 (0.8%)   262/1680 (15.6%)   \u2014   155/380 (40.8%)   \u2014   \u2014   \u2014   \u2014   HbA1c5.7: 184/822 (22.4%) HbA1c5.7 and IFG5.6: 292/2092 (14%)  HbA1c6.0: 100/203 (49.3%)  HbA1c6.0 and IFG5.6: 271/1748 (15.5%)      Inoue 1996  (2.5)    1/22 (4.5%)   \u2014   \u2014   \u2014   \u2014   5/37 (13.5%)   \u2014   \u2014   \u2014     Janghorbani 2015  (6.8)    14/627 (2.2%)   \u2014   23/230 (10%)   \u2014   \u2014   \u2014   26/150 (17.3%)   78/214 (36.4%)   \u2014     Jaruratanasirikul 2016 (3\u20136)    12/108 (11.1%)   \u2014   \u2014   \u2014   \u2014   \u2014   9/33 (27.3%)   \u2014   \u2014     Jeong 2010e  (5)    228/792 (28.8%)   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014     Jiamjarasrangsi 2008a  (2.6)    15/2050 (0.7%)   33/320 (10.3%)   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014     Kim 2005  (5)    Unclear/2009   \u2014   \u2014   15/276 (5.5%)   \u2014   \u2014   \u2014   \u2014   \u2014     Kim 2008  (2)    21/5382 (0.4%)   22/1335 (1.6%)   \u2014   48/494 (9.7%)   \u2014   \u2014   \u2014   \u2014   \u2014     Kim 2014  (3.8)    0 (cohort with intermediate hyperglycaemia)   \u2014   24/158(15.2%)   \u2014   \u2014   \u2014   12/65 (18.5%)   38/119 (31.9%)   i\u2010HbA1c5.7: 7/64 (10.9%)      Kim 2016a  (5.2)    43/10,763 (0.4%)   \u2014   \u2014   357/1433 (24.9%)   \u2014   \u2014   \u2014   \u2014   HbA1c6.0: 322/1103 (29.2%) IFG5.6 and HbA1c5.7: 435/1951 (22.3%)      Kleber 2010  (1)    0 (IGT cohort)   \u2014   \u2014   \u2014   \u2014   1/79 (1.3%)   \u2014   \u2014   \u2014     Kleber 2011  (3.9)    0 (IGT cohort)   \u2014   \u2014   \u2014   \u2014   3/119 (2.5%)   \u2014   \u2014   \u2014     Ko 1999  (1.4)    0 (IGT cohort)   \u2014   \u2014   \u2014   \u2014   29/123 (23.6%)   \u2014   \u2014   \u2014     Ko 2001  (1.7)    13/264 (4.9%)   \u2014   \u2014   14/55 (25.5%)   \u2014   \u2014   \u2014   \u2014   \u2014     Larsson 2000  (10)    5/127 (3.9%)   \u2014   \u2014   \u2014   5/42 (11.9%)   \u2014   8/66 (12.1%)   6/30 (20.0%)   \u2014     Latifi 2016  (5)    25/394 (6.3%)   21/124 (16.9%)   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014     Lecomte 2007  (5)    0 (IFG cohort)   \u2014   \u2014   127/743 (17.1%)   \u2014   \u2014   \u2014   \u2014   \u2014     Lee 2016  (3.7)    0 (cohort with intermediate hyperglycaemia)   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   HbA1c5.7: 390/3497 (11.2%)      Leiva 2014  (6)    0 (IFG cohort)   \u2014   \u2014   11/28 (39.3%)   \u2014   \u2014   \u2014   \u2014   \u2014     Levitzky 2008  (4)    0 (IFG cohort)   \u2014   \u2014   Women: 87/313 (27.8%) Men: 92/460 (20.0%)   \u2014   \u2014   \u2014   \u2014   \u2014     Li 2003  (5)    38/435 (8.7%)   \u2014   \u2014   \u2014   16/42 (38.1%)   2 years: 23/131 (17.6%)   33/118 (28%)   20/49 (40.8%)   \u2014     Ligthart 2016  (14.7)    Unclear/7462   \u2014   \u2014   425/1382 (30.8%)   \u2014   \u2014   \u2014   \u2014   \u2014     Lipska 2013  (7)    38/1690 (2.2%)   20/189 (10.6%)   \u2014   48/100 (48%)   \u2014   \u2014   \u2014   \u2014   i\u2010HbA1c5.7: 44/207 (21.3%) IFG and HbA1c5.7: 81/169 (47.9%)      Liu 2008  (5)    9/470 (1.9%)   18/169 (10.7%)   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014     Liu 2014f  (3)    153/1821 (8.4%)   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014     Liu 2016  (10.9)    Unclear/1635   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014     Liu 2017  (7.8)    Unclear/15003   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014     Lorenzo 2003 (7\u20138)    Unclear/1503   \u2014   \u2014   14/29 (48.3%)   \u2014   88/202 (43.6%)   \u2014   \u2014   \u2014     Lyssenko 2005g  (6)    41/1429 (2.9%)   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014     Magliano 2008  (5)    58/4715 (1.2%)   \u2014   \u2014   44/370 (11.9%)   \u2014   122/757 (16.1%)   \u2014   \u2014   \u2014     Man 2017  (6)    15/462 (3.2%)   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   HbA1c5.7: 112/675 (16.6%)      Marshall 1994  (1.9)    0 (IGT cohort)   \u2014   \u2014   \u2014   \u2014   20/123 (16.3%)   \u2014   \u2014   \u2014     McNeely 2003  (10)    5\u20136 years: 5/277 (1.8%) 10 years: 13/277 (4.5%)   5\u20136 years: 27/125 (21.6%) 10 years: 39/103 (37.9%)   \u2014   5\u20136 years: 7/30 (23.3%) 10 years: 18/28 (64.3%)   \u2014   5\u20136 years: 45/178 (25.3%) 10 years: 59/157 (37.6%)    \u2014   \u2014   \u2014     Meigs 2003  (5, 10)    6 (SD 5) years: 55/488 (11.3%)   \u2014   \u2014   \u2014   6 (SD 5) years: 6/20 (30.0%)   \u2014   6 (SD 5) years: 81/218 (37.1%)   6 (SD 5) years: 15/27 (55.6%)    \u2014     Mohan 2008  (8)    64/476 (13.4%)   \u2014   \u2014   \u2014   \u2014   15/37 (40.5%)   \u2014   \u2014   \u2014     Motala 2003  (10)    36/482 (7.5%)   \u2014   \u2014   \u2014   \u2014   13/35 (37.1%) 4 years: 16/72 (22.2%)   \u2014   \u2014   \u2014     Motta 2010  (3)    52/2018 (2.6%)   \u2014   \u2014   50/295 (16.9%)   \u2014   \u2014   \u2014   \u2014   \u2014     Mykk\u00e4nen 1993  (3.5)    21/689 (3.0%)   \u2014   \u2014   \u2014   \u2014   48/203 (23.6%)   \u2014   \u2014   \u2014     Nakagami 2016  (5)    1528   77/467 (16.5%)   \u2014   50/134 (37.3)   \u2014   \u2014   \u2014   \u2014   HbA1c6.0: 58/156 (37.2%)  HbA1c5.7: 87/583 (14.9%)      Nakanishi 2004  (7)    51/5500 (0.9%)   \u2014   \u2014   5/246 (2.0%)   \u2014   \u2014   \u2014   \u2014   \u2014     Noda 2010  (5)    Total: 30/1649 (1.8%) Men: 13/540 (2.4%) Women: 17/1109 (6.4%)   Total: 37/405 (9.1%) Men: 18/202 (8.9%) Women: 19/203 (9.4%)    \u2014   Total: 58/153 (37.9%) Men: 25/79 (31.6%) Women: 33/74 (44.6%)    \u2014   \u2014   \u2014   \u2014   \u2014     Park 2006  (4.1)    116/4975 (2.3%)   40/321 (12.5%)   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014     Peterson 2017  (10)    2/39 (5.1%)   \u2014   \u2014   \u2014   \u2014   6/29 (20.7%)   \u2014   \u2014   \u2014     Qian 2012  (5)    59/843 (7.0%)   \u2014   \u2014   \u2014   17/46 (37%)   \u2014   49/120 (41%)   17/33 (51%)   \u2014     Rajala 2000  (4.6)    0 (IGT cohort)   \u2014   \u2014   \u2014   \u2014   32/171 (18.7%) 2.1 years: 14/183 (7.7%)   \u2014   \u2014   \u2014     Ramachandran 1986  (5.1)    0 IGT cohort)   \u2014   \u2014   \u2014   \u2014   39/107 (36.4%)   \u2014   \u2014   \u2014     Rasmussen 2008 (3.5) (i\u2010IFG5.6 : 2.5, IGT: 2.1 )    0 (IFG, IGT cohort)   \u2014   141/442 (32%)   \u2014   \u2014   181/442 (41%)   1 year: 35/296 (11.8%)    1 year: 60/207 (29%)    \u2014     Rathmann 2009  (7)    25/649 (3.9%)   \u2014   \u2014   12/71 (16.9%)   \u2014   \u2014   34/120 (28.3%)   22/47 (46.8%)   \u2014     Rijkelijkhuizen 2007  (6.4)    51/1125 (4.5%)   101/488 (20.7%)   \u2014   62/149 (41.6%)   35/106 (33%)   36/111 (32.4%) 2 years: 45/158 (28.5%)   27/80 (33.8%)   20/31 (64.5%)   \u2014     Sadeghi 2015  (7)    141/2607 (5.4%)   \u2014   134/373 (35.9%)   \u2014   \u2014   \u2014   49/373 (13.1%)   65/373 (17.4%)   \u2014     Sasaki 1982  (7)    7/161/4.3%)   \u2014   \u2014   \u2014   \u2014   5/13 (38.5%)   \u2014   \u2014   \u2014     Sato 2009  (4)    118/4147 (2.9%)   \u2014   \u2014   334/794 (42.1%)   \u2014   \u2014   \u2014   \u2014   HbA1c6.0: 90/215 (41.9%)      Schranz 1989  (6)    54/1251 (4.3%)   \u2014   \u2014   \u2014   \u2014   23/75 (30.7%)   \u2014   \u2014   \u2014     Sharifi 2013  (7)    0 (IFG cohort)   24/123(19.5%)   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014     Shin 1997  (2)    47/1040 (4.5%)   \u2014   \u2014   \u2014   \u2014   20/153 (13.1%)   \u2014   \u2014   \u2014     S\u00f6derberg 2004  (11)    Unclear/2522   \u2014   \u2014   5 years: 32/148 (21.6%)   153/402 (38%)   575/1253 (45.9%)   5 years: 103/489 (21.1%)   5 years: 45/118 (38.1%)   \u2014     Song 2015  (4)    74/1758 (4.2%)   \u2014   68/321 (21.2%) Men: 30/154 (19.5%) Women: 38/167 (22.8%)    \u2014   \u2014   \u2014   \u2014   \u2014   \u2014     Song 2016a  (10.8)    0 (cohort with intermediate hyperglycaemia)   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014     Soriguer 2008  (6)    13/1806 (0.7%)   \u2014   23/56 (41.1%)   \u2014   \u2014   14/54 (25.9%)   \u2014   14/28 (50%)   \u2014     Stengard 1992  (5)    6/216 (2.8%)   \u2014   \u2014   \u2014   \u2014   17/234 (7.3%)   \u2014   \u2014      Toshihiro 2008 (3.2)h     0 (cohort with IFG and/or IGT)   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014     Vaccaro 1999  (11.5)    36/500 (7.2%)   \u2014   1/11 (9.1%)   \u2014   \u2014   \u2014   13/40 (32.5%)   4/9 (44.4%)   \u2014     Valdes 2008  (6.3)    16/510 (3.1%)   14/114 (12.3%)   7/32 (21.9%)   19/52 (36.5%)   \u2014   21/88 (23.9%)   9/68 (13.2%)   12/20 (60%)   \u2014     Vijayakumar 2017 (adults: 4.6,children: 5.2)    Adults: 58/1466 (3.9) Children: 26/1795 (1.4%) [estimated from figure 2]   Adults: 222/424 (52.4%) Children: 52/193 (26.9%)    \u2014   \u2014   \u2014   Adults: 196/347 (56.5%) Children: 55/169 (32.5%)    \u2014   IFG5.6/IGT:  Adults: 116/169 (68.7%) Children: 26/53 (49.1%)    HbA1c5.7: adults: 75/168 (44.6%) HbA1c5.7: children: 18/62 (29%)      Viswanathan 2007  (5)    Total: 154/465 33.1%) M: 99/265 (37.4%) W: 55/200 (27.5%)   \u2014   \u2014   \u2014   \u2014   Total: 416/619 (67.2%) M: 251/391 (64.2%) W: 165/228 (72.4%)   \u2014   \u2014   \u2014     Wang 2007  (5)    51/358 (14.2%)   \u2014   53/261 (20%)   28/112 (25%)   \u2014   126/141 (89.4%)   31/95 (32.6%)   IFG5.6/IGT: 54/109 (49.5%)  IFG6.1/IGT: 36/52 (69.2%)    \u2014     Wang 2011  (7.8)    84/595 (14.1%)   Total: 345/947 (36.4%)  Men: 137/418 (32.8%) Women: 208/529 (39.3%)   \u2014   \u2014   \u2014   Total: 233/491 (47.5%) Men: 75/154 (48.7%): Women: 158/337 (46.9%) 4 years: Total 198/532 (37.2%)   \u2014   Total: 185/356 (52%%) Men: 66/125 (52.8%) Women: 119/231 (51.5%)   HbA1c6.0: 19/121 (15.7%)      Warren 2017  (cohort 1: 22, cohort 2: 16)    22 years: 8322 16 years: 4772   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014     Wat 2001  (2)    4/333 (0.1%)   \u2014   \u2014   \u2014   \u2014   31/322 (9.6%)   \u2014   \u2014   \u2014     Weiss 2005  (1.7)    8/84 (9.5%)   \u2014   \u2014   \u2014   \u2014   \u2014   8/33 (24.2%)   \u2014   \u2014     Wheelock 2016  (4.3)    Unclear/5363   \u2014   \u2014   5 years: 31%    \u2014   Non\u2010overweight: 5 years: 9/37 (24%) 10 years: 11/37 (29.7%) Overweight: 5 years: 49/132 (37%) 10 years: 84/132 (63.6%)    \u2014   5 years: 41.2%    \u2014     Wong 2003  (8)    12/278 (4.3%)   \u2014   \u2014   \u2014   \u2014   102/291 (35.1%)   \u2014   \u2014   \u2014     Yeboah 2011  (7.5)    Unclear/4973   273/940 (29.0%)   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014     Zethelius 2004  (7)    Unclear/466   \u2014   \u2014   \u2014   \u2014   Not reported/201   \u2014   \u2014   \u2014     aDevelopment of T2DM from 'prediabetes' (not defined) at year 1: 11/217 (5.1%), at year 2: 16/217 (7.6%).  bDevelopment of T2DM from 'prediabetes' (IFG6.1 and/or IGT): 46/122 (37.7%). cDevelopment of T2DM from IFG5.6and/or IGT: 11.7 years150/523 (28.7%); 2.3 years: 121/911 (13.3%). dDevelopment of T2DM from IFG5.6or IGT or HbA1c5.7: 20/186 (10.8%).  eDevelopment of T2DM from IFG or IGT: not reported.  fDevelopment of T2DM from IFG or IGT: 78/450 (17.3%).  gDevelopment of T2DM from IFG or IGT:86/686 (12.5%).  hDevelopment of T2DM from IFG and/or IGT: 36/128 (28.1%).  FPG: fasting plasma glucose; HbA1c: glycosylated haemoglobin A1c; HbA1c5.7/6.0 : HbA1c threshold 5.7% or 6.0% (usually reflecting 5.7% to 6.4% and 6.0% to 6.4%, respectively); HbA1c/IFG: both HbA1c and IFG; i\u2010: isolated; IFG5.6/6.1 : impaired fasting glucose (threshold 5.6 mmol/L or 6.1 mmol/L); IGT: impaired glucose tolerance; IFG/IGT: both IFG and IGT; NGT: normal glucose tolerance; PG: postload glucose; SD: standard deviation; T2DM: type 2 diabetes mellitus",
        "Appendix 12. Diabetes incidence (cases per 1000 person\u2010years)": "Study ID    Rate (diabetes cases/1000 person\u2010years (95% CI))      Follow\u2010up (years)    NGT cohort    'Prediabetes' cohort    IFG6.1 cohort    IFG5.6 cohort    IGT cohort    IFG/IGT cohort    Elevated HbA1c cohort    Elevated HbA1c/IFG cohort      Anjana 2015     9.1   22.2 (19.4\u201325.4)   78.9 (68.0\u201390.9)   \u2014   61.0 (42.1\u201385.0)   67.8 (54.6\u201383.0)   133.6 (103.1\u2013 169.3)   \u2014   \u2014     Bae 2011     4   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   Per 100 person\u2010years: HbA1c5.7: 5.6  HbA1c6.0: 14.0    \u2014     Bonora 2011     15   10 years: 4.3 (2.7\u20135.9)   \u2014   10 years: 37.0 (20.2\u201353.8)   \u2014   10 years: 17.0 (5.3\u201328.7)   10 years: 49.2 (17.9\u201380.5)   HbA1c6.0: 25.8    \u2014     De Abreu 2015     10   \u2014   \u2014   \u2014   18.1 (10.7\u201328.2)   \u2014   \u2014   \u2014   \u2014     Derakhshan 2016     11.7   \u2014   30.3   6.5 years: 69.4 (56.0\u201386.1)    6.5 years: 39.5 (34.4\u201345.4)    6.5 years: 41.6 (36.1\u201347.9)    \u2014   \u2014   \u2014     Dowse 1991     6.2   10.5   \u2014   \u2014   \u2014   40.4   \u2014   \u2014   \u2014     Forouhi 2007     10   2.4 (1.2\u20134.8) 4 years: 2.64 (1.23\u20134.05)   \u2014   17.5 (12.5\u201324.5)   10.6 (8.1\u201313.9) (IFG5.6: FPG 5.6\u20136.9)    4 years: 22.5 (20.4\u201324.6)   \u2014   \u2014   \u2014     Han 2017     12   12.3   IFG or IGT: 58.0   \u2014   i\u2010IFG5.6: 51.3    i\u2010IGT: 53.1   114.4   10 years: HbA1c5.7: 43.2    \u2014     Heianza 2012     5   2.3   \u2014   104   34.6   \u2014   \u2014   HbA1c5.7: 51.0  HbA1c6.0: 129.2    HbA1c5.7 and IFG5.6: 30.6  HbA1c6.0 and IFG5.6: 34.4      Janghorbani 2015     6.8   3.1 (1.5\u20134.7) 2.3 years: 4.6 (1.28\u201311.7)    \u2014   \u2014   16.3 (10.3\u201324.4) 2.3 years: i\u2010IFG5.6: 50.7 (20.7\u2013102.0)    25.9 (17.0\u201337.7) 2.3 years: i\u2010IGT: 99.7 (77.1\u2013126.0)   57.9 (46.1\u201371.7)   \u2014   \u2014     Jiamjarasrangsi 2008a     2.6   \u2014   \u2014   \u2014   31.5 (11.4\u201386.8)   \u2014   \u2014   \u2014   \u2014     Latifi 2016     5   21.9   \u2014   \u2014   34.5   \u2014   \u2014   \u2014   \u2014     Li 2003     5   18.8   \u2014   93.7   \u2014   60.7   117   \u2014   \u2014     Ligthart 2016     14.7   \u2014   \u2014   43.0 (39.2\u201347.2)   \u2014   \u2014   \u2014   \u2014   \u2014     Liu 2008     5   9   \u2014   \u2014   22.5   \u2014   \u2014   \u2014   \u2014     Magliano 2008     5   0.2 (0.2\u20130.3) (incidence percent per years)    \u2014   i\u2010IFG6.1: 2.6 (1.8\u20133.4)  (incidence percent per years)   \u2014   i\u2010IGT: 3.5 (2.9\u20134.2) (incidence percent per years)   \u2014   \u2014   \u2014     Meigs 2003     5, 10   Per 100 person\u2010years (annualised rate): FPG \u2265 7.0: 0.64 (0.32\u20131.13) 2\u2010h PG \u2265 11.1:  2.77 (2.01\u20133.71)   \u2014   \u2014   \u2014   \u2014   Per 100 person\u2010years (annualised rate): IFG or IGT  FPG \u2265 7.0: 0.98 (0.65\u20131.41) 2\u2010h PG \u2265 11.1:  4.61 (3.77\u20135.56)   \u2014   \u2014     Mohan 2008     8   17.5   \u2014   \u2014   \u2014   64.8   \u2014   \u2014   \u2014     Nakagami 2016     5   \u2014   \u2014   1   \u2014   \u2014   \u2014   \u2014   \u2014     Nakanishi 2004     7   1.5   \u2014   3.3   \u2014   \u2014   \u2014   \u2014   \u2014     Park 2006     4.1   5.7   \u2014   \u2014   31.3   \u2014   \u2014   \u2014   \u2014     Rajala 2000     4.6   \u2014   \u2014   \u2014   \u2014   41 (28\u201357)   \u2014   \u2014   \u2014     Rasmussen 2008     3.5 (i\u2010IFG5.6: 2.5 , IGT: 2.1 )    \u2014   \u2014   \u2014   i\u2010IFG5.6: 11.8 (9.9\u201313.8) per 100 person\u2010years    17.0 (14.9\u201319.1) per 100 person\u2010years  (i\u2010IGT: 11.8 (9.7\u201313.9)   27 (22.5\u201331.7) per 100 person\u2010years    \u2014   \u2014     Rathmann 2009     7   \u2014   \u2014   i\u2010IFG6.1: 24.2 (12.5\u201342.3)    \u2014   i\u2010IGT: 42.0 (29.0\u201358.7)    77.9 (48.8\u2013117.9)   \u2014   \u2014     Rijkelijkhuizen 2007     6.4   7   \u2014   66.5 (49.9\u201383.0)   32.7 (26.3\u201339.1)   i\u2010IGT: 57.9   112.2   \u2014   \u2014     Sadeghi 2015     7   Total: 14.1 (12.5\u201315.9) Men: 12.8 (10.7\u201315.3) Women: 15.5 (13.1\u201318.3)    \u2014   \u2014   Total: 48.4 (35.0\u201366.7) Men: 46.4 (28.9\u201374.7) Women: 50.1 (32.3\u201377.7)    Total: 40.3 (30.2\u201353.8) Men: 41.4 (25.7\u201366.6) Women: 39.6 (27.5\u201357.0)    Total: 137.6 (103.7\u2013182.5) Men: 129.9 (83.0\u2013203.7) Women: 143.1 (99.4\u2013205.9)    \u2014   \u2014     S\u00f6derberg 2004     11   \u2014   \u2014   87\u201392: Men: 54.1 (48.0\u201360.1) Women: 35.1 (30.3\u201340.0)  92\u201398: Men: 60.5 (54.1\u201367.0) Women: 74\u20137 (67.8\u201381.8)    \u2014   87\u201392: Men: 60.7 (54.3\u201367.1) Women: 47.9 (42.2\u201353.6)  92\u201398: Men: 119.6 (110.6\u2013128.6) Women: 81.0 (73.6\u201388.4)    \u2014   \u2014   \u2014     Soriguer 2008     6   7.2 (4.2\u201312.4)   \u2014   \u2014   38.1 (25.3\u201357.3)   31.1 (18.4\u201352.5)   66.0 (39.1\u2013111.5)   \u2014   \u2014     Valdes 2008     6.3   3.8 (2.1\u20136.8) for i\u2010IGT and IFG/IGT: 5.0 (2.8\u20138)   \u2014   58.0 (37\u201390.9)   19.5 (11.5\u201332.9)   37.9 (24.7\u201358.1) i\u2010IGT: 21 (10.9\u201340.4)   95.2 (54.1\u2013167.7)   \u2014   \u2014     Vijayakumar 2017     Adults: 4.6 Children: 5.2    \u2014   \u2014   \u2014   Boys: 22 Men: 70 Girls: 55 Women: 101    Boys: 38 Men: 94 Girls: 60 Women: 118    \u2014   Boys: 52 Men: 100 Girls: 100 Women: 118    \u2014     Wang 2011     7.8   21.1   \u2014   \u2014   Total: 66.2 Men: 57.7 Women: 73.4   Total: 95.8 Men: 98.1 Women: 94.8   Total: 109 Men: 109 Women: 109   \u2014   \u2014     CI: confidence interval; FPG: fasting plasma glucose; HbA1c: glycosylated haemoglobin A1c; HbA1c5.7/6.0 : HbA1c threshold 5.7% or 6.0% (usually reflecting 5.7% to 6.4% and 6.0% to 6.4%, respectively); HbA1c/IFG: both HbA1c and IFG; i\u2010: isolated; IFG5.6/6.1 : impaired fasting glucose (threshold 5.6 mmol/L or 6.1 mmol/L); IGT: impaired glucose tolerance; IFG/IGT: both IFG and IGT;NGT: normal glucose tolerance; T2DM: type 2 diabetes mellitus",
        "Appendix 13. T2DM cases and person\u2010time (for calculation incidence rate ratios)": "Study ID    Persons (cases) with diabetes with/without IH at baseline      Follow\u2010up (years)    Cases in IH group    Person\u2010years for IH group    Cases in normoglycaemic group    Person\u2010years for normoglycaemic group      Anjana 2015     9.1   i\u2010IFG5.6: 32 i\u2010IGT: 86 IFG/IGT: 58    i\u2010IFG5.6: 525 i\u2010IGT: 1269 IFG5.6/IGT: 434    209   9398     De Abreu 2015     10   IFG5.6: 21    IFG5.6: 1768    11   \u2014     Bae 2011     4   HbA1c5.7: 373  HbA1c6.0: 187    HbA1c5.7: 6594  HbA1c6.0: 1338    \u2014   \u2014     Bonora 2011     10   IFG6.1: 18  IGT: 8 IFG/IGT: 9   IFG6.1: 486  IGT: 471 IFG/IGT: 183   29   6704     Derakhshan 2016     11.7   IFG5.6: 150    IFG5.6: 4950    162   39,901     Dowse 1991     6.2   IGT: 13   IGT: 322   14   1339     Forouhi 2007     10   IFG6.1: 34 IFG5.6: 53  4.44 years: IGT: 17   IFG6.1: 1943 IFG5.6: 5000  4.44 years: IGT: 756   8 4.44 years: 9   3333 4.44 years: 3409     Guerrero\u2010Romero 2006     5   IGT: 20   IGT: 343   1   1388     Han 2017     12   i\u2010IFG5.6: 81  i\u2010IGT: 624 IFG/IGT: 138   i\u2010IFG5.6: 1579  i\u2010IGT: 11,744 IFG/IGT: 1206   657   53,461     Heianza 2012     5   IFG5.6: 108 HbA1c5.7: 30 HbA1c5.7/IFG5.6: 154    IFG5.6: 5920 HbA1c5.7: 1965 HbA1c5.7/IFG5.6: 1641    46   19,961     Janghorbani 2015     6.8   i\u2010IFG5.6: 23 i\u2010IGT: 26 IFG/IGT: 214    i\u2010IFG5.6: 1409 i\u2010IGT: 1005 IFG/IGT: 1347    14   4578     Li 2003     5   i\u2010IFG6.1: 16 i\u2010IGT: 33 IFG/IGT: 20    i\u2010IFG6.1: 171 i\u2010IGT: 544 IFG/IGT: 179    38   2026     Ligthart 2016     14.7   IFG6.1: 425    iFG6.1: 9884    \u2014   \u2014     Meigs 2003     5, 10   IFG or IGT  T2DM measured by: FPG \u2265 7.0: 26 2\u2010h PG \u2265 11.1: 101    IFG or IGT  T2DM measured by: FPG \u2265 7.0: 2647 2\u2010h PG \u2265 11.1: 2192    28   1539     Mohan 2008     8   IGT: 15   IGT: 247   64   3665     Nakanishi 2004     7   IFG6.1: 5    IFG6.1: 1506    51   34,308     Park 2006     4.1   IFG5.6: 40    IFG5.6: 1278    116   20,298     Rijkelijkhuizen 2007     6.4   i\u2010IFG6.1: 35  i\u2010IGT: 27 IFG/IGT: 20   i\u2010IFG6.1: 681  i\u2010IGT: 466 IFG/IGT: 178   51   7286     Soriguer 2008     6   IFG5.6: 23 IGT: 14 IFG/IGT: 14    IFG5.6: 604 IGT: 450 IFG/IGT: 212    13   1806     Valdes 2008     6.3   IFG5.6: 14 IFG6.1: 19  i\u2010IGT: 9 IFG/IGT: 12   IFG5.6: 718 IFG6.1:328  i\u2010IGT: 429 IFG/IGT: 126   11 (16 for i\u2010IGT and IFG/IGT)   2923 (3200 for i\u2010IGT and IFG/IGT)     Wang 2011     7.8   IFG5.6: 137  IGT: 75 IFG/IGT: 66   IFG5.6: 2374  IGT: 765 IFG/IGT: 605   34   1613     FPG: fasting plasma glucose; HbA1c: glycosylated haemoglobin A1c; HbA1c5.7/6.0 : HbA1c threshold 5.7% or 6.0% (usually reflecting 5.7% to 6.4% and 6.0% to 6.4%, respectively); HbA1c/IFG: both HbA1c and IFG; i\u2010: isolated; IFG5.6/6.1 : impaired fasting glucose (threshold 5.6 mmol/L or 6.1 mmol/L); IGT: impaired glucose tolerance; IFG/IGT: both IFG and IGT; IH: intermediate hyperglycaemia;T2DM: type 2 diabetes mellitus",
        "Appendix 14. Odds ratios and hazard ratios as the effect measures for the development of T2DM": "Study ID    Adjusted [unadjusted] ratios (95% CI) for the development of diabetes comparing IH with normoglycaemia at baseline      Follow\u2010up (years)    IFG6.1     IFG5.6     IGT    'Prediabetes'    IFG/IGT    HbA1c    HbA1c/IFG    Ratio      Admiraal 2014     10   \u2014   Total cohort: 6.1 (3.1\u201312.1) [5.7 (3.1\u201310.5)]  South\u2010Asian Surinamese: 11.1 (3.0\u201340.8) [9.9 (2.9\u201334.3)] African Surinamese: 5.1 (2.0\u201313.3) [6.2 (2.6\u201314.9)] \"Ethnic Dutch\": 2.2 (0.5\u201310.2) [2.1 (0.5\u20139.3)]    \u2014   \u2014   \u2014   \u2014   \u2014   Odds ratio     Aekplakorn 2006     12   \u2014   [2.41 (1.78\u20133.28)]   [4.36 (3.41\u20135.57)]   \u2014   \u2014   \u2014   \u2014   Odds ratio     Bae 2011     4   \u2014   \u2014   \u2014   \u2014   \u2014   HbA1c5.7: 6.5 (3.7\u201310.2)  HbA1c6.0:41.3 (24.7\u201369.2)  [compared with HbA1c < 5.0]   \u2014   Hazard ratio     Bergman 2016     24   20 years: i\u2010IFG6.1: 3.43 (1.88\u20136.28)    20 years: i\u2010IFG5.6: 1.11 (0.76\u20131.61)    5.64 (2.74\u201312.33) 20 years: 3.03 (1.80\u20135.09)    \u2014   IFG5.6 + IGT: 2.79 (1.56\u20135.00)  IFG6.1 + IGT: 3.85 (1.73\u20138.54)    \u2014   \u2014   Odds ratio     Bonora 2011     15   5.83 (3.23\u201310.54) 10 years: 5.7 (2.8\u201311.4) [3.9 (1.56\u20139.3)]     10 years: [3.9 (1.6\u20139.3)]   \u2014   10 years: [20.5 (7.6\u201355.3)]   HbA1c6.0: 9.74 (4.21\u201322.56)    \u2014   Hazard ratio, odds ratio (10 years)     Cederberg 2010     9.7   2.37 (1.49\u20133.78) [2.56 (1.57\u20134.16)]    \u2014   2.90 (1.90\u20134.43) [2.98 (1.94\u20134.569]    \u2014   \u2014   HbA1c5.7: 2.42 (1.50\u20133.91) [2.78 (1.80\u20134.31)]    \u2014   Risk ratio     Chamnan 2011     3   \u2014   \u2014   \u2014   \u2014   \u2014   HbA1c6.0: 15.6 (6.9\u201335.7) [15.5 (7.2\u201333.3)]    \u2014   Odds ratio     Chen 2003     3   4.4 (1.9\u201310.6)   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   Odds ratio     Coronado\u2010Malagon 2009     1, 2   \u2014   \u2014   \u2014   [At 1 year: 7.7 (2.1\u201327.9)]    \u2014   \u2014   \u2014   Relative risk     Cugati 2007     10   [19.13 (11.59\u201331.66)]   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   Odds ratio     De Abreu 2015     10   5.75 (1.86\u201317.78)   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   Odds ratio     Derakhshan 2016     11.7   6.5 years: 4.1 (2.9\u20135.6)    6.5 years: 3.0 (2.3\u20133.9)    \u2014   IFG5.6 and/or IGT: 4.98 (4.08\u20136.07)    \u2014   \u2014   \u2014   Hazard ratio, relative risk (6.5 years)     Dowse 1991     6.2   \u2014   \u2014   [3.6 (1.4\u20139.1)]   \u2014   \u2014   \u2014   \u2014   Odds ratio     Ferrannini 2009     7   [3.73 (2.18\u20136.39)]   [4.28 (3.21\u20135.71)]   [4.01 (3.12\u20135.14)]   \u2014   \u2014   \u2014   \u2014   Relative risk     Filippatos 2016     10   \u2014   3.43 (2.17\u20135.44)   \u2014   \u2014   \u2014   \u2014   \u2014   Odds ratio     Forouhi 2007     10   4.4 (1.9\u201310.0)   2.9 (1.3\u20136.3)   \u2014   \u2014   \u2014   \u2014   \u2014   Hazard ratio     Han 2017     12   \u2014   i\u2010IFG5.6: 3.61 (2.85\u20134.57)    i\u2010IGT: 4.06 (3.62\u20134.55)   \u2014   8.21 (6.79\u20139.94)   6 years: HbA1c6.0:  Men: 4.28 (2.41\u20137.58) Women: 4.05 (1.36\u201312.07)   \u2014   Hazard ratio     Hanley 2005     5.2   \u2014   \u2014   5.42 (3.60\u20138.17)   \u2014   \u2014   \u2014   \u2014   Odds ratio     Heianza 2012     5   11.4 (8.09\u201316.1)   6.18 (4.34\u20138.80)   \u2014   \u2014   \u2014   HbA1c5.7: 6.53 (3.79\u20139.64) HbA1c6.0: 7.42 (3.67\u201315.0)    HbA1c5.7 + IFG5.6:  32.5 (23.0\u201345.8) HbA1c5.7 + IFG6.1:  37.9 (28.1\u201351.1) HbA1c6.0 + IFG5.6:  53.7 (38.4\u201375.1) HbA1c6.0 + IFG6.1:  52.3 (37.8\u201372.3)   Hazard ratio     Janghorbani 2015     6.8   \u2014   7.4 (3.7\u201314.8) [8.2 (4.2\u201316.0)]    9.4 (4.8\u201318.6) [10.0 (5.2\u201319.1)]    \u2014   22.5 (12.4\u201341.0) [26.7 (15.1\u201347.2)]    \u2014   \u2014   Hazard ratio     Jeong 2010     5   \u2014   5.66 (3.44\u20139.31)   6.01 (3.23\u201311.2)   \u2014   \u2014   \u2014   \u2014   Odds ratio     Kim 2005     5   Total: 34.57 (12.18\u201398.10) Men: 76.02 (10.42\u2013544.51) Women: 15.46 (4.08\u201358.61)    Total: 4.77 (1.60\u201314.15) Men: 9.5 (1.25\u201372.24) Women: 1.91 (0.45\u20138.21)   \u2014   \u2014   \u2014   \u2014   \u2014   Hazard ratio     Kim 2016a     5.2   21.1 (16.8\u201326.3)   \u2014   \u2014   \u2014   \u2014   HbA1c6.0: 23.2 (18.7\u201328.7)    HbA1c5.7 + IFG5.6:  46.7 (33.5\u201364.9)   Odds ratio     Latifi 2016     5   \u2014   1.04 (1.00\u20131.07)   \u2014   \u2014   \u2014   \u2014   \u2014   Odds ratio     Leiva 2014     6   2.06 (1.76\u20105.14)   \u2010   \u2010   \u2010   \u2010   \u2010   \u2010   Odds ratio     Levitzky 2008     4   Women: 26.3 (17.4\u201339.8) Men: 12.9 (9.3\u201318.1)    Women: 22.3 (13.0\u201338.1) Men: 12.7 (8.1\u201320.0)    \u2014   \u2014   \u2014   \u2014   \u2014   Odds ratio     Li 2003     5   5.78 (3.20\u201310.43)   \u2014   i\u2010IGT: 2.94 (1.81\u20134.76)   \u2014   6.17 (3.41\u201311.15)   \u2014   \u2014   Hazard ratio     Lipska 2013     7   11.4 (7.1\u201318.4)   IFG5.6: Total: 3.5 (1.9\u20136.3)  Men: 8.6 (3.4\u201321.9) Women: 1.5 (0.5\u20134.6)  White: 3.2 (1.5\u20136.6) Black: 4.6 (1.6\u201313.3)    \u2014   \u2014   \u2014   i\u2010HbA1c5.7: Total: 8.0 (4.8\u201313.2)  Men: 24.2 (9.5\u201361.8) Women: 4.6 (2.4\u20138.7)  White: 10.2 (5.0\u201320.8)  Black: 5.8 (2.9\u201311.7)   HbA1c5.7 + IFG5.6:  Total: 26.2 (16.3\u201342.1) Men: 51.1 (21.2\u2013123.2) Women: 20.4 (10.9\u201338.0) White: 34.9 (19.1\u201363.8) Black: 14.9 (6.8\u201332.6)   Odds ratio     Liu 2008     5   \u2014   4.5 (2.0\u201310.1)   \u2014   \u2014   \u2014   \u2014   \u2014   Risk ratio     Liu 2016     10.9   1.99 (1.37\u20132.90) [2.12 (1.46\u20133.08)]    \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   Hazard ratio     Liu 2017     7.8   \u2014   3.67 (3.20\u20134.21) [4.36 (3.83\u20134.97)]   \u2014   \u2014   \u2014   \u2014   \u2014   Odds ratio     Lorenzo 2003     7\u20138   \u2014   \u2014   6.37 (4.37\u20139.28)   \u2014   \u2014   \u2014   \u2014   Odds ratio     Lyssenko 2005     6   [i\u2010IFG6.1: 2.3 (1.4\u20133.7)]    \u2014   [i\u2010IGT: 3.5 (2.1\u20135.8)]   \u2014   [3.8 (2.3\u20136.2)]   \u2014   \u2014   Hazard ratio     Man 2017     6   \u2014   \u2014   \u2014   \u2014   4.54 (2.65\u20137.78)   \u2014   \u2014   Risk ratio     Mykk\u00e4nen 1993     3.5   \u2014   \u2014   [9.85 (6.14\u201315.8)]   \u2014   \u2014   \u2014   \u2014   Odds ratio     Nakagami 2016     5   34.89 (19.65\u201361.95) [37.85 (22.73\u201363.05)]    \u2014   \u2014   \u2014   \u2014   HbA1c6.0:  [63.16 (33.94\u2013117.52)] HbA1c5.7:  8.77(4.47\u201317.21) [9.72(4.96\u201319.05)]   \u2014   Hazard ratio     Nakanishi 2004     7   1.31 (0.51\u20133.34)   \u2014   \u2014   \u2014   \u2014   \u2014   \u2014   Risk ratio     Rathmann 2009     7   [4.7 (2.2\u201310.0)]   \u2014   [8.8 (5.0\u201315.6)]   \u2014   [21.2 (10.4\u201343.3)]   \u2014   \u2014   Odds ratio     Rijkelijkhuizen 2007     6.4   i\u2010IFG6.1: 10.0 (6.1\u201316.5)    \u2014   i\u2010IGT: 10.9 (6.0\u201319.9)   \u2014   39.5 (17.0\u201392.1)   \u2014   \u2014   Odds ratio     Sadeghi 2015     7   \u2014   i\u2010IFG5.6: 3.30 (2.16\u20135.06)    i\u2010IGT: 2.52 (1.73\u20133.69)   \u2014   12.6 (7.39\u201321.4)   \u2014   \u2014   Odds ratio     Sato 2009     4   22.52 (17.73\u201328.60)    \u2014   \u2014   \u2014   \u2014   \u2014   Odds ratio     Song 2015     4   \u2014   Men: 7.50 (2.76\u201320.33) Women: 4.27 (1.52\u201312.00)    \u2014   \u2014   \u2014   \u2014   \u2014   Relative risk     Soriguer 2008     6   \u2014   [5.3 (2.7\u201310.4)]   4.3 (2.0\u20139.2)   \u2014   9.2 (4.3\u201319.5)   \u2014   \u2014   Relative risk     Stengard 1992     5   \u2014   \u2014   3.1 (1.2\u20138.2)   \u2014   \u2014   \u2014   \u2014   Odds ratio     Vaccaro 1999     11.5    [i\u2010IFG6.1: 1.2 (0.3\u201310.2)]    [i\u2010IGT: 6.2 (2.7\u201313.8)]   \u2014   [10.3 (2.2\u201346.8)]   \u2014   \u2014   Odds ratio     Valdes 2008     6.3   12.1 (4.6\u201331.7) [11.5 (5.6\u201323.6]   3.9 (1.6\u20139.8)   [6.7 (3.4\u201313.3)] [i\u2010IGT: 4.7 (1.9\u201311.7)]   \u2014   [45.6 (15.8\u2013131.4)]   \u2014   \u2014   Odds ratio     Viswanathan 2007     5   \u2014   \u2014   1.57   \u2014   \u2014   \u2014   \u2014   Odds ratio     Wang 2007     5   2.71 (1.43\u20135.16) Men: 2.29 (0.95\u20135.49) Women: 1.95 (0.83\u20134.61)   1.80 (0.96\u20133.40) Men: 1.79 (0.70\u20134.57) Women: 2.08 (0.93\u20134.67)   3.15 (1.60\u20136.19) i\u2010IGT(IFG6.1): Men: 7.33 (2.62\u201320.51)  Women: 1.65 (0.76\u20133.60) i\u2010IGT(IFG5.): Men: 7.50 (1.62\u201334.63)  Women: 2.21 (0.77\u20136.36)   \u2014   IGT/IFG6.1: Men: 10.23 (3.84\u201327.30)  Women: 7.11 (2.56\u201319.72) IGT/IFG5.6:  Men: 9.81 (3.5\u201327.21) Women: 4.67 (1.87\u201311.62)   \u2014   \u2014   Risk ratio, odds ratio     Wang 2011     7, 8   \u2014   Total: 2.38 (1.85\u20133.05) [2.68 (2.25\u20133.63] Men: 2.10 (1.40\u20133.15) [2.78 (1.91\u20134.04)] Women: 2.46 (1.78\u20133.39) [ 2.92 (2.15\u20133.98] 4 years: [3.12 (2.31\u20134.22)]   Total: 3.47 (2.64\u20134.55) [4.11 (3.20\u20135.27)] Men: 3.82 (2.41\u20136.04) [4.72 (3.15\u20137.09)] Women: 3.16 (2.26\u20134.43) [3.74 (2.72\u20135.14)]   \u2014   Total: 4.06 (3.05\u20135.40) [4.68 (3.62\u20136.07) ] Men: 4.44 (2.75\u20137.15) [5.28 (3.49\u20137.99)] Women: 3.80 (2.66\u20135.42) [4.30 (3.09\u20135.99)]   4 years: HbA1c6.0: 5.89 (4.23\u20138.19)    \u2014   Hazard ratio, odds ratio (4 years)     Warren 2017     Cohort 1: 22 Cohort 2: 16   Cohort 1: 2.85 (2.60\u20133.12)  Black: 2.66 (2.26\u20133.13) White: 2.86 (2.57\u20133.19)  Cohort 2: 3.41 (3.01\u20133.85)  Black: 3.16 (2.47\u20134.06) White: 3.67 (3.18\u20134.23)    Cohort 1: 2.26 (2.08\u20132.45) Black: 2.05 (1.75\u20132.40) White: 2.30 (2.10\u20132.53)  Cohort 2: 2.70 (2.43\u20133.00)  Black: 2.65 (2.11\u20133.32) White: 2.87 (2.54\u20133.23)    Cohort 2: 2.06 (1.84\u20102.31)  Black: 2.55 (2.01\u20133.22) White: 1.95 (1.71\u20132.21)    \u2014   \u2014   Cohort 1: HbA1c5.7: 2.71 (2.48\u20132.95)  Black: 2.24 (1.92\u20132.61) White: 2.91 (2.63\u20133.22)  HbA1c6.0: 3.12 (2.81\u20133.46)  Black: 2.60 (2.21\u20133.05) White: 3.64 (3.20\u20134.14)  6 years: HbA1c6.0: 9.24 (7.20\u201311.86)    \u2014   Hazard ratio     Yeboah 2011     7.5   \u2014   10.5 (8.4\u201313.1) [13.2 (10.7\u201316.2)]    \u2014   \u2014   \u2014   \u2014   \u2014   Hazard ratio     Zethelius 2004     7   \u2014   \u2014   [2.18 (1.43\u20133.34)]   \u2014   \u2014   \u2014   \u2014   Odds ratio     aUnreliable adjusted HbA1c6.0 interval in publication: 105.47 (29.30\u2013101.86)  CI: confidence interval; FPG: fasting plasma glucose; HbA1c: glycosylated haemoglobin A1c; HbA1c5.7/6.0 : HbA1c threshold 5.7% or 6.0% (usually reflecting 5.7% to 6.4% and 6.0% to 6.4%, respectively); HbA1c/IFG: both HbA1c and IFG; i\u2010: isolated; IFG5.6/6.1 : impaired fasting glucose (threshold 5.6 mmol/L or 6.1 mmol/L); IGT: impaired glucose tolerance; IFG/IGT: both IFG and IGT; IH: intermediate hyperglycaemia; T2DM: type 2 diabetes mellitus",
        "Appendix 15. Regression from intermediate hyperglycaemia to normoglycaemia": "Study ID    Follow\u2010up (years)    Regression to normoglycaemia from IH at baseline      Ammari 1998     2   IGT: 27/68 (39.7%)     Anjana 2015     9.1   i\u2010IFG5.6 or i\u2010IGT: 52/299 (17.4%)      Baena\u2010Diez 2011     10   IFG6.1: 57/115 (49.6%)      Bai 1999     1   IGT: 162/252 (64.3%)     Charles 1997     2   IGT: 273/418 (65.3%)     Chen 2003     3   IFG6.1: 129/156 (82.6%)      Coronado\u2010Malagon 2009     1, 2   'Prediabetes': 76/217 (35%)     Cugati 2007     10   IFG5.6: 5 years: 94/229 (27.9%); 10 years: 15/229 (6.6%)  IFG6.1: 5 years: 34/50 (68%); 10 years: 2/50 (4%)      De Abreu 2015     10   IFG5.6: 104/187 (55.6%)      Dowse 1991     6.2   IGT: 20/51 (39%)     Ferrannini 2009     7   IGT: 73/170 (42.9%)     Forouhi 2007     10   IFG6.1: 143/257 (55.6%)      Guerrero\u2010Romero 2006     5   IGT: 3/75 (4%)     Heianza 2012     5   IFG5.6: 383/1680 (22.8%) IFG6.1: 101/380 (26.5%) HbA1c5.7: 263/822 (32%) HbA1c6.0: 63/203 (31.0%) HbA1c5.7/IFG5.6: 428/2092 (20.5%) HbA1c6.0/IFG5.6: 392/1748 (22.4%)      Inoue 1996     2.5   IGT: 11/37 (29.7%)     Jiamjarasrangsi 2008a     2.6   IFG5.6: 197/320 (61.6%)      Kim 2008     2   IFG total: 908/1829 (49.6%) IFG5.6: 747/1335 (56%) IFG6.1: 161/494 (32.6%)      Kleber 2010     1   IGT: 52/79 (65.8%)     Kleber 2011     3.9   IGT: 96/119 (80.1%)     Ko 1999     1.4   IGT: 60/123 (48.8%)     Ko 2001     1.7   IFG6.1: 17/55 (30.9%)      Larsson 2000     10   i\u2010IFG6.1: 27/42 (64.3%) i\u2010IGT: 36/66 (54.6%) IFG/IGT: 17/30 (56.7%)      Latifi 2016     5   IFG5.6: 62/124 (50%)      Lecomte 2007     5   IFG6.1: 297/743 (44%)      Leiva 2014     6   IFG6.1: 0/28 (0%)      Li 2003     2   IGT: 22/131 (16.8%)     Liu 2014     3   IFG or IGT: 130/450 (28.9%)     Lyssenko 2005     6   IFG or IGT: 379/686 (55.2%)     Marshall 1994     1.9   IGT: 60/123 (48.8%)     Mohan 2008     8   IGT: 6/37 (16.2%)     Motala 2003     10   IGT: 16/35 (45.7%) 4 years: IGT: 28/72 (38.9%)     Mykk\u00e4nen 1993     3.5   IGT: 72/203 (35.5%)     Peterson 2017     10   IGT: 8/29 (27.6%)     Qian 2012     5   i\u2010IFG6.1: 14/46 (30.4%) i\u2010IGT: 45/120 (37.5%) IFG/IGT: 8/33 (24.2%)      Rajala 2000     4.6   IGT: 96/171 (56.1%) (2.1 years) IGT: 115/183 (62.8%)     Ramachandran 1986     3.3   IGT: 34/107 (31.8%)     Rijkelijkhuizen 2007     6.4   IFG6.1: 28/149 (18.8%) IFG5.6: 33/488 (6.8%)  (3 years) IGT: 35/158 (22.2%)     Sadeghi 2015     7   IFG5.6and/or IGT: 148/373 (39.7%)      Sasaki 1982     7   IGT: 5/13 (38.5%)     Schranz 1989     6   IGT: 25/75 (33.3%)     Sharifi 2013     7   IFG5.6: 53/123 (43.1%)      S\u00f6derberg 2004     11   i\u2010IFG6.1: 153/402 (38%) IGT: 296/1253 (23.6%)      Song 2016a     10.8   Total: 75/334 (22.5%) Men: 28/125 (22.4%) Women: 47/209 (22.5%)      Stengard 1992     5   IGT: 79/234 (33.8%)     Toshihiro 2008     3.2   IFG and/or IGT: 39/128 (30.5%)     Wang 2011     4   IGT: 147/532 (27.6%)     Wat 2001     2   IGT: 174/322 (54%)     Weiss 2005     1.7   i\u2010IGT: 15/33 (45.5%)     Wong 2003     8   IGT: 122/291 (41.9%)     HbA1c: glycosylated haemoglobin A1c; HbA1c5.7/6.0 : HbA1c threshold 5.7% or 6.0% (usually reflecting 5.7% to 6.4% and 6.0% to 6.4%, respectively); HbA1c/IFG: both HbA1c and IFG;i\u2010: isolated; IFG5.6/6.1 : impaired fasting glucose (threshold 5.6 mmol/L or 6.1 mmol/L); IGT: impaired glucose tolerance; IFG/IGT: both IFG and IGT; IH: intermediate hyperglycaemia; IQR: interquartile range; SD: standard deviation",
        "Appendix 16. Confounder adjustment (I)": "Study ID    Age    Sex    Body mass index, waist circumference, waist\u2010to\u2010hip ratio    'Ethnicity'    Site    Smoking status    Drinking status    Physical activity    Medications      Admiraal 2014     Yes   Yes   Yes   No   No   No   No   No   No     Aekplakorn 2006     No   No   No   No   No   No   No   No   No     Bae 2011     Yes   Yes   No   No   No   No   No   No   No     Bergman 2016     Yes   Yes   Yes   No   No   Yes   No   No   No     Bonora 2011     Yes   Yes   Yes   No   No   Yes   Yes   Yes   No     Cederberg 2010     No   Yes   Yes   No   No   Yes   Yes   Yes   No     Chamnan 2011     Yes   Yes   Yes   No   No   Yes   No   No   Yes     Chen 2003     Yes   Yes   Yes   No   No   No   No   No   No     Coronado\u2010Malagon 2009     No   No   No   No   No   No   No   No   No     Cugati 2007     Yes   Yes   No   No   No   No   No   No   No     De Abreu 2015     Yes   No   Yes   No   No   Yes   Yes   Yes   No     Derakhshan 2016     Yes   Yes   Yes   No   No   Yes   No   Yes   No     Dowse 1991     No   No   No   No   No   No   No   No   No     Ferrannini 2009     No   No   No   No   No   No   No   No   No     Filippatos 2016     Yes   Yes   No   No   No   Yes   No   Yes   No     Forouhi 2007     Yes   Yes   Yes   No   No   Yes   No   Yes   No     Han 2017     Yes   Yes   Yes   No   Yes   Yes   Yes   Yes   No     Hanley 2005     Yes   Yes   No   Yes   Yes   No   No   No   No     Heianza 2012     Yes   Yes   Yes   No   No   Yes   No   No   No     Janghorbani 2015     Yes   Yes   Yes   No   No   No   No   No   No     Jeong 2010     No   No   Yes   No   No   No   No   No   No     Kim 2005     Yes   Yes   Yes   No   No   No   No   No   No     Kim 2016a     Yes   Yes   Yes   No   No   Yes   Yes   Yes   No     Latifi 2016     Yes   No   Yes   Yes   No   No   No   No   No     Leiva 2014     No   No   No   No   No   Yes   No   No   Yes     Levitzky 2008     Yes   No   Yes   No   No   Yes   No   No   No     Li 2003     Yes   Yes   Yes   No   No   No   No   No   No     Lipska 2013     Yes   Yes   No   Yes   Yes   Yes   No   Yes   No     Liu 2008     Yes   Yes   No   No   No   Yes   Yes   No   No     Liu 2016     Yes   No   Yes   No   No   No   No   Yes   No     Liu 2017     Yes   No   No   No   No   Yes   Yes   Yes   No     Lorenzo 2003     Yes   Yes   No   No   No   No   No   No   No     Lyssenko 2005     No   No   Yes   No   No   No   No   No   No     Man 2017     Yes   Yes   Yes   No   No   Yes   No   No   No     Mykk\u00e4nen 1993     No   No   No   No   No   No   No   No   No     Nakagami 2016     Yes   No   Yes   No   No   Yes   Yes   No   No     Nakanishi 2004     Yes   No   No   No   No   Yes   Yes   No   No     Rathmann 2009     Yes   Yes   No   No   Yes   No   No   No   No     Rijkelijkhuizen 2007     Yes   Yes   No   No   No   No   No   No   No     Sadeghi 2015     Yes   Yes   Yes   No   No   No   No   No   No     Sato 2009     Yes   NA   Yes   No   No   Yes   Yes   Yes   No     Song 2015     Yes   No   Yes   No   No   Yes   Yes   Yes   No     Soriguer 2008     Yes   Yes   Yes   No   No   No   No   No   No     Stengard 1992     Yes   No   Yes   No   No   No   No   No   No     Vaccaro 1999     No   No   No   No   No   No   No   No   No     Valdes 2008     Yes   Yes   Yes   No   No   No   No   No   No     Viswanathan 2007     Yes   No   Yes   No   No   No   No   No   No     Wang 2007     Yes   Yes   No   No   No   Yes   No   No   No     Wang 2011     Yes   Yes   Yes   No   No   Yes   No   No   No     Warren 2017     Yes   Yes   Yes   Yes   No   Yes   Yes   No   Yes     Yeboah 2011     Yes   Yes   Yes   Yes   No   No   No   Yes   No     Zethelius 2004     Yes   No   Yes   No   No   No   No   No   No     'No' denotes possible confounder but statistical analysis did not adjust for this covariate  'Yes' indicates that statistical analysis adjusted for this confounder NA: not applicable",
        "Appendix 17. Confounder adjustment (II)": "Study ID    Cardiovascular disease    Glomerular filtration rate, albuminuria    Blood pressure, hypertension    Family history of diabetes    Socioeconomic status    Region    Depression    Triglycerides    Cholesterol      Admiraal 2014     No   No   No   No   No   No   No   No   No     Aekplakorn 2006     No   No   No   No   No   No   No   No   No     Bae 2011     No   No   No   No   No   No   No   No   No     Bergman 2016     Yes   No   Yes   No   No   No   No   Yes   Yes     Bonora 2011     No   No   Yes   Yes   Yes   No   No   Yes   Yes     Cederberg 2010     No   No   No   No   No   No   No   No   No     Chamnan 2011     No   No   Yes   Yes   Yes   No   No   Yes   Yes     Chen 2003     No   No   No   Yes   No   No   No   Yes   No     Coronado\u2010Malagon 2009     No   No   No   No   No   No   No   No   No     Cugati 2007     No   No   No   No   No   No   No   No   No     De Abreu 2015     No   No   Yes   No   No   No   No   Yes   Yes     Derakhshan 2016     No   No   No   Yes   Yes   No   No   Yes   Yes     Dowse 1991     No   No   No   No   No   No   No   No   No     Ferrannini 2009     No   No   No   No   No   No   No   No   No     Filippatos 2016     No   No   Yes   No   No   No   No   Yes   Yes     Forouhi 2007     No   No   No   Yes   No   No   No   No   No     Han 2017     No   No   Yes   Yes   No   Yes   No   Yes   Yes     Hanley 2005     No   No   No   No   No   No   No   No   No     Heianza 2012     No   No   Yes   Yes   No   No   No   Yes   Yes     Janghorbani 2015     No   No   No   No   No   No   No   Yes   Yes     Jeong 2010     No   No   Yes   No   No   No   No   Yes   Yes     Kim 2005     No   No   Yes   Yes   No   No   No   Yes   Yes     Kim 2016a     No   No   Yes   Yes   No   No   No   Yes   Yes     Latifi 2016     No   No   Yes   Yes   No   No   No   No   No     Leiva 2014     No   No   No   Yes   No   No   No   No   No     Levitzky 2008     No   No   No   No   No   No   No   No   No     Li 2003     No   No   No   No   No   No   No   No   No     Lipska 2013     No   No   Yes   No   No   No   No   No   No     Liu 2008     No   No   No   Yes   No   No   No   No   No     Liu 2016     No   No   No   No   No   No   No   No   No     Liu 2017     No   No   No   No   Yes   Yes   No   No   No     Lorenzo 2003     No   No   No   Yes   No   No   No   No   No     Lyssenko 2005     No   No   No   No   No   No   No   No   No     Man 2017     No   No   Yes   Yes   Yes   No   No   No   Yes     Mykk\u00e4nen 1993     No   No   No   No   No   No   No   No   No     Nakagami 2016     No   No   Yes   Yes   No   No   No   No   Yes     Nakanishi 2004     No   No   No   Yes   No   No   No   No   No     Rathmann 2009     No   No   Yes   No   No   No   No   No   No     Rijkelijkhuizen 2007     No   No   No   No   No   No   No   No   No     Sadeghi 2015     No   No   No   Yes   No   No   No   No   No     Sato 2009     No   No   No   Yes   No   No   No   No   No     Song 2015     No   No   Yes   Yes   No   No   No   Yes   No     Soriguer 2008     No   No   Yes   Yes   No   No   No   Yes   No     Stengard 1992     No   No   No   No   No   No   No   No   No     Vaccaro 1999     No   No   No   No   No   No   No   No   No     Valdes 2008     No   No   No   No   No   No   No   Yes   No     Viswanathan 2007     No   No   No   Yes   No   No   No   No   No     Wang 2007     No   No   No   Yes   Yes   No   No   No   Yes     Wang 2011     No   No   Yes   Yes   No   No   No   Yes   Yes     Warren 2017     No   Yes   Yes   Yes   Yes   No   No   Yes   Yes     Yeboah 2011     No   No   No   No   Yes   No   No   No   No     Zethelius 2004     No   No   No   No   No   No   No   No   No     'No' denotes possible confounder but statistical analysis did not adjust for this covariate  'Yes' indicates that statistical analysis adjusted for this confounder"
    }
}